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Thyroid cancer is the most common cancer of the endocrine system. The incidence of thyroid 
cancer has increased worldwide for decades in the general populations and in the US military 
personnel. Although emerging evidence indicates that exposure to polybrominated diphenyl ethers 
(PBDEs) is related to disruption of thyroid hormone homeostasis, the association between exposure 
to PBDEs and risk of thyroid cancer is still unclear. Additionally, mutations in genes coding for 
enzymes involved in regulation, metabolism, or functional activation of PBDEs and thyroid 
hormones could modify the PBDEs and thyroid hormones related risk of thyroid carcinogenesis. 
Using data from a nested case-control study including 742 pairs of papillary thyroid cancer (PTC) 
cases and individually matched controls with pre-diagnostic serum concentrations of PBDEs and 
thyroid hormones from the Department of Defense Serum Repository (DoDSR), we tested the 
hypothesis that exposure to elevated PBDEs increases the risk of PTC and the increased risk posed 
by PBDEs is through the disruption of thyroid hormones. We also investigated the effects of genetic 
variants in genes involved in metabolism/detoxification of PBDEs and thyroid hormones on the 
association between PBDEs, thyroid hormones, and risk of PTC. Results from this study suggested 
that exposure to BDE-28 and dysregulate serum levels of thyroid stimulating hormone (TSH) were 
associated with increased risk of PTC. This study also observed significantly nonmonotonic 
relationships between serum concentrations of BDE-153 and 2,2’,4,4’,5,5’-hexabromobiphenyl 
(BB-153) and serum levels of total triiodothyronine (TT3) and total thyroxine (TT4) in PTC cases, 
and between BDE-47, -100, and -153 in relation to free T4 (FT4) level in controls. However, results 
from the causal mediation analysis did not support the hypothesis that thyroid carcinogenesis of 
PBDEs is mainly operated through disruption of thyroid hormone homeostasis. Investigation on 
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the genetic polymorphisms and gene-environment interactions suggested significant interactions 
between BDE-28 and single nucleotide variants (SNVs) on CYP2E1 rs7092584 and DIO2 
rs12885300. Serum level of TSH also interacted with UGT1A rs1875263, DIO2 rs1288530, and 
UGT1A rs2011404. Findings of this study provides evidence to the link between exposure to 
PBDEs and risk of PTC, which will promote further regulations on production and application of 
PBDEs. Also, there could be significant clinical implications to monitor and regulate thyroid 
hormone levels among the most susceptible populations. Results from the gene-environment 
interaction analysis provide novel evidence to understand the basis of the molecular biology behind 
the initiation and promotion of PTC. With further understanding the pathogenesis of PTC, as well 
as implementing appropriate regulation and intervention, it should be pursued to decrease the 
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Thyroid cancer is the most common cancer of the endocrine system. The age-adjusted incidence 
rates of thyroid cancer have increased worldwide for decades and have been increasing faster than 
any other malignancies [1-4]. The incidence of thyroid cancer increased by 148% among men (from 
3.1 to 7.7 per 100,000 persons) and 247% among women (from 6.4 to 22.2 per 100,000 persons) 
in the US between 1975 and 2014 [5]. Most of the increased incidence is in papillary thyroid cancer 
(PTC), which is the most common histologic type and accounts for more than 80% of all thyroid 
carcinomas [6, 7]. A pattern of increasing rates was also observed in the US military personnel. 
The incidence of papillary thyroid cancer increased from 2.52 to 2.76 per 100,000 persons among 
servicemen and from 13.31 to 19.64 among servicewomen between the periods 1990-1997 and 
1998-2004 [8]. Additionally, the incidence was significantly higher in servicewomen than women 
in the general population for ages 20-49 years when thyroid cancer risk is at its highest [8, 9]. 
 
Etiologic factors underlying thyroid cancer are poorly understood. The most well-established risk 
factors include age, female gender, exposure to ionizing radiation, history of benign thyroid disease, 
and family history of thyroid cancer [10-13]. Recent studies have also identified higher body weight 
and height [14, 15] and insulin resistance syndrome [16] as risk factors. While the advanced 
medical surveillance and diagnostic technology have enhanced diagnosis rate of thyroid cancer, 
emerging environmental chemicals or physical agents have also been suggested to contribute to the 
increasing trend of incidence [17-19]. 
 
Since 1970s, polybrominated diphenyl ethers (PBDEs) have been widely used as flame retardants 
in a variety of commercial and household products, including plastics, furniture, upholstery, textiles, 
electrical equipment, and electronic devices [20]. Commercial PBDEs are usually present as 
mixtures of various congeners combined in different percentages. Because PBDEs are physically 
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mixed into products as additives, rather than chemically bond with polymer resins, they have a 
potential to release into environment through production process or from products usage [21]. The 
environmental PBDEs are persistent, with degradation half-lives in the order of years [22]. Due to 
their high lipophilicity, PBDEs could also bioaccumulate and be biomagnified through food chains 
[23, 24]. Humans could be exposed to environmental PBDEs via inhalation, dust ingestion, and 
dietary intake [20, 25]. 
 
The environment and human body burdens of PBDEs have been increasing rapidly worldwide in 
the last few decades. An approximately 100-fold increased levels of PBDEs in human populations 
have been noticed from 1970 to 2002 [26]. Despite concerns about increasing exposure and 
potential adverse health effects (e.g., immunotoxicity, endocrine disruption, and adverse effects on 
neurological development and reproductive system [25, 27-31]), the US government did not 
implement any regulations on PBDEs until 2004 [32, 33], and the prohibition on PBDEs only 
enacted in 10 US states so far [33]. Even with increased regulation, PBDEs remain ubiquitous in 
environment due to their persistence and bioaccumulation [19, 20]. Although some investigations 
suggest a moderate decline of PBDE body burdens approximately after 2000 [33, 34], others have 
reported a significant increase of several PBDE congeners from 2011 to 2015 [32, 35]. The 
observed trends suggest PBDEs could be following the trend of other legacy pollutants, where 
temporal declines were followed by an exposure plateau that persisted for decades [32, 34]. 
 
Emerging evidence indicates that exposure to PBDEs is related to disruption of thyroid hormone 
homeostasis [36-38]. Since the chemical structures of PBDE congeners are similar to those of 
thyroid hormones (i.e., triiodothyronine [T3] and thyroxine [T4]), the hydroxylated metabolites of 
PBDE congeners could competitively bind to thyroid hormone transport proteins and receptors [19]. 
Additionally, PBDEs can induce the activity of major thyroid hormone metabolic enzymes, 
including cytochrome P450 isozymes (CYPs), uridine 5'-diphospho-glucuronosyltransferases 
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(UDPGTs), sulfotransferases (SULTs), and deiodinases [19]. Thus, PBDEs can affect the 
distribution and metabolism of T3 and T4. The disruption of thyroid hormone homeostasis could 
further influence the secretion of thyroid stimulating hormone (TSH) through a negative feedback 
loop on the hypothalamus-pituitary-thyroid axis. 
 
Although the association between exposure to PBDEs and risk of thyroid cancer is still unclear, it 
is biologically possible that PBDEs can increase the risk of thyroid cancer through disruption of 
thyroid hormone homeostasis. Since TSH plays an essential role in regulating thyroid function and 
increasing thyroid cell proliferation [39], thyroid carcinogenesis can be caused by fluctuation of 
TSH level or disruption of thyroid hormone homeostasis, which inversely regulates the secretion 
of TSH. The associations between dysregulation of TSH and thyroid hormones and risk of thyroid 
cancer have been suggested by several previous epidemiological studies [40-42]. However, there 
is still lacking evidence neither on association between PBDEs and risk of thyroid cancer nor on 
potential mediation effect of TSH and thyroid hormones on this association. Animal studies of 
carcinogenic effects of PBDEs are limited to deca-brominated diphenyl ethers (deca-BDEs). These 
studies reported a slightly elevated incidence of thyroid gland adenoma or carcinoma (combined) 
and a significantly increased incidence of follicular cell hyperplasia, which is considered as a 
precursor of thyroid tumors, in exposed mice [20]. Thus far, only three epidemiological studies 
have investigated the relationship between exposure to PBDEs and risk of thyroid cancer and have 
reached inconsistent results. A population-based case-control study from Connecticut reported 
some suggestive evidence of an inverse association between serum level of BDE-209 and PTC in 
250 female cases and 250 female controls frequency matched on age [43], while one hospital-based 
case-control study investigated PBDEs in house dust and serum samples of 70 PTC cases and 70 
non-cancer controls, and reported a positive association with the dust level of BDE-209 [44]. 
Another nested case-control study including 104 incident thyroid cancer cases and 208 individually 
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matched controls from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Cohort 
did not find any associations [45]. 
 
Based on the biologically possible effects of PBDEs and thyroid hormones on the risk of thyroid 
cancer, mutations in genes coding for enzymes involved in regulation, metabolism, or functional 
activation of PBDEs and thyroid hormones could modify the PBDEs and thyroid hormones related 
risk of thyroid carcinogenesis. Some genes involved in metabolism/detoxification enzymes (e.g., 
CYP1A1, CYP2D6, CYP2E1, GSTM1, and GSTT1) have been suggested to be associated with 
thyroid cancer [46-49]. One study examined the modification effects of genetic variants in 
metabolism/detoxification pathways on the associations between tobacco and alcohol use and risk 
of PTC, and reported significant interactions between CYP26B1 and cigarette smoking and between 
UGT2B7 and alcohol consumption [50]. However, no study has investigated the effects of genetic 
polymorphisms on the association between environmental chemicals and thyroid cancer. 
 
Using data from a nested case-control study including 742 pairs of PTC cases and individually 
matched controls with pre-diagnostic serum concentrations of PBDEs and thyroid hormones from 
the Department of Defense Serum Repository (DoDSR), we tested the hypothesis that exposure to 
elevated PBDEs increases the risk of PTC and the increased risk posed by PBDEs is through the 
disruption of thyroid hormones. We also investigated the effects of genetic variants in genes 
involved in metabolism/detoxification of PBDEs and thyroid hormones on the association between 
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Background: A nested case-control study was carried out using data from the Department of 
Defense cohort to investigate the associations of papillary thyroid cancer (PTC) with serum 
concentrations of polybrominated diphenyl ethers (PBDEs) and polybrominated biphenyls (PBBs). 
 
Methods: This study included 742 (341 women and 401 men) histologically confirmed PTC cases 
and 742 matched controls with pre-diagnostic serum samples from the Department of Defense 
Serum Repository. Lipid-corrected serum concentrations of seven PBDE congeners and one PBB 
congener were measured. Multivariate conditional logistic regression analyses were performed for 
classical PTC and follicular variant of PTC, respectively. We also examined effect modification by 
gender. 
 
Results: BDE-28 was associated with significantly increased risk of classical PTC [OR=2.09; 95% 
CI, 1.05, 4.15, for the 3rd tertile vs. below limit of detection; Ptrend=0.02] adjusting for other 
congeners, body mass index, and branch of military service. This association was mainly observed 
for larger classical PTC (tumor size >10 mm) with a significantly stronger association among 
women than men (Pinteraction=0.004). No consistent associations were observed for other PBDE and 
PBB congeners, including those at higher concentrations. 
 
Conclusions: This study found a significantly increased risk of classical PTC associated with 
increasing levels of BDE-28. The risk varied by gender and tumor size. 
 





Thyroid cancer is the most prevalent cancer of the endocrine system, and its incidence has been 
increasing faster than any other malignancy [1]. In the United States, the incidence of thyroid cancer 
increased by 148% among men (from 3.1 to 7.7 per 100,000 persons) and by 247% among women 
(from 6.4 to 22.2 per 100,000 persons) between 1975 and 2014 [5]. A pattern of increasing rates 
was also observed in the US military personnel, among men (from 2.53 to 2.76 per 100,000 persons) 
and women (from 9.62 to 13.51 per 100,000 persons) between the periods 1990-1997 and 1998-
2004, and the incidence was significantly higher in military women than women in the general 
population for ages 20-49 years [51]. The majority of increase is in papillary thyroid cancer (PTC), 
which is the most common histologic type and accounts for more than 80% of all thyroid 
carcinomas [6, 7]. While the increased detection of occult disease has contributed to the increasing 
trend, environmental chemicals or physical agents have also been suggested to play a role [18, 19, 
52]. 
 
Since 1970s, polybrominated diphenyl ethers (PBDEs) and polybrominated biphenyls (PBBs) have 
been widely used as flame retardants in the US general and military population in a variety of 
commercial and household products, including plastics, furniture, upholstery, textiles, electrical 
equipment, and electronic devices [40, 41]. Since PBDEs and PBBs are physically mixed into 
products, they have the potential to release into the environment and enter the human body [40, 41]. 
The environmental and human levels of PBDEs have been increasing rapidly in the last three 
decades [19]. Due to concerns about increasing exposure and potential adverse health effects, the 
US government banned the production of PBBs in 1976 increased regulations on PBDEs in 2004 
[53, 54]. Despite this, PBDEs and PBBs remain ubiquitous in the environment and are being 
detected in human populations due to their persistence and bioaccumulation [19, 41]. Among 
Michigan women exposed to PBBs in an accidental contamination of food supply (1973-1974), 
their blood concentrations of PBB-153 in 2004 were still substantially higher as compared with the 
National Health and Nutrition Examination Survey (NHANES) data 2003-2004 [55, 56]. Although 
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some investigations on temporal trends of PBDE body burdens suggest a moderate decline starting 
approximately after 2000 [54, 57], others have reported a significant increase of several PBDE 
congeners from 2011-2015 [53, 58]. The observed trends suggest PBDEs could be following the 
trend of other legacy pollutants, where temporal declines were followed by an exposure plateau 
that persisted for decades [53, 57]. 
 
Experimental evidence has suggested that exposures to PBDEs and PBBs are related to disruption 
of thyroid hormone homeostasis and thyroid function in vitro and in rats [59, 60], but 
epidemiological studies have yielded conflicting findings in the associations between PBDE and 
PBB exposures and thyroid function [55, 61-63]. 
 
Animal studies of carcinogenic effects of PBDEs are limited to deca-brominated diphenyl ethers 
(BDE). These studies report a slightly elevated incidence of thyroid gland adenoma or carcinoma 
(combined) and a significantly increased incidence of follicular cell hyperplasia, which is 
considered as a precursor of thyroid tumors, in exposed mice [40]. To our knowledge, only three 
epidemiological studies have investigated the relationship between exposure to PBDEs and risk of 
thyroid cancer. One study, including 70 PTC cases and 70 controls, reported a positive association 
with BDE-209 [44], while another two studies, one including 104 cases and 207 controls and the 
other including 250 female cases and 250 female controls, did not find any positive association 
with PBDEs or PBBs [43, 45]. 
 
Considering parallel increasing trends of thyroid cancer incidence and PBDE body burdens, 
combined with the paucity of epidemiological studies directly investigating their association, we 
conducted a nested case-control study using data from the Department of Defense (DoD) 
Automated Central Tumor Registry (ACTUR) and the Defense Medical Surveillance System 
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(DMSS), with pre-diagnostic serum samples from the Department of Defense Serum Repository 




Detailed information regarding the study design has been described [64]. In brief, 742 pairs of PTC 
cases and controls were selected from US military personnel who had serum samples stored in the 
DoDSR. Serum samples from all military members were drawn during active duty. Inclusion 
criteria for cases: (i) histologically confirmed (ICD-O-3: 8050, 8260, and 8340-8343); (ii) at least 
three 0.5-mL pre-diagnostic (total 1.5 mL) and one 0.5-mL post-diagnostic serum samples stored 
in the DoDSR since 1989; (iii) diagnosis between 2000 and 2013; (iv) age 21 years or older at 
diagnosis, and (v) without any cancers (except for non-melanoma skin cancer) prior to the date of 
PTC diagnosis. Controls who had no diagnosis with any cancer (except for non-melanoma skin 
cancer) were randomly selected and individually matched to cases on date of birth (±1 year), gender, 
race/ethnicity, and midpoint of dates of the selected four samples drawn (±1 year). Demographic 
and military characteristics for all participants were abstracted from the DMSS. All study 
procedures were approved by the Uniformed Services University Institutional Review Board, the 
Walter Reed National Military Medical Center, the DoD Joint Pathology Center, and the Human 
Investigation Committee of Yale University. The involvement of the Centers for Disease Control 
and Prevention (CDC) laboratory did not constitute engagement in human subjects research. 
 
Measurement of PBDEs and PBBs 
Serum concentrations of PBDEs and PBBs were measured in the earliest pre-diagnostic serum 
sample. The measurement was conducted at the Persistent Organic Pollutants Laboratory, CDC 
(Atlanta, Georgia). The methodology used has been published [65]. Briefly, the serum samples 
were at first automatically fortified with internal standards using Gilson 215 liquid handler (Gilson, 
 
10 
Inc.; Middleton, WI). The samples were then extracted by automated liquid-liquid extraction (LLE) 
using a liquid handler. Removal of co-extracted lipids were performed on a silica: silica/sulfuric 
acid column using the Rapid Trace (Biotage; Uppsala, Sweden) equipment for automation. The 
final analytical determinations of PBDE and PBB congeners were performed by using gas 
chromatography isotope dilution high resolution mass spectrometry (GC-ID/HRMS) employing a 
DFSTM (Thermo DFS, Bremen, Germany) instrument. 
 
Laboratory personnel were blinded to case and control status. Internal laboratory controls included 
method blanks (n=3) and duplicates (n=3) in every set of 24 study samples. Serum concentrations 
of PBDE and PBB congeners were reported as the concentration after subtraction of the median 
amount of the congener present as a contaminant in blank samples. 
 
A total of 11 PBDE congeners and one PBB congener were measured (Table 1). The detection rates 
for each PBDE and PBB congener were similar among cases and controls (p-values from the χ2 
tests ranged 0.089-0.90). Levels of the 12 congeners were reported as lipid-corrected serum 
concentration (ng/g of serum lipid). The distributions of the concentrations were similar between 
cases and controls (p-values from the Mann-Whitney U tests ranged 0.14-0.74). We also examined 
the distributions of concentrations by participants’ demographic characteristics and military 
services, and summarized the results in Supplementary Tables 1 and 2. 
 
Statistical analyses 
The distributions of demographic and military characteristics were compared between cases and 
controls using the χ2 test. Since the distributions of lipid-corrected serum concentrations of PBDE 
and PBB congeners were right skewed, they were compared between cases and controls using the 




Among the 12 congeners measured, seven PBDE congeners (BDE-28, -47, -85, -99, -100, -153, 
and -154) and the PBB congener (BB-153) that were detected in >20% of the control samples were 
included in the final analyses. For the five congeners with ≤25% of data below the limits of 
detection (LODs) (BDE-47, -99, -100, -153, and BB-153), the lipid-corrected serum concentrations 
were categorized into quartiles based on the distribution among controls, with the first quartile used 
as the reference category. For congeners with >25% of data below the LODs (BDE-28, -85, and -
154), the reference values were defined as those below the LODs, and the values above the LODs 
were categorized into tertiles. 
 
Given the individual-matched case-control design, conditional logistic regression models were 
employed to estimate the associations between risk of PTC and levels of PBDE and PBB congeners. 
We applied two approaches: single chemical models and multi-chemical models. Both single and 
multi-chemical models were adjusted for body mass index (BMI) and branch of military service. 
Additional adjustment for the years between serum sample collection and PTC diagnosis did not 
change the results, so this variable was not included in the final models. In the single chemical 
models, the associations between risk of PTC and concentrations of each PBDE congener and the 
PBB-153 were individually estimated. In the multi-chemical model, we included all the categorical 
PBDE and PBB congeners in one model to additionally control for potential confounding effects 
from other congeners. Given that the categorized congeners were not highly correlated (Cramer's 
Vs ranged 0.05-0.73; Supplementary Table 3), the estimated associations are not likely to be 
affected by multicollinearity. 
 
Statistical analyses were performed for histologic subtype, classical PTC (ICD-O-3: 8050, 8260, 
8341-8343) and follicular variant of PTC (ICD-O-3: 8340), respectively. Further stratified analyses 
were conducted by tumor size (classical PTC microcarcinoma with tumor size ≤10 mm and large 
classical PTC with tumor size >10 mm) and then by gender among classical PTC cases and matched 
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controls, but not for follicular variant of PTC due to small case numbers. Dose-response 
relationships were investigated using tests for trend by assigning each participant the quartile 
number of PBDE and PBB congeners. A sensitivity analysis was conducted by excluding 
participants whose serum samples were drawn within a likely latency period (<5 years before 
diagnosis) among classical PTC cases and matched controls [66]. The remaining participants were 
stratified by tumor size and each cut-point of years between the time of serum sample collection 
and PTC diagnosis (5-12 years) to evaluate if the timing of sample collection modified the 
associations. 
 
Since a variety of PBDE congeners usually exist in a certain product, exposure to one congener is 
likely to be correlated with exposure to others that containing in the same product. The high 
correlation between PBDE congeners could lead to an issue of multicollinearity, which confounds 
the estimated effect of each congener on risk of PTC. Thus, the estimates from single- and multiple-
chemical conditional logistic regression models are further confirmed by performing alternative 
statistical methods, including principal component analysis (PCA) and conditional logistic 
regression with elastic net penalties, to avoid the effect of multicollinearity. The principal 
components created by PCA are included in one conditional logistic regression model to test their 
associations with risk of PTC. 
 
All tests were 2-sided with α=0.05. Since seven PBDE and one PBB congeners were included in 
the final analysis, a Bonferroni adjusted α of 0.05/8=0.006 was applied to control for multiple 
comparisons. Because single and multi-chemical models provided similar risk estimates, all results 
are presented from the multi-chemical models. All statistical analyses were conducted using SAS 





As shown in Table 2, PTC cases were more likely to have served in the Army or Air Force at the 
time of diagnosis, whereas controls were more likely to have served in the Navy or Marines/Coast 
Guard. Because of matching criteria, distributions of age, gender, race/ethnicity, and date of sample 
drawn were similar between cases and controls. Distribution of BMI was also similar between cases 
and controls, although there was a high percentage of participants with missing BMI data. 
 
All serum samples used for the measurement of PBDEs and PBBs were drawn from 1994-2009 
and between 1,132-4,383 days (approximately 3-12 years) before the cases were diagnosed with 
PTC. The median age at sample collection was 25 years, with interquartile range (IQR) from 21-
32 years. 
 
An elevated risk of classical PTC was associated with higher levels of BDE-28 (OR=2.09; 95% CI, 
1.05, 4.15 for the 3rd tertile vs. <LOD; Ptrend=0.020) (Table 3), although the Ptrend was no longer 
significant after the Bonferroni adjustment. A borderline significantly reduced OR was observed 
for the 2nd tertile of BDE-85 (OR=0.43; 95% CI, 0.19, 0.99). There were no associations between 
individual PBDE congeners or PBB-153 and risk of follicular variant PTC. 
 
When the analyses were further stratified by tumor size of classical PTC, an increased risk 
associated with higher levels of BDE-28 was observed only for large classical PTC (OR=2.35; 95% 
CI, 1.15, 4.80 for the 2nd tertile vs. <LOD; OR=4.77; 95% CI, 1.84, 12.35 for the 3rd tertile vs. 
<LOD; Ptrend=0.0014) (Table 4). The Ptrend remained significant after the Bonferroni adjustment. 
There were significantly increased ORs for large classical PTC with BDE-154 for the 1st and 2nd 
tertiles vs. <LOD (OR=3.33; 95% CI, 1.50, 7.36 and OR=3.40; 95% CI, 1.18, 9.85, respectively), 
but not for the 3rd tertile vs. <LOD (Ptrend=0.039). For classical PTC microcarcinoma, there were 
significantly decreased ORs with BDE-154 for the 2nd and 3rd tertiles vs. <LOD (OR=0.15; 95% 
CI, 0.02, 0.93 and OR=0.04; 95% CI, 0.003, 0.51, respectively; Ptrend=0.017). A significantly 
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reduced OR was also observed for large classical PTC with the 2nd tertile of BDE-85 (OR=0.23; 
95% CI, 0.08, 0.65). No association was observed for the other PBDE and PBB congeners in 
relation to neither large classical PTC nor classical PTC microcarcinoma. 
 
Gender significantly modified the associations between levels of BDE-28 and risk of large classical 
PTC (Table 5). The association between serum levels of BDE-28 and risk of large classical PTC 
was stronger in women (OR=10.74; 95% CI, 1.93, 59.72 for the 3rd tertile vs. <LOD; Ptrend=0.0054) 
than men (OR=3.39; 95% CI, 0.98, 11.71 for the 3rd tertile vs. <LOD; Ptrend=0.071; 
Pinteraction=0.0040). After Bonferroni adjustment, the Ptrend remained significant only among women, 
and the effect modification by gender remained significant. No significant association was observed 
for the other PBDE and PBB congeners among either men or women. The null associations between 
levels of BDE-28 and risk of classical PTC microcarcinoma were among both men and women 
(Supplementary Table 4). 
 
The association between BDE-28 and risk of classical PTC was stronger after exclusion of case-
control pairs whose serum samples were drawn <5 years before cancer diagnosis (OR=1.80; 95% 
CI, 1.00, 3.21 for the 2nd tertile vs. <LOD; OR=2.53; 95% CI, 1.19, 5.36 for the 3rd tertile vs. <LOD; 
Ptrend=0.014) (Supplementary Table 5). The associations for most other congeners were also slightly 
strengthened in this sensitivity analysis. Similar associations were observed for BDE-153 before 
and after exclusion samples drawn <5 years from diagnosis. There was no effect modification by 
timing of sample collection for either large classical PTC or classical PTC microcarcinoma (data 
not shown). 
 
Results from the PCA suggested that the first component was associated with an increased risk of 
classical PTC (OR=1.96; 95% CI: 1.00, 1.12; P=0.043) (Supplementary Table 6). According to the 
eigenvector values, all PBDE congeners, except BDE-153, were almost equally correlated with this 
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component (eigenvectors ranged 0.3785-0.3971), which may suggest that PBDEs as a mixture is 
associated with increased risk of classical PTC. BDE-28 was the dominant congener in the third 
component. Increased value of the third component was mainly associated with decreased BDE-
28. Since the point estimate of OR was less than 1 with this component, this result may support a 
positive association between BDE-28 and risk of classical PTC. 
 
The penalized conditional logistic regression was conducted by including a penalty parameter in 
the multiple-chemical conditional logistic regression. When pure Lasso and pure ridge were used 
as penalty parameters, the ridge traces suggested that BDE-28 had the largest risk effect, while 
BDE-100 had the greatest protective effect, on the risk of classical PTC. Also, these effects were 
less influenced by collinearity between other congeners (Supplementary Figure 1). These results 
were consistent with findings that BDE-28 was associated with an increased risk of PTC. 
 
Discussion 
In this large nested case-control study among US military personnel, we found that increasing 
serum levels of BDE-28 were associated with an elevated risk of classical PTC. This association 
was mainly observed for classical PTC among cases with tumor size >10 mm, and was stronger 
among women. 
 
The geometric means of concentrations for BDE-28, -47, -99, -100, -153, and BB-153 in controls 
of this study were higher than those in the US general population from the NHANES 2003-2004 
[56]. When we restricted our comparisons to the subset of our study population with serum samples 
taken during 2003-2004, the geometric means were comparable to those in the NHANES 2003/04 
population. However, the 90th and 95th percentiles of concentrations for most PBDE and PBB 
congeners in this study population were lower than those in the NHANES 2003/04 population, 
indicating a more centralized range of concentrations in the current military population as compared 
 
16 
to the NHANES general population. A similar range of concentrations was only observed for BDE-
153 between the study population and NHANES 2003/04 population. 
 
Although accumulating evidence has illustrated that exposure to PBDEs and PBBs alters thyroid 
hormone homeostasis, the underlying mechanisms linking PBDEs and PBBs to thyroid cancer are 
not fully understood. Since the chemical structures of PBDE and PBB congeners are similar to 
those of thyroid hormones, the hydroxylated metabolites of PBDEs and PBBs could competitively 
bind to thyroid hormone transport proteins and receptors [19]. Additionally, PBDEs can induce 
thyroid hormone metabolic enzyme activity [19]. These two potential mechanisms suggested 
PBDEs and PBBs could disrupt thyroid hormone homeostasis and could contribute to cancer risk 
and severity [44]. 
 
A recent prospective cohort study [67] reported that significant decrements in thyroid stimulating 
hormone (TSH) levels of 3-year-olds were associated with increased prenatal serum concentrations 
of several PBDE congeners, including BDE-28. This inverse relationship was modified by child 
sex, with stronger decrease in TSH among females. Since there is an indication from two other 
prospective cohort studies [64, 68] that lower TSH levels are associated with a significantly 
increased risk of thyroid cancer, it is possible that elevated levels of BDE-28 increase the risk of 
classical PTC through the mediation of TSH. 
 
Although the latency period between chemical exposure and appearance of thyroid cancer is still 
unclear, a 5-10 years latency period has been reported for thyroid cancer after radiation exposure 
[66]. The present study included only samples collected ≥3 years before PTC diagnosis. We also 
observed a stronger association between BDE-28 and risk of classical PTC among cases whose 




To our knowledge, only three epidemiological studies have investigated the associations between 
PBDE congeners and risk of thyroid cancer. One hospital-based case-control study investigated 
PBDEs in house dust and serum samples of 70 PTC cases and 70 non-cancer controls [44]. An 
elevated risk of PTC associated with a higher dust level of BDE-209 was observed, but no 
association with serum concentrations of any PBDE congeners was reported. A nested case-control 
study including 104 incident thyroid cancer cases and 207 matched controls in the Prostate, Lung, 
Colorectal, and Ovarian (PLCO) Cancer Screening Trial Cohort reported no association between 
PBDEs and risk of thyroid cancer [45]. The main congener found to be associated with PTC risk 
in our study (i.e., BDE-28) had a low detection rate in both previous studies and the risk of thyroid 
cancer was not evaluated. Another population-based case-control study including 250 female cases 
and 250 female controls from Connecticut also did not find any positive association between 
PBDEs and PTC [43]. The lower serum concentrations of PBDEs in Connecticut women as 
compared to those in ours and other populations may contribute to the observed null associations. 
 
BDE-28 mainly exists in the penta-BDE commercial mixture [53], which is commonly used as 
flame retardant in flexible polyurethane foam, and is also used in printed circuit boards and other 
applications. A recent study reported a unique trend of BDE-28 body burdens, which was 
decreasing from 2008/09 to 2011/12, flattened between 2011/12 and 2014, and then increasing in 
2014, among pregnant women in California [53]. This recently increasing trend of BDE-28 may be 
due to the debromination of the higher brominated congeners [53], but still need to be further 
explored. 
 
The present study has several strengths. The sample size was relatively large, providing sufficient 
statistical power to investigate and compare the associations by gender, which is important because 
women are approximately three times more likely to develop thyroid cancer than men. The study 
population was composed entirely of US active-duty military personnel, a younger population 
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represents the age groups at which thyroid cancer risk is at its highest. Additionally, the single-
payer universal (i.e., equal access) military healthcare system minimizes potential selection bias 
from differences in access to medical care. Although we did not suspect a specific source of 
exposure to PBDEs related to military service, PBDEs are persistent, with half-lives range between 
3-12 years, and temporal trends of levels measured in the environment suggest that human exposure 
is widespread, despite bans on the various BDEs. The levels of PBDE and PBB congeners were 
prospectively assessed in the DoDSR cohort, which provides an opportunity to estimate potentially 
causal relationships between exposure to these chemicals and risk of thyroid cancer. 
 
The limitations of this study should also be considered. There was a lack of information on several 
potential confounding factors, such as ionizing radiation exposure, history of benign thyroid disease, 
and a family history of thyroid cancer. There were also a high percentage of participants with 
missing BMI data, which may have led to insufficient adjustment for BMI. Previous evidence has 
suggested lower prevalence of obesity and larger lean body mass of military personnel than the US 
civilian population [69], indicating less variation of BMI among the US military personnel. Thus, 
any effect of under-adjustment for BMI would likely be minimized in this study population. We 
also restricted the analysis among case-control pairs who had BMI measurements, the associations 
remained the same. Furthermore, the stratified analyses and the results for follicular variation of 
PTC may have yielded unstable results due to the small subgroup counts. It is also possible that the 
findings for BDE-28 were observed by chance due to the multiple comparisons. However, the 
association between BDE-28 and large classical PTC remained statistically significant after 
Bonferroni adjustment, indicating a true association. 
 
In conclusion, this large nested case-control study suggested a significantly increased risk of 
classical PTC associated with increasing levels of BDE-28. This increased risk was found for cases 
with a tumor size >10 mm, and particularly among women. Since a recent study reported an 
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increasing trend of BDE-28 concentrations in the serum of pregnant women in California between 
2008-2014 [53], and accumulative evidence has suggested potential adverse effects on the thyroid 
for PBDE alternatives [44, 70], further investigation into the association between BDE-28, other 
PBDE congeners and alternatives, and thyroid cancer is warranted. Additionally, more 
epidemiological studies among different populations are also warranted to confirm these findings 
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BDE-17 1.0 41 (5.5) 2.1 (2.0) <LOD (<LOD-<LOD)  30 (4.0) 1.9 (1.9) <LOD (<LOD-<LOD)  0.18 
BDE-28 1.1 251 (33.8) 3.0 (2.5) <LOD (<LOD-1.5)  236 (31.8) 2.6 (2.3) <LOD (<LOD-1.3)  0.25 
BDE-47 2.5 708 (95.4) 21.5 (3.7) 16.3 (7.9-38.8)  707 (95.3) 21.0 (3.2) 16.9 (8.4-38.6)  0.74 
BDE-66 1.2 66 (8.9) 2.9 (2.3) <LOD (<LOD-<LOD)  52 (7.0) 2.3 (2.1) <LOD (<LOD-<LOD)  0.15 
BDE-85 1.0 208 (28.0) 3.3 (3.0) <LOD (<LOD-1.0)  204 (27.5) 2.8 (2.6) <LOD (<LOD-1.0)  0.67 
BDE-99 2.0 549 (74.0) 9.1 (3.6) 4.3 (<LOD-10.6)  577 (77.8) 8.2 (3.2) 4.4 (2.2-10.6)  0.60 
BDE-100 1.0 621 (83.7) 5.7 (3.5) 3.4 (1.5-8.8)  643 (86.7) 5.4 (3.0) 3.7 (1.8-8.7)  0.43 
BDE-153 1.0 679 (91.5) 6.4 (3.4) 4.3 (2.1-11.5)  691 (93.1) 6.3 (3.0) 4.6 (2.5-11.2)  0.37 
BDE-154 1.0 217 (29.3) 3.0 (2.9) <LOD (<LOD-1.1)  209 (28.2) 2.6 (2.5) <LOD (<LOD-1.0)  0.56 
BDE-183 1.1 79 (10.7) 1.7 (2.0) <LOD (<LOD-<LOD)  85 (11.5) 1.5 (1.7) <LOD (<LOD-<LOD)  0.68 
BDE-209 5.2 62 (8.4) 9.7 (2.2) <LOD (<LOD-<LOD)  80 (10.8) 8.5 (1.8) <LOD (<LOD-<LOD)  0.14 
BB-153 1.0 544 (73.3) 3.0 (2.3) 2.0 (<LOD-3.5)   550 (74.1) 3.1 (2.2) 2.1 (0.9-3.6)   0.36 
Abbreviation: PBDE, polybrominated diphenyl ether; PBB, polybrominated biphenyl; PTC, papillary thyroid cancer; LOD: limit of detection; GSD, geometric 
standard deviation; IQR, interquartile range; BDE-17, 2,2',4-tribromodiphenyl ether; BDE-28, 2,4,4'-tribromodiphenyl ether; BDE-47, 2,2',4,4'-
tetrabromodiphenyl ether; BDE-66, 2,3',4',4-tetrabromodiphenyl ether; BDE-85, 2,2',3,4,4'-pentabromodiphenyl ether; BDE-99, 2,2',4,4',5-pentabromodiphenyl 
ether; BDE-100, 2,2',4,4',6-pentabromodiphenyl ether; BDE-153, 2,2',4,4',5,5'-hexabromodiphenyl ether; BDE-154, 2,2',4,4',5,6'-hexabromodiphenyl ether; 
BDE-183, 2,2',3,4,4',5',6-heptabromodiphenyl ether; BDE-209, 2,2',3,3',4,4',5,5',6,6'-decabromodiphenyl ether; BB-153, 2,2',4,4',5,5'-hexabromobiphenyl. 
a Calculated among cases and controls combined. 









  P-value a 
No. (%) No. (%) 
Age at serum samples collection (year)      
 <20 124 (16.7)  121 (16.3)   
 20-29 348 (46.9)  352 (47.4)   
 30-40 220 (29.7)  221 (29.8)   
 ≥40 50 (6.7)  48 (6.5)  0.99 
Age at diagnosis (year)      
 <30 210 (28.3)  203 (27.4)   
 30-39 310 (41.8)  323 (43.5)   
 40-49 185 (24.9)  179 (24.1)   
 ≥50 37 (5.0)  37 (5.0)  0.92 
Gender      
 Male 401 (54.0)  401 (54.0)   
 Female 341 (46.0)  341 (46.0)  1.00 
Ethnicity      
 White 468 (63.1)  467 (63.0)   
 Black 131 (17.7)  132 (17.8)   
 Hispanic 68 (9.2)  68 (9.2)   
 Other 55 (7.4)  55 (7.4)   
 Unknown 20 (2.7)  20 (2.7)  1.00 
BMI (kg/m2)      
 <25 257 (34.6)  285 (38.4)   
 25-29.9 148 (20.0)  129 (17.4)   
 ≥30 16 (2.2)  10 (1.4)   
 Missing 321 (43.3)  318 (42.9)  0.25 
Service      
 Army 300 (40.4)  263 (35.4)   
 Air Force 197 (26.6)  152 (20.5)   
 Marines and Coast Guard combined 61 (8.2)  83 (11.2)   
 Navy 184 (24.8)  244 (32.9)  0.0002 
Year of serum samples collection      
 1994-2000 570 (76.8)  571 (77.0)   
 2001-2004 135 (18.2)  133 (17.9)   
 2005-2009 37 (5.0)  38 (5.1)  0.99 
Years between serum samples collection and PTC diagnosis     
 <5 115 (15.5)  -   
 5-9 344 (46.4)  -   
 10-12 283 (38.1)  -  - 
Histologic subtype      
 Classical PTC 600 (80.9)  -   
 Follicular variation of PTC 142 (19.1)  -  - 
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Tumor size (mm)      
 ≤10 235 (31.7)  -   
 >10 463 (62.4)  -   
 Missing 44 (5.9)  -  - 
Abbreviation: BMI, body mass index; PTC, papillary thyroid cancer. 








Follicular variation of PTC 
Cases Controls ORa (95% CI) Cases Controls ORa (95% CI) 
BDE-28        
 <LOD 383 406 1.00  97 88 1.00 
 >LOD-1.56 55 63 0.91 (0.57, 1.45)  16 15 1.06 (0.40, 2.80) 
 1.57-3.18 68 62 1.58 (0.93, 2.69)  11 17 0.42 (0.12, 1.40) 
 3.19-80.10 87 61 2.09 (1.05, 4.15)  14 18 0.39 (0.07, 2.23) 
 P for trend b   0.020    0.35 
BDE-47        
 <LOD-8.43 159 150 1.00  36 32 1.00 
 8.44-16.91 141 150 1.16 (0.74, 1.81)  38 33 1.18 (0.43, 3.26) 
 16.92-38.63 137 142 1.37 (0.74, 2.54)  36 40 0.94 (0.24, 3.58) 
 38.64-2189.00 156 150 1.00 (0.41, 2.44)  28 33 2.74 (0.36, 20.64) 
 P for trend b   0.89    0.95 
BDE-85        
 <LOD 423 433 1.00  102 99 1.00 
 >LOD-1.68 61 55 1.06 (0.58, 1.95)  15 12 1.49 (0.41, 5.44) 
 1.69-3.18 30 56 0.43 (0.19, 0.99)  6 13 1.18 (0.21, 6.52) 
 3.19-79.08 81 53 1.76 (0.57, 5.47)  15 15 4.98 (0.31, 79.67) 
 P for trend b   0.64    0.34 
BDE-99        
 <LOD-2.17 168 149 1.00  40 35 1.00 
 2.18-4.40 133 150 0.87 (0.55, 1.35)  29 34 0.93 (0.37, 2.35) 
 4.41-10.61 142 147 0.92 (0.52, 1.62)  39 37 1.88 (0.53, 6.69) 
 10.62-993.30 152 151 0.86 (0.39, 1.87)  30 33 1.65 (0.32, 8.45) 
 P for trend b   0.59    0.22 
BDE-100        
 <LOD-1.84 177 151 1.00  39 31 1.00 
 1.85-3.71 134 148 0.73 (0.46, 1.18)  36 35 0.53 (0.19, 1.47) 
 3.72-8.65 120 144 0.61 (0.32, 1.17)  39 38 0.33 (0.07, 1.53) 
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 8.66-368.00 162 149 0.67 (0.27, 1.65)  24 34 0.19 (0.03, 1.41) 
 P for trend b   0.29    0.13 
BDE-153        
 <LOD-2.49 176 146 1.00  36 38 1.00 
 2.50-4.61 134 155 0.82 (0.57, 1.18)  38 29 1.91 (0.84, 4.36) 
 4.62-11.23 122 154 0.69 (0.45, 1.08)  39 30 2.08 (0.81, 5.35) 
 11.24-285.50 163 142 0.94 (0.55, 1.61)  25 42 0.78 (0.24, 2.57) 
 P for trend b   0.71    0.94 
BDE-154        
 <LOD 412 426 1.00  102 95 1.00 
 >LOD-1.60 60 54 1.49 (0.82, 2.70)  16 15 0.97 (0.29, 3.29) 
 1.61-3.11 50 57 1.37 (0.61, 3.07)  6 13 0.39 (0.07, 2.26) 
 3.12-66.22 71 55 0.61 (0.19, 1.99)  14 15 0.85 (0.06, 13.17) 
 P for trend b   0.49    0.76 
BB-153        
 <LOD-0.85 154 149 1.00  37 33 1.00 
 0.86-2.12 146 146 0.91 (0.65, 1.28)  38 37 0.87 (0.41, 1.84) 
 2.13-3.60 152 155 0.85 (0.60, 1.21)  31 27 1.25 (0.56, 2.79) 
 3.61-451.30 141 142 0.92 (0.65, 1.31)  32 41 0.76 (0.35, 1.68) 
 P for trend b   0.47    0.60 
Abbreviation: BB-153, 2,2',4,4',5,5'-hexabromobiphenyl; BDE-28, 2,4,4'-tribromodiphenyl ether; BDE-47, 2,2',4,4'-tetrabromodiphenyl ether; 
BDE-85, 2,2',3,4,4'-pentabromodiphenyl ether; BDE-99, 2,2',4,4',5-pentabromodiphenyl ether; BDE-100, 2,2',4,4',6-pentabromodiphenyl ether; 
BDE-153, 2,2',4,4',5,5'-hexabromodiphenyl ether; BDE-154, 2,2',4,4',5,6'-hexabromodiphenyl ether; BMI, body mass index; LOD: limit of 
detection; OR, odds ratio; PBB, polybrominated biphenyl; PBDE, polybrominated diphenyl ether; PTC, papillary thyroid cancer. 
a Multi-chemical conditional logistic regression, adjusted for all PBDE and PBB congeners, BMI (<18.5, 18.5-24.9, 25-29.9, ≥30 kg/m2, and 
missing), and branch of military service (Army, Air Force, Navy, and Marines/Coast Guard). 









Cases Controls ORa (95% CI) Cases Controls ORa (95% CI) 
BDE-28        
 <LOD 141 125 1.00  215 249 1.00 
 >LOD-1.56 14 22 0.47 (0.19, 1.19)  40 39 1.33 (0.73, 2.42) 
 1.57-3.18 22 22 0.82 (0.30, 2.22)  43 37 2.35 (1.15, 4.80) 
 3.19-80.10 25 30 0.55 (0.16, 1.87)  58 31 4.77 (1.84, 12.35) 
 P for trend b   0.57    0.0014 
BDE-47        
 <LOD-8.43 62 48 1.00  89 91 1.00 
 8.44-16.91 44 47 0.99 (0.43, 2.32)  84 92 1.27 (0.70, 2.30) 
 16.92-38.63 44 50 1.23 (0.41, 3.76)  87 81 1.49 (0.65, 3.46) 
 38.64-2189.00 52 54 2.86 (0.48, 17.10)  96 92 0.61 (0.18, 2.10) 
 P for trend b   0.54    0.75 
BDE-85        
 <LOD 151 142 1.00  244 258 1.00 
 >LOD-1.68 19 22 2.68 (0.81, 8.83)  39 30 0.61 (0.27, 1.38) 
 1.69-3.18 7 14 3.93 (0.52, 29.91)  22 41 0.23 (0.08, 0.65) 
 3.19-79.08 25 24 13.41 (0.97, 185.94)  53 29 0.93 (0.23, 3.83) 
 P for trend b   0.017    0.067 
BDE-99        
 <LOD-2.17 63 50 1.00  94 87 1.00 
 2.18-4.40 44 47 0.95 (0.42, 2.15)  82 92 0.83 (0.46, 1.52) 
 4.41-10.61 46 49 1.16 (0.42, 3.19)  86 88 0.74 (0.34, 1.62) 
 10.62-993.30 49 56 0.90 (0.19, 4.34)  96 91 0.68 (0.24, 1.92) 
 P for trend b   0.92    0.46 
BDE-100        
 <LOD-1.84 69 49 1.00  97 86 1.00 
 1.85-3.71 43 48 0.57 (0.25, 1.33)  82 95 0.66 (0.35, 1.25) 
 3.72-8.65 43 49 0.51 (0.16, 1.65)  70 82 0.61 (0.25, 1.48) 
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 8.66-368.00 47 53 0.26 (0.05, 1.32)  107 93 0.83 (0.24, 2.82) 
 P for trend b   0.094    0.72 
BDE-153        
 <LOD-2.49 67 49 1.00  98 86 1.00 
 2.50-4.61 48 57 0.76 (0.40, 1.44)  76 86 0.94 (0.58, 1.53) 
 4.62-11.23 38 55 0.80 (0.37, 1.76)  81 87 0.84 (0.47, 1.50) 
 11.24-285.50 49 41 2.74 (0.96, 7.86)  103 99 0.66 (0.33, 1.32) 
 P for trend b   0.21    0.33 
BDE-154        
 <LOD 155 135 1.00  230 258 1.00 
 >LOD-1.60 14 20 0.35 (0.11, 1.14)  44 31 3.33 (1.50, 7.36) 
 1.61-3.11 10 18 0.15 (0.02, 0.93)  37 38 3.40 (1.18, 9.85) 
 3.12-66.22 23 26 0.04 (0.003, 0.51)  45 29 1.74 (0.39, 7.80) 
 P for trend b   0.017    0.039 
BB-153        
 <LOD-0.85 48 43 1.00  92 92 1.00 
 0.86-2.12 51 49 1.02 (0.55, 1.90)  88 84 0.81 (0.51, 1.28) 
 2.13-3.60 55 54 0.86 (0.46, 1.62)  90 95 0.74 (0.47, 1.18) 
 3.61-451.30 48 53 0.87 (0.45, 1.67)  86 85 0.85 (0.54, 1.36) 
 P for trend b   0.42    0.67 
Abbreviation: BB-153, 2,2',4,4',5,5'-hexabromobiphenyl; BDE-28, 2,4,4'-tribromodiphenyl ether; BDE-47, 2,2',4,4'-tetrabromodiphenyl ether; BDE-
85, 2,2',3,4,4'-pentabromodiphenyl ether; BDE-99, 2,2',4,4',5-pentabromodiphenyl ether; BDE-100, 2,2',4,4',6-pentabromodiphenyl ether; BDE-153, 
2,2',4,4',5,5'-hexabromodiphenyl ether; BDE-154, 2,2',4,4',5,6'-hexabromodiphenyl ether; BMI, body mass index; LOD: limit of detection; OR, odds 
ratio; PBB, polybrominated biphenyl; PBDE, polybrominated diphenyl ether; PTC, papillary thyroid cancer. 
a Multi-chemical conditional logistic regression, adjusted for all PBDE and PBB congeners, BMI (<18.5, 18.5-24.9, 25-29.9, ≥30 kg/m2, and missing), 
and branch of military service (Army, Air Force, Navy, and Marines/Coast Guard). 




Table 5. Risk of large classical PTC (>10 mm) associated with lipid-corrected serum concentrations of PBDE and PBB congeners (ng/g), 







interaction b Cases Controls ORa (95% CI) Cases Controls ORa (95% CI) 
BDE-28          
 <LOD 129 138 1.00  86 111 1.00   
 >LOD-1.56 25 21 1.50 (0.69, 3.26)  15 18 1.13 (0.39, 3.30)   
 1.57-3.18 26 25 2.07 (0.86, 4.94)  17 12 3.56 (0.87, 14.63)   
 3.19-80.10 26 20 3.39 (0.98, 11.71)  32 11 10.74 (1.93, 59.72)   
 P for trend b   0.071    0.0054  0.0040 
BDE-47          
 <LOD-8.43 52 50 1.00  37 41 1.00   
 8.44-16.91 52 46 1.26 (0.56, 2.82)  32 46 1.43 (0.57, 3.59)   
 16.92-38.63 56 54 0.94 (0.31, 2.87)  31 27 3.08 (0.79, 12.02)   
 38.64-2189.00 46 54 0.41 (0.08, 2.12)  50 38 0.67 (0.07, 6.09)   
 P for trend b   0.47    0.70  0.0095 
BDE-85          
 <LOD 148 142 1.00  96 116 1.00   
 >LOD-1.68 25 23 0.56 (0.21, 1.45)  14 7 1.03 (0.17, 6.40)   
 1.69-3.18 11 21 0.28 (0.08, 1.02)  11 20 0.17 (0.02, 1.49)   
 3.19-79.08 22 19 0.40 (0.07, 2.52)  31 10 2.46 (0.12, 51.74)   
 P for trend b   0.065    0.50  0.0087 
BDE-99          
 <LOD-2.17 54 47 1.00  40 40 1.00   
 2.18-4.40 51 50 0.89 (0.39, 2.03)  31 42 0.72 (0.29, 1.81)   
 4.41-10.61 52 52 1.02 (0.34, 3.02)  34 36 0.48 (0.14, 1.61)   
 10.62-993.30 49 56 1.00 (0.24, 4.25)  47 35 0.51 (0.09, 2.85)   
 P for trend b   0.92    0.33  0.036 
BDE-100          
 <LOD-1.84 55 45 1.00  42 41 1.00   
 1.85-3.71 49 48 0.74 (0.31, 1.77)  33 47 0.58 (0.21, 1.56)   
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 3.72-8.65 46 52 0.73 (0.22, 2.35)  24 30 0.43 (0.10, 1.89)   
 8.66-368.00 56 59 0.89 (0.18, 4.36)  51 34 0.91 (0.09, 9.18)   
 P for trend b   0.88    0.60  0.014 
BDE-153          
 <LOD-2.49 48 32 1.00  50 54 1.00   
 2.50-4.61 45 49 0.78 (0.40, 1.54)  31 37 0.95 (0.44, 2.07)   
 4.62-11.23 51 55 0.82 (0.38, 1.76)  30 32 0.70 (0.25, 1.96)   
 11.24-285.50 62 69 0.59 (0.23, 1.55)  41 30 0.59 (0.18, 1.91)   
 P for trend b   0.39    0.50  0.077 
BDE-154          
 <LOD 139 141 1.00  91 117 1.00   
 >LOD-1.60 28 22 2.57 (0.98, 6.73)  16 9 4.43 (0.94, 20.80)   
 1.61-3.11 18 24 2.59 (0.69, 9.64)  19 14 4.65 (0.56, 38.40)   
 3.12-66.22 21 17 3.45 (0.52, 22.96)  24 12 0.54 (0.02, 13.54)   
 P for trend b   0.061    0.40  0.0070 
BB-153          
 <LOD-0.85 41 34 1.00  51 58 1.00   
 0.86-2.12 41 41 0.66 (0.32, 1.35)  47 43 0.84 (0.44, 1.63)   
 2.13-3.60 61 63 0.67 (0.35, 1.27)  29 32 0.83 (0.40, 1.75)   
 3.61-451.30 63 66 0.70 (0.37, 1.34)  23 19 0.99 (0.42, 2.32)   
 P for trend b   0.46    0.92  0.16 
Abbreviation: BB-153, 2,2',4,4',5,5'-hexabromobiphenyl; BDE-28, 2,4,4'-tribromodiphenyl ether; BDE-47, 2,2',4,4'-tetrabromodiphenyl 
ether; BDE-85, 2,2',3,4,4'-pentabromodiphenyl ether; BDE-99, 2,2',4,4',5-pentabromodiphenyl ether; BDE-100, 2,2',4,4',6-
pentabromodiphenyl ether; BDE-153, 2,2',4,4',5,5'-hexabromodiphenyl ether; BDE-154, 2,2',4,4',5,6'-hexabromodiphenyl ether; BMI, body 
mass index; LOD: limit of detection; OR, odds ratio; PBB, polybrominated biphenyl; PBDE, polybrominated diphenyl ether; PTC, papillary 
thyroid cancer. 
a Multi-chemical conditional logistic regression, adjusted for all PBDE and PBB congeners, BMI (<18.5, 18.5-24.9, 25-29.9, ≥30 kg/m2, and 
missing), and branch of military service (Army, Air Force, Navy, and Marines/Coast Guard). 




Supplementary Table 1. Geometric means and GSDs of lipid-corrected serum concentrations of selected PBDE and PBB congeners (ng/g) 
among PTC cases by demographic characteristics and military services. 
  BDE-28 BDE-47 BDE-85 BDE-99 BDE-100 BDE-153 BDE-154 BB-153 
Age at serum samples collection (year)           
 <20 2.3 (2.2) 17.2 (3.0) 2.6 (2.4) 7.8 (2.8) 4.9 (2.9) 6.1 (3.0) 2.5 (2.4) 2.2 (2.0) 
 20-30 3.2 (2.6) 26.5 (3.8) 3.4 (3.3) 10.1 (3.8) 6.7 (3.5) 7.4 (3.5) 3.0 (3.0) 2.7 (2.2) 
 30-40 3.1 (2.6) 19.0 (3.8) 4.1 (2.9) 8.8 (3.8) 5.2 (3.7) 5.6 (3.6) 3.4 (2.8) 3.6 (2.1) 
 ≥40 2.4 (2.1) 16.0 (3.5) 2.0 (2.6) 7.2 (3.6) 4.4 (3.5) 4.4 (3.1) 2.3 (2.7) 4.3 (2.9) 
Age at diagnosis (year)         
 <30 2.6 (2.1) 19.1 (3.3) 2.8 (2.6) 8.7 (3.1) 5.5 (3.1) 6.4 (3.2) 2.4 (2.5) 2.1 (2.0) 
 30-39 3.2 (2.8) 25.0 (3.8) 3.5 (3.5) 9.4 (3.8) 6.1 (3.6) 7.0 (3.4) 3.2 (3.2) 3.0 (2.3) 
 40-49 3.1 (2.4) 20.6 (3.9) 3.7 (2.8) 9.4 (3.6) 5.7 (3.7) 5.7 (3.7) 3.2 (2.7) 3.7 (2.2) 
 ≥50 2.4 (2.3) 14.6 (3.7) 2.5 (2.7) 7.5 (4.0) 4.4 (4.0) 5.2 (3.5) 2.9 (2.6) 4.1 (2.6) 
Gender         
 Male 2.7 (2.6) 19.7 (3.5) 2.7 (3.0) 8.0 (3.3) 5.5 (3.4) 6.6 (3.4) 2.6 (2.8) 3.4 (2.4) 
 Female 3.4 (2.4) 23.9 (3.9) 4.1 (2.9) 10.6 (3.9) 6.1 (3.6) 6.1 (3.5) 3.4 (2.9) 2.6 (2.0) 
Ethnicity         
 White 3.0 (2.5) 21.4 (3.7) 3.4 (3.1) 9.0 (3.6) 5.8 (3.6) 7.0 (3.6) 3.1 (3.0) 3.0 (2.2) 
 Black 3.8 (2.5) 24.4 (4.2) 4.2 (3.1) 10.9 (4.1) 6.2 (3.7) 5.9 (3.3) 3.6 (2.8) 3.5 (2.6) 
 Hispanic 2.7 (2.6) 20.9 (3.4) 2.7 (2.5) 8.1 (3.2) 5.4 (3.3) 6.0 (3.2) 2.8 (2.5) 2.0 (1.9) 
 Other 2.1 (1.9) 17.3 (3.1) 1.7 (1.7) 7.1 (2.6) 4.6 (2.6) 4.3 (2.5) 1.6 (1.6) 2.9 (2.5) 
 Unknown 2.8 (3.5) 23.0 (4.1) 2.7 (4.1) 10.5 (4.4) 5.2 (3.8) 5.0 (3.4) 2.9 (4.4) 3.2 (2.2) 
BMI (kg/m2)         
 <25 2.9 (2.3) 20.5 (3.2) 3.0 (2.8) 8.2 (3.2) 5.3 (3.1) 6.5 (3.2) 2.8 (2.7) 2.7 (2.2) 
 25-29.9 2.4 (2.3) 22.8 (3.4) 2.7 (2.8) 9.3 (3.3) 5.8 (3.2) 6.5 (3.1) 2.6 (2.7) 2.5 (2.0) 
 ≥30 2.6 (1.7) 18.4 (3.9) 3.0 (2.1) 9.9 (3.6) 6.3 (4.4) 6.5 (4.3) 3.6 (1.6) 2.3 (1.9) 
 Missing 3.4 (2.7) 21.9 (4.2) 3.8 (3.3) 9.7 (4.1) 6.0 (4.0) 6.2 (3.7) 3.3 (3.1) 3.5 (2.4) 
Service         
 Army 2.7 (2.6) 17.2 (3.4) 3.2 (2.9) 7.4 (3.2) 4.6 (3.3) 5.4 (3.3) 2.8 (2.8) 3.2 (2.4) 
 Air Force 3.1 (2.7) 28.4 (3.8) 3.2 (3.5) 10.8 (3.9) 7.1 (3.7) 7.8 (3.6) 3.2 (3.3) 2.9 (1.9) 
 Marines and Coast Guard combined 3.2 (2.3) 19.6 (3.6) 4.3 (3.0) 8.8 (3.5) 5.4 (3.5) 7.3 (3.3) 3.3 (3.1) 3.1 (2.7) 
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 Navy 3.2 (2.2) 23.6 (3.9) 3.2 (2.7) 10.7 (3.8) 6.8 (3.5) 6.5 (3.5) 2.9 (2.6) 2.9 (2.3) 
Year of serum samples collection         
 1994-2000 3.4 (2.6) 22.1 (3.9) 3.8 (3.2) 9.4 (3.9) 5.8 (3.7) 6.0 (3.5) 3.5 (3.0) 3.1 (2.2) 
 2001-2004 1.9 (1.9) 19.5 (2.9) 1.9 (2.0) 7.8 (2.4) 5.6 (2.8) 7.3 (3.2) 1.8 (2.0) 2.6 (2.7) 
 2005-2009 2.0 (1.3) 19.3 (2.4) 2.3 (2.4) 9.0 (2.7) 5.6 (2.5) 9.8 (3.2) 1.9 (2.1) 2.6 (2.0) 
Years between serum samples collection and PTC diagnosis       
 <5 2.4 (1.8) 18.6 (3.0) 2.5 (2.7) 7.7 (3.0) 5.4 (3.0) 7.0 (3.5) 2.2 (2.4) 2.6 (2.1) 
 5-9 2.8 (2.6) 20.8 (3.7) 3.2 (3.1) 8.9 (3.6) 5.6 (3.6) 6.2 (3.5) 2.9 (2.9) 3.0 (2.3) 
 10-12 3.3 (2.6) 23.0 (3.9) 3.5 (3.0) 9.6 (3.7) 6.0 (3.6) 6.4 (3.3) 3.2 (2.9) 3.2 (2.3) 
Abbreviation: GSD, geometric standard deviation; PBED, polybrominated diphenyl ether; PBB, polybrominated biphenyl; PTC, papillary 
thyroid cancer; BDE-28, 2,4,4'-tribromodiphenyl ether; BDE-47, 2,2',4,4'-tetrabromodiphenyl ether; BDE-85, 2,2',3,4,4'-pentabromodiphenyl 
ether; BDE-99, 2,2',4,4',5-pentabromodiphenyl ether; BDE-100, 2,2',4,4',6-pentabromodiphenyl ether; BDE-153, 2,2',4,4',5,5'-




Supplementary Table 2. Geometric means and GSDs of lipid-corrected serum concentrations of selected PBDE and PBB congeners (ng/g) 
among controls by demographic characteristics and military services. 
  BDE-28 BDE-47 BDE-85 BDE-99 BDE-100 BDE-153 BDE-154 BB-153 
Age at serum samples collection (year)           
 <20 2.3 (1.9) 19.0 (3.0) 2.6 (2.2) 7.9 (3.0) 5.2 (2.9) 6.7 (2.7) 2.7 (2.3) 2.5 (2.1) 
 20-30 2.5 (2.2) 23.2 (3.1) 2.9 (2.5) 8.8 (3.2) 5.6 (3.0) 6.7 (3.0) 2.5 (2.6) 2.8 (2.2) 
 30-40 2.8 (2.4) 21.8 (3.5) 2.8 (2.8) 8.2 (3.3) 5.6 (3.2) 5.8 (3.2) 2.7 (2.6) 3.7 (2.3) 
 ≥40 2.6 (2.6) 10.2 (2.9) 2.5 (2.9) 4.9 (2.9) 3.2 (2.9) 4.5 (3.5) 2.9 (2.8) 4.0 (1.7) 
Age at diagnosis (year)         
 <30 2.2 (1.8) 18.1 (2.7) 2.2 (2.0) 7.4 (2.7) 4.6 (2.6) 6.4 (2.7) 2.4 (2.1) 2.3 (2.0) 
 30-39 2.6 (2.3) 24.4 (3.3) 3.1 (2.7) 9.1 (3.4) 6.0 (3.1) 6.7 (3.1) 2.7 (2.7) 3.1 (2.3) 
 40-49 2.9 (2.4) 21.6 (3.7) 3.0 (2.8) 8.3 (3.4) 5.6 (3.5) 6.0 (3.4) 2.7 (2.6) 3.5 (2.0) 
 ≥50 1.6 (1.5) 10.5 (2.5) 1.9 (1.4) 5.2 (2.5) 3.5 (2.1) 4.1 (2.7) 1.9 (2.0) 4.5 (2.4) 
Gender         
 Male 2.5 (2.2) 21.1 (3.1) 2.6 (2.4) 8.0 (3.1) 5.4 (3.0) 7.1 (3.0) 2.5 (2.5) 3.4 (2.2) 
 Female 2.7 (2.3) 20.9 (3.4) 3.2 (2.7) 8.5 (3.3) 5.3 (3.1) 5.4 (3.0) 2.8 (2.6) 2.7 (2.2) 
Ethnicity         
 White 2.6 (2.2) 19.7 (3.1) 2.7 (2.4) 7.4 (3.0) 5.1 (3.0) 6.5 (3.0) 2.4 (2.4) 3.1 (2.3) 
 Black 3.2 (2.4) 24.2 (3.7) 3.1 (2.6) 11.0 (3.7) 6.0 (3.3) 5.4 (3.2) 3.6 (2.5) 3.1 (1.9) 
 Hispanic 2.0 (2.0) 24.3 (2.9) 2.8 (2.8) 8.7 (3.1) 6.0 (2.8) 6.2 (2.9) 2.7 (2.8) 2.7 (2.1) 
 Other 2.4 (2.8) 20.9 (3.7) 2.8 (3.6) 8.9 (3.2) 5.4 (3.4) 6.8 (3.4) 2.4 (2.9) 2.8 (1.9) 
 Unknown 2.4 (2.0) 24.5 (3.1) 3.1 (2.6) 8.9 (3.4) 5.8 (2.9) 6.2 (3.0) 2.5 (2.5) 5.9 (3.6) 
BMI (kg/m2)         
 <25 2.3 (2.0) 19.3 (2.9) 2.7 (2.2) 7.5 (2.9) 5.0 (2.7) 6.4 (2.7) 2.4 (2.3) 2.7 (2.1) 
 25-29.9 2.3 (2.1) 21.1 (2.8) 2.7 (2.2) 7.6 (2.7) 5.2 (2.8) 6.8 (2.9) 2.6 (2.3) 2.5 (2.2) 
 ≥30 1.9 (2.6) 25.2 (3.1) 2.3 (4.1) 7.1 (4.3) 4.2 (3.1) 3.5 (2.5) 3.6 (5.9) 3.1 (2.2) 
 Missing 2.9 (2.4) 22.5 (3.8) 3.0 (2.9) 9.3 (3.6) 5.9 (3.4) 6.1 (3.4) 2.8 (2.8) 3.6 (2.2) 
Service         
 Army 3.0 (2.5) 23.1 (3.6) 3.8 (2.7) 9.1 (3.6) 5.9 (3.4) 6.7 (3.3) 3.5 (2.6) 3.3 (2.3) 
 Air Force 2.2 (2.0) 22.2 (2.6) 2.1 (2.1) 7.1 (2.5) 4.9 (2.5) 6.7 (2.8) 1.7 (2.0) 2.6 (2.0) 
 Marines and Coast Guard combined 2.4 (2.6) 20.5 (3.2) 3.2 (3.3) 7.7 (3.6) 5.1 (3.3) 6.6 (3.1) 3.0 (3.3) 3.2 (2.1) 
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 Navy 2.4 (2.0) 18.4 (3.2) 2.3 (2.2) 8.3 (3.0) 5.1 (2.9) 5.5 (2.9) 2.3 (2.3) 3.2 (3.3) 
Year of serum samples collection         
 1994-2000 2.7 (2.3) 22.1 (3.4) 3.1 (2.6) 9.0 (3.4) 5.7 (3.3) 6.1 (3.2) 2.9 (2.6) 3.3 (2.2) 
 2001-2004 2.1 (1.9) 18.4 (2.6) 2.0 (2.1) 6.3 (2.6) 4.7 (2.3) 6.8 (2.4) 1.8 (2.1) 2.1 (1.9) 
 2005-2009 2.0 (1.8) 14.7 (2.3) 1.3 (1.3) 6.1 (1.8) 3.6 (2.2) 8.3 (2.2) 1.4 (1.1) 1.6 (1.5) 
Years between serum samples collection and PTC diagnosis       
 <5 2.3 (2.1) 16.8 (3.1) 2.7 (2.5) 7.7 (3.3) 4.0 (2.9) 5.5 (2.6) 3.0 (2.5) 2.9 (2.4) 
 5-9 2.5 (2.3) 19.6 (3.0) 2.4 (2.4) 7.5 (2.9) 5.0 (2.8) 6.0 (3.0) 2.4 (2.4) 3.1 (2.2) 
 10-12 2.7 (2.3) 23.7 (3.5) 3.3 (2.7) 9.2 (3.4) 6.1 (3.3) 6.8 (3.2) 2.8 (2.6) 3.2 (2.2) 
Abbreviation: GSD, geometric standard deviation; PBED, polybrominated diphenyl ether; PBB, polybrominated biphenyl; PTC, papillary 
thyroid cancer; BDE-28, 2,4,4'-tribromodiphenyl ether; BDE-47, 2,2',4,4'-tetrabromodiphenyl ether; BDE-85, 2,2',3,4,4'-pentabromodiphenyl 
ether; BDE-99, 2,2',4,4',5-pentabromodiphenyl ether; BDE-100, 2,2',4,4',6-pentabromodiphenyl ether; BDE-153, 2,2',4,4',5,5'-




Supplementary Table 3. Cramer's Vs between categorical PBDE and PBB congeners detected in >20% of controls. 
  BDE-28 BDE-47 BDE-85 BDE-99 BDE-100 BDE-153 BDE-154 BB-153 
BDE-28 1 0.49 0.55 0.44 0.45 0.34 0.54 0.10 
BDE-47  1 0.47 0.68 0.67 0.40 0.47 0.05 
BDE-85   1 0.48 0.48 0.38 0.73 0.08 
BDE-99    1 0.62 0.38 0.48 0.07 
BDE-100     1 0.53 0.48 0.06 
BDE-153      1 0.40 0.05 
BDE-154       1 0.09 
BB-153               1 
Abbreviation: PBED, polybrominated diphenyl ether; PBB, polybrominated biphenyl; BDE-28, 2,4,4'-tribromodiphenyl ether; BDE-
47, 2,2',4,4'-tetrabromodiphenyl ether; BDE-85, 2,2',3,4,4'-pentabromodiphenyl ether; BDE-99, 2,2',4,4',5-pentabromodiphenyl ether; 
BDE-100, 2,2',4,4',6-pentabromodiphenyl ether; BDE-153, 2,2',4,4',5,5'-hexabromodiphenyl ether; BDE-154, 2,2',4,4',5,6'-




Supplementary Table 4. Risk of classical PTC microcarcinoma (≤10 mm) associated with lipid-corrected serum concentrations of PBDE 







interaction b Cases Controls ORa (95% CI) Cases Controls ORa (95% CI) 
BDE-28          
 <LOD 65 55 1.00  76 70 1.00   
 >LOD-1.56 11 13 0.84 (0.24, 2.94)  3 9 0.18 (0.03, 1.00)   
 1.57-3.18 10 11 0.94 (0.21, 4.17)  12 11 0.80 (0.15, 4.28)   
 3.19-80.10 11 18 0.53 (0.08, 3.37)  14 12 0.40 (0.05, 3.10)   
 P for trend b   0.99    0.45  0.93 
BDE-47          
 <LOD-8.43 35 23 1.00  27 25 1.00   
 8.44-16.91 19 21 0.87 (0.21, 3.68)  25 26 1.31 (0.39, 4.42)   
 16.92-38.63 20 27 0.82 (0.15, 4.63)  24 23 1.61 (0.25, 10.38)   
 38.64-2189.00 23 26 1.97 (0.11, 34.11)  29 28 1.84 (0.10, 33.43)   
 P for trend b   0.99    0.68  0.77 
BDE-85          
 <LOD 71 60 1.00  80 82 1.00   
 >LOD-1.68 13 17 2.22 (0.42, 11.76)  6 5 14.39 (1.01, 205.97)   
 1.69-3.18 2 8 1.75 (0.05, 58.41)  5 6 26.72 (0.89, 802.15)   
 3.19-79.08 11 13 1.58 (0.04, 68.13)  14 11 ―   
 P for trend b   0.28    0.017  0.85 
BDE-99          
 <LOD-2.17 33 24 1.00  30 26 1.00   
 2.18-4.40 22 19 2.92 (0.66, 12.98)  22 28 0.68 (0.22, 2.07)   
 4.41-10.61 19 25 2.02 (0.38, 10.79)  27 24 1.39 (0.30, 6.43)   
 10.62-993.30 23 30 2.04 (0.16, 25.64)  26 26 0.65 (0.05, 8.67)   
 P for trend b   0.71    0.91  0.72 
BDE-100          
 <LOD-1.84 35 19 1.00  34 30 1.00   
 1.85-3.71 19 24 0.23 (0.05, 1.00)  24 24 0.85 (0.25, 2.88)   
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 3.72-8.65 22 30 0.22 (0.03, 1.43)  21 19 0.84 (0.12, 5.95)   
 8.66-368.00 21 24 0.26 (0.02, 3.75)  26 29 0.25 (0.02, 3.17)   
 P for trend b   0.17    0.49  0.70 
BDE-153          
 <LOD-2.49 25 15 1.00  42 34 1.00   
 2.50-4.61 26 32 0.71 (0.25, 2.01)  22 25 0.68 (0.26, 1.77)   
 4.62-11.23 20 31 0.80 (0.23, 2.80)  18 24 0.70 (0.20, 2.42)   
 11.24-285.50 26 20 2.68 (0.56, 12.91)  23 21 3.18 (0.54, 18.88)   
 P for trend b   0.15    0.75  0.81 
BDE-154          
 <LOD 76 61 1.00  79 74 1.00   
 >LOD-1.60 7 11 0.30 (0.05, 2.06)  7 9 0.24 (0.03, 1.81)   
 1.61-3.11 3 12 0.09 (0.004, 1.76)  7 6 0.15 (0.01, 3.26)   
 3.12-66.22 11 13 0.14 (0.003, 7.87)  12 13 ―   
 P for trend b   0.16    0.033  0.92 
BB-153          
 <LOD-0.85 18 15 1.00  30 28 1.00   
 0.86-2.12 24 19 1.33 (0.44, 4.03)  27 30 0.85 (0.37, 1.93)   
 2.13-3.60 28 27 1.09 (0.35, 3.39)  27 27 0.80 (0.34, 1.86)   
 3.61-451.30 27 36 0.96 (0.32, 2.92)  21 17 1.15 (0.44, 2.97)   
 P for trend b   0.16    0.66  0.92 
Abbreviation: BB-153, 2,2',4,4',5,5'-hexabromobiphenyl; BDE-28, 2,4,4'-tribromodiphenyl ether; BDE-47, 2,2',4,4'-tetrabromodiphenyl 
ether; BDE-85, 2,2',3,4,4'-pentabromodiphenyl ether; BDE-99, 2,2',4,4',5-pentabromodiphenyl ether; BDE-100, 2,2',4,4',6-
pentabromodiphenyl ether; BDE-153, 2,2',4,4',5,5'-hexabromodiphenyl ether; BDE-154, 2,2',4,4',5,6'-hexabromodiphenyl ether; BMI, 
body mass index; LOD: limit of detection; OR, odds ratio; PBB, polybrominated biphenyl; PBDE, polybrominated diphenyl ether; PTC, 
papillary thyroid cancer. 
a Multi-chemical conditional logistic regression, adjusted for all PBDE and PBB congeners, BMI (<18.5, 18.5-24.9, 25-29.9, ≥30 kg/m2, 
and missing), and branch of military service (Army, Air Force, Navy, and Marines/Coast Guard). 




Supplementary Table 5. Risk of PTC associated with lipid-corrected serum concentrations of PBDE and PBB congeners 




Follicular variation of PTC 
Cases Controls ORa (95% CI) Cases Controls ORa (95% CI) 
BDE-28        
 <LOD 322 331 1.00  82 75 1.00 
 >LOD-1.56 47 55 1.03 (0.62, 1.70)  14 13 1.06 (0.36, 3.13) 
 1.57-3.18 56 52 1.80 (1.00, 3.21)  9 14 0.41 (0.10, 1.70) 
 3.19-80.10 80 55 2.53 (1.19, 5.36)  11 14 0.37 (0.06, 2.42) 
 P for trend   0.014    0.39 
BDE-47        
 <LOD-8.43 137 116 1.00  29 28 1.00 
 8.44-16.91 120 128 1.13 (0.69, 1.85)  35 29 1.22 (0.40, 3.68) 
 16.92-38.63 111 119 1.42 (0.71, 2.81)  31 33 0.96 (0.23, 3.99) 
 38.64-2189.00 137 130 1.09 (0.41, 2.90)  21 26 1.88 (0.21, 17.24) 
 P for trend   0.64    0.99 
BDE-85        
 <LOD 358 353 1.00  88 85 1.00 
 >LOD-1.68 48 48 1.04 (0.53, 2.04)  11 10 1.45 (0.35, 6.04) 
 1.69-3.18 24 46 0.47 (0.19, 1.18)  5 10 2.01 (0.24, 16.46) 
 3.19-79.08 75 49 2.11 (0.60, 7.40)  12 11 7.35 (0.38, 141.12) 
 P for trend   0.81    0.24 
BDE-99        
 <LOD-2.17 145 113 1.00  31 28 1.00 
 2.18-4.40 113 125 0.79 (0.48, 1.30)  29 31 0.95 (0.33, 2.73) 
 4.41-10.61 114 126 0.80 (0.42, 1.52)  33 30 1.63 (0.38, 6.89) 
 10.62-993.30 133 132 0.79 (0.33, 1.87)  23 27 1.20 (0.18, 8.24) 
 P for trend   0.36    0.51 
BDE-100        
 <LOD-1.84 154 119 1.00  32 27 1.00 
 1.85-3.71 110 118 0.72 (0.43, 1.23)  32 30 0.58 (0.19, 1.74) 
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 3.72-8.65 103 126 0.51 (0.25, 1.05)  33 33 0.43 (0.08, 2.30) 
 8.66-368.00 138 130 0.52 (0.19, 1.40)  19 26 0.40 (0.04, 3.80) 
 P for trend   0.13    0.43 
BDE-153        
 <LOD-2.49 147 118 1.00  32 33 1.00 
 2.50-4.61 115 130 0.88 (0.59, 1.32)  33 24 1.93 (0.78, 4.75) 
 4.62-11.23 109 124 0.88 (0.54, 1.43)  31 25 1.78 (0.62, 5.06) 
 11.24-285.50 134 124 0.96 (0.53, 1.75)  20 34 0.59 (0.15, 2.31) 
 P for trend   0.99    0.64 
BDE-154        
 <LOD 351 345 1.00  87 81 1.00 
 >LOD-1.60 48 50 1.30 (0.68, 2.47)  12 12 0.82 (0.21, 3.19) 
 1.61-3.11 41 47 1.19 (0.50, 2.84)  6 12 0.35 (0.05, 2.67) 
 3.12-66.22 65 51 0.48 (0.13, 1.75)  11 11 0.76 (0.04, 14.34) 
 P for trend   1.00    0.59 
BB-153        
 <LOD-0.85 127 106 1.00  28 26 1.00 
 0.86-2.12 120 128 0.73 (0.50, 1.07)  32 29 0.92 (0.39, 2.19) 
 2.13-3.60 135 138 0.72 (0.49, 1.05)  28 24 1.35 (0.56, 3.26) 
 3.61-451.30 123 121 0.80 (0.54, 1.18)  28 37 0.80 (0.33, 1.94) 
 P for trend   0.24    0.75 
Abbreviation: PTC, papillary thyroid cancer; PBED, polybrominated diphenyl ether; PBB, polybrominated biphenyl; OR, 
odds ratio; BDE-28, 2,4,4'-tribromodiphenyl ether; BDE-47, 2,2',4,4'-tetrabromodiphenyl ether; BDE-85, 2,2',3,4,4'-
pentabromodiphenyl ether; BDE-99, 2,2',4,4',5-pentabromodiphenyl ether; BDE-100, 2,2',4,4',6-pentabromodiphenyl ether; 
BDE-153, 2,2',4,4',5,5'-hexabromodiphenyl ether; BDE-154, 2,2',4,4',5,6'-hexabromodiphenyl ether; BB-153, 2,2',4,4',5,5'-
hexabromobiphenyl; LOD: limit of detection; BMI, body mass index. 
a Multi-chemical conditional logistic regression, adjusted for all PBDE and PBB congeners, BMI (<18.5, 18.5-24.9, 25-29.9, 




Supplementary Table 6. Statistical significance of associations between seven principal components of PBDEs and risk of classical PTC. 
  
Principal components (% variance explained) 
#1 (87.2%) #2 (8.7%) #3 (2.5%) #4 (0.7%) #5 (0.5%) #6 (0.2%) #7 (0.1%) 
Congeners Eigenvectors 
 PBDE-28 0.3785 -0.0627 -0.8160 0.2523 0.3097 -0.0563 0.1555 
 PBDE-47 0.3966 -0.1760 -0.1374 0.0869 -0.6147 0.1455 -0.6215 
 PBDE-85 0.3968 -0.1771 0.2219 -0.0375 -0.1664 -0.8273 0.2200 
 PBDE-99 0.3829 -0.3018 0.4247 0.5295 0.0589 0.4192 0.3497 
 PBDE-100 0.3967 0.1253 -0.0634 -0.6905 -0.2189 0.3362 0.4303 
 PBDE-153 0.2835 0.9068 0.1297 0.2753 -0.0297 -0.0422 -0.0466 
 PBDE-154 0.3971 -0.0690 0.2546 -0.3072 0.6680 0.0251 -0.4811 
Test of association with risk of classical PTC a 
 OR 1.06 1.12 0.92 1.17 1.25 1.08 1.38 
  P-value 0.043 0.18 0.60 0.57 0.48 0.87 0.66 
Abbreviation: PTC, papillary thyroid cancer; PBED, polybrominated diphenyl ether; OR, odds ratio; BDE-28, 2,4,4'-tribromodiphenyl ether; BDE-47, 
2,2',4,4'-tetrabromodiphenyl ether; BDE-85, 2,2',3,4,4'-pentabromodiphenyl ether; BDE-99, 2,2',4,4',5-pentabromodiphenyl ether; BDE-100, 2,2',4,4',6-
pentabromodiphenyl ether; BDE-153, 2,2',4,4',5,5'-hexabromodiphenyl ether; BDE-154, 2,2',4,4',5,6'-hexabromodiphenyl ether; BB-153, 2,2',4,4',5,5'-
hexabromobiphenyl; BMI, body mass index. 
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Background: The effects of thyroid-stimulating hormone (TSH) and thyroid hormones on the 
development of human papillary thyroid cancer (PTC) remain poorly understood. 
 
Methods: The study population consisted of 741 (341 women, 300 men) histologically confirmed 
PTC cases and 741 matched controls with pre-diagnostic serum samples stored in the Department 
of Defense Serum Repository. Concentrations of TSH, total T3 (TT3), total T4 (TT4), and free T4 
(FT4) were measured in serum samples. Conditional logistic regression models were used to 
calculate ORs and 95% CIs. 
 
Results: The median time between blood draw and PTC diagnosis was 1,454 days. Compared to 
the middle tertile of TSH levels within the normal range, serum TSH levels below the normal range 
were associated with an elevated risk of PTC among women (OR=3.74, 95% CI: 1.53, 9.19) but 
not men. TSH levels above the normal range were associated with an increased risk of PTC among 
men (OR=1.96, 95% CI: 1.04, 3.66) but not women. The risk of PTC decreased with increasing 
TSH levels within the normal range among both men and women (Ptrend=0.0005 and 0.041, 
respectively). 
 
Conclusions: We found a significantly increased risk of PTC associated with TSH levels below the 
normal range among women and with TSH levels above the normal range among men. An inverse 
association between PTC and TSH levels within the normal range was observed among both men 
and women. These results could have significant clinical implications for physicians who are 
managing patients with abnormal thyroid functions and those with thyroidectomy. 
 




Thyroid cancer has the highest prevalence of all endocrine malignancies, and its incidence is rising 
faster than any other malignancy in both men and women [71]. In the United States, thyroid cancer 
is the 9th most common cancer, accounting for 3.8% of all malignancies and 0.3% of all deaths 
from cancer [72]. The most common histological type of thyroid cancer is papillary thyroid cancer 
(PTC), which accounts for more than 80% of all thyroid carcinomas [73]. The causal factors 
underlying thyroid cancer are poorly understood. The most well-established risk factors for thyroid 
cancer include increased age, female gender, exposure to ionizing radiation, history of benign 
thyroid disease, and a family history of thyroid cancer [10, 11, 13, 74]. Recent studies have 
identified higher body weight and height as risk factors for thyroid cancer [14, 15]. 
 
Thyroid-stimulating hormone (TSH) is the major growth factor for thyroid cells and regulator of 
thyroid functions. It controls the processes that lead to increased thyroid hormone production and 
secretion [39]. Blood concentrations of thyroid hormones (i.e., triiodothyronine [T3] and its 
prohormone thyroxine [T4]) inversely regulate the release of TSH through a negative feedback 
loop at the pituitary levels. High TSH levels have been associated with PTC pathogenesis in a 
mouse model [75]. Suppression of TSH is currently recommended to manage differentiated thyroid 
cancer (DTC) patients, which has shown benefits to patient survival [76]. Thyroid hormones have 
also been suggested to have a tumor promoting effect on several cancers, including pancreatic, 
breast, ovarian, and prostate cancer [77]. However, findings of epidemiological studies linking TSH 
and thyroid hormones to the risk of thyroid cancer have been inconsistent [41, 42, 68, 78-101]. 
 
The majority of early studies reported an increased risk of thyroid cancer associated with elevated 
TSH levels [41, 42, 78-92], several studies found no significant association [93-101], and one 
reported a reduced risk [68]. All studies that reported a positive association between TSH and 
thyroid cancer were cross-sectional [41, 42, 78-91] or case-control studies [92]. Therefore, the 
possibility of reverse causation or treatment effect could be of potential concern because the TSH 
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levels were measured after diagnosis. There are only three previous prospective cohort studies. One 
reported a significantly reduced risk of thyroid cancer associated with elevated TSH levels [68]. 
Two smaller studies reported lower, but not significant TSH levels in thyroid cancer cases than in 
controls [100, 101]. The relationship between thyroid hormones and risk of thyroid cancer has also 
been inconclusive [41, 42, 68, 78, 79, 99, 100]. Two studies found lower thyroid hormone levels 
were associated with a higher risk of thyroid cancer [41, 42], while the remaining five reported no 
association [68, 78, 79, 99, 100]. 
 
In light of the inconclusive associations between TSH, thyroid hormones, and thyroid cancer, we 
conducted a nested case-control study using data from the Department of Defense (DoD) 
Automated Central Tumor Registry (ACTUR) and the Defense Medical Surveillance System 
(DMSS), with pre-diagnostic serum samples from the Department of Defense Serum Repository 
(DoDSR) to investigate the associations of PTC with TSH and thyroid hormones (total T3 [TT3], 




Our study population was US military personnel who had serum samples stored in the DoDSR 
[102]. These stored samples were leftover sera collected for the routine HIV test of military 
personnel. The DoDSR is maintained by the Armed Forces Health Surveillance Center, US Army 
Public Health Command. As of August 2013, the repository stored more than 55 million serum 
samples from over 10 million individuals, most of whom were active-duty and reserve personnel. 
Serum samples on all military members were typically drawn at the time of service entry and, on 




We designed an individually matched nested case-control study. Cases were identified by linkage 
of the ACTUR with the DoDSR database. The ACTUR was established in 1986 and is the data 
collection and clinical tracking system for cancer cases diagnosed and treated at military treatment 
facilities among DoD beneficiaries, including active-duty military personnel, retired military 
personnel, and their dependents. The registry includes information on demographic variables, 
diagnostic factors, and tumor characteristics [105]. Cases met the following criteria: 1) 
histologically confirmed with International Classification of Diseases for Oncology, third edition 
(ICD-O-3 for thyroid gland: C739) histology codes 8021, 8050, 8052, 8130, 8260, 8290, 8330-
8332, 8335, 8340-8346, 8450, 8452, and 8510; 2) at least 1.5ml pre-diagnostic and 0.5ml post-
diagnostic serum samples stored in the DoDSR; 3) diagnosis between 2000 and 2013; and 4) aged 
21 years or older at diagnosis. Cases with any prior cancers (excluding non-melanoma skin cancer) 
recorded in the ACTUR at the date of diagnosis of thyroid cancer were excluded from the study. A 
total of 800 eligible cases were identified. The histology of all reported thyroid cancer cases was 
abstracted from ACTUR. Of these eligible cases, 742 (92.8%) were PTC (ICD-O-3: 8050, 8260, 
and 8340-8343). IDs for all cases were sent from ACTUR to Armed Forces Health Surveillance 
Center via encrypted methods. Those IDs were excluded from the eligible pool of controls. Controls’ 
eligibility criteria were: having at least four serum samples in DoDSR, and according to the 
matching criteria, the midpoint of those four samples within one year of the control’s matched 
case’s midpoint of their four samples. Controls were randomly selected with replacement from the 
cohort of service members who were not diagnosed with any cancer (with the exception of non-
melanoma skin cancer), as per query of the ACTUR. Controls were matched one-to-one to cases 
by date of birth (±1 year), gender, race/ethnicity (White, Black, Hispanic, and other), average date 
of the selected four samples drawn (±1 year), and component at diagnosis/matching. Demographic 
and military characteristics for all cases and controls were abstracted from DMSS. The DMSS now 
serves as the central repository of medical surveillance data for the US armed forces and contains 
longitudinal records which have been continuously updated since 1990. The system includes 
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demographic and military characteristics as well as military and medical experiences of service 
members throughout their military careers [102]. All study procedures were approved by the 
Uniformed Services University Institutional Review Board, the Walter Reed National Military 
Medical Center, the DoD Joint Pathology Center, and The Human Investigation Committee of Yale 
University. 
 
Measurement of TSH and thyroid hormones 
A calibrated Roche Cobas e601 analyzer was used to measure the serum concentrations of TSH 
and thyroid hormones using the manufacturer’s reagents and calibrators. TSH was captured 
between two monoclonal antibodies (one was biotinylated, the other labeled with a ruthenium 
complex) which specific for sterically non-interfering epitopes of human TSH. TT3 and TT4 were 
dissociated from binding proteins using 8-anilino-1-naphthalene sulfonic acid (ANS) and competed 
with the exogenous biotinylated-T3 or -T4 for binding to a T3- or T4-specific antibody labeled with 
a ruthenium complex. FT4 directly competed with the exogenous biotinylated-T4 for binding to a 
T4-specific antibody labeled with a ruthenium complex. All the antibodies were captured by 
streptavidin-coated magnetic microparticles, which were then magnetically captured by an 
electrode and the application of voltage induced emission of photons by the ruthenium complex. 
The intensities of the luminescence were inversely proportional to the serum concentrations of TSH 
and thyroid hormones. The normal ranges for serum concentrations of TSH, TT3, TT4, and FT4 
were 0.3-4.2 μU/ml, 79-149 ng/dl, 5.0-10.6 μg/dl, and 0.80-1.80 ng/dl, respectively. All control 
samples were tested in the same batch as their matched case samples. Based on results obtained 
from quality-control samples (5%), intra-batch coefficient of variation ranged from 3.9% to 7.7%. 
 
Statistical analyses 
Measurements of TSH and thyroid hormones failed in one serum sample, leaving 741 pairs of PTC 
cases and matched controls included in the final analysis. The distributions of demographic and 
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military characteristics between cases and controls were compared by chi-square tests. The 
correlations between TSH, TT3, TT4, and FT4 were estimated using the Pearson correlation 
coefficients. Given the individual-matched case-control design, conditional logistic regression 
analyses were employed to calculate odds ratios (ORs) and 95% confidence intervals (95% CIs) 
for the association between TSH, thyroid hormones and PTC. Serum concentrations of TSH, TT3, 
TT4, and FT4 were divided into three categories based on the normal range (below, within, and 
above the normal range). The normal range group was further categorized into tertiles based on the 
distributions of serum concentrations among controls. Thus, there were five categories for each 
hormone: below the normal range, lower, medium, and higher levels within the normal range, and 
above the normal range. The middle tertile within the normal range was used as reference category 
for all analyses. All the conditional logistic regression models were adjusted for body mass index 
(BMI) (<18.5, 18.5-24.9, 25-29.9, and ≥30 kg/m2) and branch of military service (army, air force, 
marines and coast guard, and navy). TT3, TT4, and FT4 models were also adjusted for serum 
concentrations of TSH. However, additional adjustment for serum concentrations of TT3, TT4, and 
FT4 in TSH models did not result in material changes in the observed associations and thus were 
not included in the final models. Dose-response relationship was further investigated using P for 
trend, estimated by treating serum concentrations of TSH and thyroid hormones as continuous 
variables. Stratified analyses were performed by gender, histological subtype (classical PTC [ICD-
O-3: 8050, 8260, 8341-8343] and follicular variant of PTC [ICD-O-3: 8340]), tumor size (≤10 
and >10 mm), and years between serum samples drawn and PTC diagnosis (<3 years, 3-6 years, 
and >6 years, based on sample size). Sensitivity analysis was also conducted among women aged 
<50 years old to see if estrogen impacts the associations among premenopausal women. All tests 
were two-sided with α=0.05. Statistical analyses were conducted using SAS software, version 9.3 





PTC cases were more likely to have served in the Army or Air Force at time of diagnosis, while 
controls were more likely to have served in the Navy, Marines, or Coast Guard (Table 1). Cases 
had a slightly larger BMI compared to controls, but the difference was not statistically significant. 
Since the cases were individually matched to controls based on age, gender, and race/ethnicity, the 
distributions of these variables were similar between cases and controls. 
 
All serum samples were drawn between 83 and 4,232 days before the cases were diagnosed with 
PTC. As anticipated, there were statistically significant strong positive correlations between TT3, 
TT4, and FT4 (r=0.68 for TT3 and TT4, p<0.0001; r=0.40 for TT3 and FT4, p<0.0001; and r=0.52 
for TT4 and FT4, p<0.0001, respectively). TSH was weakly, but statistically significantly 
correlated with TT3, TT4, and FT4 (r=-0.06 for TSH and TT3, p=0.022; r=-0.17 for TSH and TT4, 
p<0.0001; and r=-0.19 for TSH and FT4, p<0.0001, respectively). Female cases had lower mean 
TSH levels as compared to their matched controls, while male cases had higher mean TSH levels 
as compared to their matched controls. None of these differences were statistically significant. We 
also observed non-significantly higher mean levels of thyroid hormones among female cases as 
compared to female controls, but thyroid hormone levels were similar between cases and controls 
among men. 
 
In the overall population, serum TSH levels below the normal range were associated with a 
significantly increased risk of PTC (OR=2.65, 95% CI: 1.27, 5.52, Figure 1) compared to the 
middle tertile of the normal range. Paradoxically, TSH levels above the normal range were also 
associated with an increased risk of PTC (OR=1.58, 95% CI: 0.97, 2.56) with borderline 
significance. Serum concentrations of TT3, TT4, and FT4 below or above the normal range were 
not significantly related to an elevated risk of PTC. Within the normal ranges, the risk of PTC 
decreased with increasing TSH levels (Ptrend=0.0001) and with decreasing TT3 levels (Ptrend=0.031), 




TSH levels below the normal range were associated with increased risk of PTC among women 
(OR=3.74, 95% CI: 1.53, 9.19) but not among men (OR=1.07, 95% CI: 0.25, 4.62, Figure 2) 
compared to the middle tertile of the normal range. Additionally, an increased risk of PTC in 
relation to TSH levels above the normal range was observed only among men (OR=1.96, 95% CI: 
1.04, 3.66) but not among women (OR=1.09, 95% CI: 0.49, 2.46). The risk of PTC decreased with 
increasing TSH levels within the normal range among both men and women (Ptrend=0.0005 and 
0.041, respectively). However, lower TSH levels within the normal range were associated with an 
increased risk of PTC and the association was stronger in women (OR=1.53, 95% CI: 1.03, 2.28) 
than in men (OR=1.17, 95% CI: 0.80, 1.71). In contrast, higher TSH levels within the normal range 
were associated with a reduced risk of PTC among men (OR=0.65, 95% CI: 0.44, 0.95). An inverse 
association between TT3 levels above the normal range and risk of PTC was observed only among 
men (OR=0.59, 95% CI: 0.36, 0.98); while the risk of PTC increased with increasing serum 
concentrations of TT3 among women (overall Ptrend=0.019). No significant associations with TT4 
and FT4 were observed. 
 
When the analyses were stratified by histological subtype among men (Figure 3), TSH levels above 
the normal range were borderline significantly associated with an increased risk of classical PTC 
(OR=1.94, 95% CI: 1.00, 3.77). A significantly inverse dose-response relationship was observed 
between TSH levels within the normal range and risk of classical PTC (Ptrend=0.0010) but not 
follicular variant PTC (Ptrend=0.16). TT3 levels above the normal range were significantly 
associated with a decreased risk of classical PTC (OR=0.53, 95% CI: 0.30, 0.94). When the 
analyses were stratified by histological subtype among women (Figure 4), TSH levels below the 
normal range were associated with a significantly increased risk of classical PTC (OR=2.72, 95% 
CI: 1.09, 6.78). The lower TSH levels within the normal range were associated with an elevated 
risk of follicular variant of PTC (OR=11.31, 95% CI: 3.10, 41.31). There was an increasing trend 
 
50 
in risk of classical PTC with increasing TT3 levels (Ptrend=0.021), but no statistically significant 
association between TT3 levels and risk of follicular variant of PTC was observed. 
 
When the analyses were stratified by tumor size among men (Figure 5), the higher TSH levels 
within the normal range were associated with a reduced risk of PTC with tumor size greater than 
10 mm (OR=0.57, 95% CI: 0.35, 0.92) but not PTC microcarcinoma (≤10 mm) (OR=0.99, 95% CI: 
0.47, 2.12). TSH levels within the normal range were inversely associated with PTC >10 mm 
(Ptrend=0.0003), whereas, there was no trend for PTC microcarcinoma (Ptrend=0.21). When the 
analyses were stratified by tumor size among women (Figure 6), TSH levels below the normal 
range were associated with a significantly increased risk of PTC >10 mm (OR=4.98, 95% CI: 1.30, 
19.06) and a non-significantly elevated risk of PTC microcarcinoma (OR=3.62, 95% CI: 0.85, 
15.48). The lower TSH levels within the normal range were associated with an elevated risk of PTC 
microcarcinoma (OR=2.47, 95% CI: 1.10, 5.55) but not PTC >10 mm (OR=1.30, 95% CI: 0.79, 
2.14). TSH levels within the normal range were inversely associated with PTC >10 mm 
(Ptrend=0.027). No significant associations were found for TT3, TT4, and FT4 for both PTC 
microcarcinoma and PTC >10 mm among men and women. 
 
Further stratified analyses were conducted by the years between serum samples drawn and PTC 
diagnosis (Supplementary Table 1). No clear pattern was observed with timing of the serum 
samples drawn, though numbers of cases were small after stratification. 
 
Sensitivity analyses showed that the associations between risk of PTC and serum concentrations of 
TSH, TT3, TT4, and FT4 did not change materially after restricting the analyses to women aged 





In this large case-control study based on pre-diagnostic serum measures and with sufficient power 
to stratify by gender, we found that serum TSH levels below the normal range were associated with 
an elevated risk of PTC among women but not men. TSH levels above the normal range were only 
associated with an increased risk of PTC among men. There was an inverse association between 
PTC and TSH levels within the normal range among both men and women. The observed 
associations varied somewhat by histological subtypes (classical vs. follicular variant PTCs) and 
by tumor size (≤10mm vs. >10mm) among men and women. The gender effect on the association 
between TSH and PTC was only observed among classical PTC cases. TSH levels showed a 
stronger association with PTC with larger tumor size. A suggestive inverse association between 
higher TT3 levels and risk of PTC was observed among men. 
 
The inverse trends between TSH levels and risk of PTC observed in the present study was in 
accordance with results from a nested case-control study within a large population-based 
prospective cohort in Europe [68]. The cohort consisted of approximately 520,000 healthy 
individuals aged 35 to 69 years when recruited between 1992 and 1998 in 10 European countries. 
A total of 357 incident thyroid cancer cases (57 men and 300 women) diagnosed during 1992 to 
2009 and 767 matched controls were included in the analyses. Blood samples were collected at 
enrollment. This European study found an inverse dose-response relationship between overall TSH 
levels and risk of differentiated thyroid cancer. The years between sample collection and thyroid 
cancer diagnosis were similar between the European study and our study. However, as compared 
to the European study, our population was younger and healthier [106], with participants aged 17 
to 56 years at blood samples collection. Additionally, our study had a larger number of the male 
cases than the European study, which provides sufficient power to examine the associations among 
men. The present study observed inconsistent associations between TSH levels and risk of PTC 
among women as compared to men, while the European study reported similar associations among 
men and women. There were another two prospective studies with smaller sample size that 
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investigated the association between TSH and risk of thyroid cancer [100, 101]. Although no 
significantly inverse association was observed in these studies, both reported lower TSH levels 
among thyroid cancer cases as compared to controls. 
 
A previous meta-analysis showed that higher TSH levels were associated with an increased thyroid 
cancer risk [107]. However, all 22 studies included in the meta-analysis were cross-sectional studies 
and measured TSH levels after treatment of thyroid cancer began. The cross-sectional design could 
not clarify whether elevated TSH levels preceded thyroid cancer diagnosis or were effects of 
treatment. The low levels of thyroid hormones due to dysfunction of the thyroid gland among 
thyroid cancer patients could cause the pituitary gland to release more TSH. Additionally, higher 
TSH levels may promote the growth of already initiated thyroid cancer, making the cancer larger 
and more easily diagnosed. Therefore, the positive association seen in the cross-sectional studies 
could be due to ascertainment bias [39]. On the other hand, controls in these studies were always 
patients with thyroid nodules or patients undergoing surgical treatment for a suspicious thyroid 
tumor. Some nodules can produce high levels of thyroid hormones, thus lowering TSH levels [68]. 
Many thyroid cancer patients also had additional benign thyroid nodules, and the mutual influence 
between those nodules and TSH concentrations has not yet been determined [80]. 
 
TSH plays an important role in regulating thyroid function, including increasing number, size, and 
secretory activity of thyrocytes, increasing thyroid blood flow, and increasing thyroid hormone 
production and secretion from follicular thyroid cells [39]. Classical TSH actions are mainly 
mediated through the Gαs-adenylyl cyclase-protein kinase A-cyclic adenosine monophosphate 
(cAMP) pathway, which is associated with production of thyroid hormones and proliferation of 
thyroid epithelial cells [108]. However, somatic mutations in thyroid epithelial cell can also activate 
the cAMP pathway, which facilitate the cell growth and clonal expansion, leading to the formation 
of an autonomously functioning thyroid adenoma. The adenoma can synthesize and secrete thyroid 
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hormones autonomously, thereby suppressing TSH secretion [109]. Therefore, constitutive 
activation of the cAMP pathway could be associated with an increased carcinogenic potential and 
a decreased TSH level. Due to the deprivation of TSH stimulation, the extra-nodular tissue would 
become quiescent. Depending on the iodine intake, growth potential, and other factors, it may take 
months to a decade or longer for an adenoma to grow large enough to cause hyperthyroidism [110]. 
 
While the underlying mechanism of lower TSH levels increasing the risk of PTC is currently 
unclear, two genome-wide association studies have found that five common variants (rs965513[A] 
on 9q22.23, rs944289[T] and rs116909374[T] on 14q13.3, rs966423[C] on 2q35, and rs2439302[G] 
on 8p12) were associated with both an increased risk of thyroid cancer and low TSH level [111, 
112]. According to Gudmundsson et al., the five variants could refer to genes FOXE1, NKX2-1, 
DIRC3, and NRG1. The FOXE1 gene can regulate the transcription of thyroglobulin and 
thyroperoxidase genes, and together with the NKX2-1 gene, plays an essential role in thyroid gland 
formation, differentiation, and function [113]. Although the function of the DIRC3 gene is 
unknown, it is presumed to have tumor suppressor activity [114]. The gene NRG1 encodes a 
signaling protein which mediates cell-cell interactions and plays a critical role in the growth and 
development of thyroid gland. The carriers of these five variants may be characterized by lower 
concentrations of TSH. The consequence of the lower TSH levels may be result in less 
differentiation of the thyroid epithelium, causing a higher predisposition to malignant cell 
transformation [112]. 
 
The present study observed positive associations in a dose-response manner between serum 
concentrations of TT3 and risk of PTC only among women. The observed inverse association 
between TSH levels and risk of PTC among women still held after excluding those ≥50 years old. 
These findings suggest that women may be more sensitive to the effect of TSH and thyroid 
hormones as compared to men. Possible explanations including effect modification of estrogen and 
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different exposure to endocrine disrupting chemicals (e.g., birth control pills and personal care 
products) by gender that need to be explored in future studies. 
 
The present study also noted different associations of TSH and thyroid hormones on risk of PTC 
by histological subtype and tumor size. Lower TSH levels showed an association with increasing 
risk of the follicular variant of PTC and PTC >10mm, while higher TSH levels were associated 
with a decreased risk of classical PTC and PTC microcarcinoma. These associations may support 
the hypothesis that follicular variant of PTC and papillary microcarcinoma are unique clinical 
entities with different etiologic profiles [17, 115]. 
 
Additionally, the present study failed to find a clear pattern between TSH levels and risk of PTC 
with timing of the serum samples drawn. The relevant time window in which TSH exerts influence 
on development of thyroid cancer needs to be further studied. 
 
The present study has several strengths. It included a relatively large number of male cases, 
providing sufficient statistical power to investigate and compare the associations by gender, which 
is important because women are much more likely to develop thyroid cancer than men. The study 
population was comprised entirely of US active duty military personnel, minimizing the potential 
differences in effects of TSH and thyroid hormones among healthy people and people with high 
risk of thyroid cancer. Potential selection bias from difference in access to medical care was also 
minimized for our study population. The serum concentrations of TSH and thyroid hormones were 
prospectively assessed and were not influenced by the disease process or treatment, which provided 
an opportunity to estimate potentially causal relationships between TSH, thyroid hormones, and 
thyroid cancer. A limitation of this study is that there was a lack of information on several potential 
confounding factors, such as ionizing radiation exposure, history of benign thyroid disease, family 
history of thyroid cancer, and smoking status. There were also a high percentage of participants 
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with missing BMI data, which may have led to insufficient adjustment for BMI. The lack of data 
on medication use preclude us from carrying out sensitivity analyses excluding people who were 
taking thyroid hormones. Furthermore, the subgroup analyses, which were stratified by years 
between samples collection and diagnosis, histological subtype, and tumor size, may have yielded 
unstable results due to the small subgroup counts. 
 
In conclusion, the present study showed a significantly increased risk of PTC associated with TSH 
levels lower than the normal range among women and higher than the normal range among men. 
The observed associations varied by histological subtype and tumor size. These results could have 
significant clinical implications for physicians who are managing patients with abnormal thyroid 
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Number %   Number %   
Age at diagnosis (years)        
 <30 210 28.3  203 27.4   
 30-39 309 41.7  322 43.5   
 40-49 185 25.0  179 24.2   
 ≥50 37 5.0  37 5.0  0.92 
Gender        
 Male 400 54.0  400 54.0   
 Female 341 46.0  341 46.0  1.00 
Race        
 White 467 63.0  466 62.9   
 Black 131 17.7  132 17.8   
 Hispanic 68 9.2  68 9.2   
 Other 55 7.4  55 7.4   
 Unknown 20 2.7  20 2.7  1.00 
BMI (kg/m²)        
 <25 256 34.6  285 38.5   
 25-29.9 148 20.0  129 17.4   
 ≥30 16 2.2  10 1.4   
 Missing 321 43.3  317 42.8  0.23 
Service        
 Army 299 40.4  253 34.1   
 Air Force 193 26.1  150 20.2   
 Marines and Coast Guard 
combined 
64 8.6  91 12.3   
  Navy 185 25.0   247 33.3   <0.0001 




Figure 1. Risk of PTC associated with serum concentrations of TSH and thyroid hormones. 
 
 
Abbreviation: PTC: Papillary Thyroid Cancer; TSH: Thyroid-Stimulating Hormone; BMI: Body 
Mass Index.  
*Conditional logistic regression, adjusted for BMI and branch of military service.  
**Estimated by continuous variables.  




Figure 2. Risk of PTC associated with serum concentrations of TSH and thyroid hormones, stratified by gender. 
 
Abbreviation: PTC: Papillary Thyroid Cancer; TSH: Thyroid-Stimulating Hormone; BMI: Body Mass Index.  
*Conditional logistic regression, adjusted for BMI and branch of military service.  
**Estimated by continuous variables.  




Figure 3. Risk of PTC associated with serum concentrations of TSH and thyroid hormones among males, stratified by histological 
subtypes. 
 
Abbreviation: PTC: Papillary Thyroid Cancer; TSH: Thyroid-Stimulating Hormone; BMI: Body Mass Index.  
*Conditional logistic regression, adjusted for BMI and branch of military service.  
**Estimated by continuous variables.  




Figure 4. Risk of PTC associated with serum concentrations of TSH and thyroid hormones among females, stratified by histological 
subtypes. 
 
Abbreviation: PTC: Papillary Thyroid Cancer; TSH: Thyroid-Stimulating Hormone; BMI: Body Mass Index.  
*Conditional logistic regression, adjusted for BMI and branch of military service.  
**Estimated by continuous variables.  




Figure 5. Risk of PTC associated with serum concentrations of TSH and thyroid hormones among males, stratified by tumor size. 
 
Abbreviation: PTC: Papillary Thyroid Cancer; TSH: Thyroid-Stimulating Hormone; BMI: Body Mass Index.  
*Conditional logistic regression, adjusted for BMI and branch of military service.  
**Estimated by continuous variables.  




Figure 6. Risk of PTC associated with serum concentrations of TSH and thyroid hormones among females, stratified by tumor size. 
 
Abbreviation: PTC: Papillary Thyroid Cancer; TSH: Thyroid-Stimulating Hormone; BMI: Body Mass Index.  
*Conditional logistic regression, adjusted for BMI and branch of military service.  
**Estimated by continuous variables.  




Polybrominated Diphenyl Ethers, Polybrominated Biphenyls, and Peripheral Circulating 




Background: Emerging evidence has suggested that exposure to polybrominated diphenyl ethers 
(PBDEs) and polybrominated biphenyls (PBBs) is related to disruption of thyroid hormone 
homeostasis. However, the effect of PBDEs and PBBs on serum levels of thyroid hormones is still 
inconclusive in human populations. Additionally, there is a lack of evidence pertaining to the 
mediation effect of thyroid hormones on the association between PBDEs/PBBs and risk of thyroid 
cancer. 
 
Methods: The study population consisted of 741 (341 women, 400 men) histologically confirmed 
papillary thyroid cancer (PTC) cases and 741 matched controls with pre-diagnostic serum samples 
stored in the Department of Defense Serum Repository. Lipid-corrected serum concentrations of 
seven PBDE congeners and one PBB congener, as well as serum levels of thyroid-stimulating 
hormone (TSH), total T3 (TT3), total T4 (TT4), and free T4 (FT4) were measured in serum samples 
collected in two consecutive time points. Relationships between serum concentrations of PBDE 
and PBB congeners and hormone levels were examined by generalized additive models and linear 
regression models. Mediation effects of TSH on the association between PBDE and PBB congeners 
and risk of PTC were estimated by causal mediation analysis. 
 
Results: Significantly nonmonotonic relationships were observed between serum concentrations of 
BDE-153 and BB-153 in relation to levels of TT3 and TT4 in PTC cases, and between BDE-47, -
100, and -153 in relation to FT4 level in controls. The associations between PBDEs/PBBs and 
levels of TSH and thyroid hormones were stronger in cases than those in controls. Among cases, 
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higher serum concentrations of BDE-153 and BB-153 were associated with increased TSH level 
and decreased levels of TT3 and TT4, while higher concentration of BDE-100 was associated with 
reduced level of TSH and reduced level of TT4. The associations were varied by gender. Mediation 
effect of TSH accounts for a nonsignificant proportion in the total effect of PBDEs/PBBs on risk 
of PTC. 
 
Conclusions: Results of this study contribute to the understanding of mechanisms underlying 
endocrine disrupting effect of PBDEs/PBBs. Further investigations using multiple longitudinal 
measurements and examining effect modification of genetic polymorphisms with PBDE 
alternatives among different populations are warranted to confirm these findings and identify high 
risk populations who are susceptible to these endocrine disrupting chemicals. 
 
Keywords: polybrominated diphenyl ethers, polybrominated biphenyls, thyroid-stimulating 




Polybrominated diphenyl ethers (PBDEs) and polybrominated biphenyls (PBBs) belong to a class 
of brominated hydrocarbons that have been used as flame retardants globally in a variety of 
commercial and household products, including plastics, furniture, upholstery, textiles, electrical 
equipment, electronic devices, and other small appliances [29, 30]. PBDEs and PBBs are not single 
chemical compounds, but rather mixtures of different congeners with distinct brominated structures 
[29, 30]. The most important commercial mixtures of PBDE and PBB congeners are penta-
bromodiphenyl ethers (BDEs) (mainly composed of BDE-47 and -99), octa-BDEs (mainly 
composed of BDE-183, -197, and -209), deca-BDEs (mainly composed of BDE-209), and 
FireMaster BP-6 (mainly composed of BB-153) [116, 117]. Because PBDEs and PBBs are 
physically mixed into products as additives, rather than chemically bond with polymer resins, they 
have a potential to be released into the environment through production process or from products 
usage [21]. Due to their high lipophilicity, PBDEs and PBBs could also bioaccumulate and be 
biomagnified through food chains [23, 37, 118]. Humans could be exposed to environmental 
PBDEs and PBBs via inhalation, dust ingestion, and dietary intake [29, 30]. Since PBDEs and 
PBBs are persistent, with degradation half-lives in the order of years in the environment and in 
human bodies [22, 119, 120], these chemicals remain ubiquitous in the environment and are being 
detected in human populations even after discontinued production for years [19]. After a moderate 
decline of PBDE body burdens since approximately 2000 [54, 57], scientists have observed a 
significant increase in human serum concentrations of several PBDE congeners from 2011 to 2015 
[32, 58]. Serum level of BB-153 among the Michigan residents exposed to PBBs in an accidental 
contamination of the food supply during 1973 and 1974 was still 10 times higher in 2012-2015, as 
compared to the 2011-2014 National Health and Nutrition Examination Survey (NHANES) data 
[121]. 
 
Emerging evidence indicates that exposure to PBDEs and PBBs is related to reduced circulating 
levels of thyroid hormones (i.e., triiodothyronine [T3] and thyroxine [T4]) in experimental animals 
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[122, 123]. Two mechanisms have been suggested to explain the endocrine-disrupting effect of 
PBDEs. Since the chemical structures of PBDE congeners are similar to those of thyroid hormones, 
both hydroxylate and sulfate metabolites of PBDE congeners could competitively bind to thyroid 
hormone transport proteins (i.e., thyroxine-binding globulin [TBG] and transthyretin [TTR]) and 
nuclear receptors (i.e., ThRα and ThRβ) [19, 124-126]. The displacement of T4 from TTR and 
TBG may cause a higher glucuronidation rate and lower half-life of T4, resulting in a decreased 
circulating level of T4 [127]. The agonist/antagonist effects of PBDEs on thyroid hormone 
receptors may disrupt thyroid hormone signaling and lead to thyroid disfunction [128]. Additionally, 
PBDEs can induce the activity of major thyroid hormone metabolic enzymes, including cytochrome 
P450 isozymes (CYPs), uridine 5'-diphospho-glucuronosyltransferases (UDPGTs), 
sulfotransferases (SULTs), and deiodinases [19], and thus affect the metabolism of T3 and T4. The 
disruption of thyroid hormone homeostasis could further influence the secretion of thyroid-
stimulating hormone (TSH) through a negative feedback loop on the hypothalamus-pituitary-
thyroid axis. The mechanism underlying the association between PBBs and thyroid hormones is 
less clear. One speculated explanation is that PBBs exposure may cause an alteration of estrogen 
level and hence an increase in the synthesis of TBG [129, 130]. PBBs exposure has also been 
suggested to be able to alter the activity of deiodinases, and then affect the conversion of T4 to T3 
[130]. 
 
Although animal studies indicate that exposure to PBDEs and PBBs is related to disruption of 
thyroid hormone homeostasis, evidence in human populations is still unestablished. Previous 
epidemiological studies yielded conflicting findings on the associations between PBDEs and PBBs 
exposure and thyroid hormone levels [55, 63, 130-139]. Some studies observed elevated levels of 
T3, T4, or TSH in relation to PBDEs exposure [131-134]; others reported inverse [133-137] or 
nonmonotonic [131] associations. A meta-analysis performed to estimate the effect of PBDEs 
exposure on serum levels of TSH and total T4 (TT4) reported substantial heterogeneities between 
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studies (I2 = 90.7% and 57.6% for TSH and TT4, respectively) [138]. Curtis and colleagues found 
that higher PBBs exposure before age 16 was associated with an increased level of T3 but a 
decreased level of T4 [130]. Studies on the relationship between PBBs and thyroid diseases also 
reported inconsistent results, with some observed positive association [55, 63], but the other found 
no association [139]. 
 
Several epidemiological studies have linked the risk of papillary thyroid cancer (PTC) in relation 
to PBDEs exposure [44, 140] and serum level of TSH [64, 68], respectively. If exposure to PBDEs 
could disrupt the homeostasis of thyroid hormones and then dysregulate TSH level, the thyroid 
carcinogenesis of PBDEs could operate through disruption of thyroid hormone homeostasis and 
fluctuation of TSH level. However, there is still lacking evidence pertaining to the mediation effect 
of TSH on the association between PBDEs/PBBs and risk of PTC. 
 
Since it is biologically possible that PBDEs and PBBs could disrupt thyroid hormone homeostasis, 
but epidemiological evidence is still inconsistent, we conducted a nested case-control study using 
serum samples from the Department of Defense Serum Repository (DoDSR), with data from the 
Department of Defense (DoD) Automated Central Tumor Registry (ACTUR) and the Defense 
Medical Surveillance System (DMSS), to investigate the associations between serum 
concentrations of PBDEs and PBBs and levels of thyroid hormone. We also conducted a mediation 
analysis to estimate the potential mediation effect of serum level of TSH on the association between 




Detailed information regarding the study design has been described elsewhere [64, 140] and in the 
Aim 1. In brief, 742 pairs of PTC cases diagnosed between 2000 and 2013 and non-cancer (except 
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for non-melanoma skin cancer) controls were enrolled from the US military personnel who had at 
least four serum samples drawn during active duty and stored in the DoDSR. Cases and controls 
were individually matched by date of birth (±1 year), gender, race/ethnicity, and midpoint of dates 
of selected four samples drawn (±1 year). All study procedures were approved by the Uniformed 
Services University Institutional Review Board, the Walter Reed National Military Medical Center, 
the DoD Joint Pathology Center, and the Human Investigation Committee of Yale University. The 
involvement of the Centers for Disease Control and Prevention (CDC) laboratory did not constitute 
engagement in human subjects research. 
 
Laboratory analyses 
Serum concentrations of PBDEs and PBBs were measured in the earliest pre-diagnostic serum 
samples. The measurement was conducted at the Persistent Organic Pollutants Laboratory, CDC 
(Atlanta, Georgia). The methodology used has been published [141] and the measured results have 
been summarized elsewhere [140]. Briefly, the analytical determinations of PBDE and PBB 
congeners were performed by using gas chromatography, isotope dilution, high-resolution mass 
spectrometry (GC-ID/HRMS) employing a DFSTM (Thermo Fisher Scientific, Waltham, 
Massachusetts) instrument. A total of 11 PBDE congeners (BDE-17, -28, -47, -66, -85, -99, -100, 
-153, -154, -183, and -209) and one PBB congener (BB-153) were measured. The levels of the 12 
congeners were reported as lipid-corrected serum concentration (ng/g of serum lipid). Detection 
rates of PBDE and PBB congeners were similar among cases and controls (p-values from the χ2 
tests range: 0.089-0.90) [140]. 
 
Serum levels of TSH and thyroid hormones, including total T3 (TT3), TT4, and free T4 (FT4), 
were detected in the second earliest samples collected before cancer diagnosis. The measurement 
was performed by using electrochemiluminescence immunoassay at the Yale Medical Laboratory 
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(Yale University; New Haven, CT) [64]. The normal ranges for TSH, TT3, TT4, and FT4 were 0.3-
4.2 mU/mL, 79-149 ng/dL, 5.0-10.6 mg/dL, and 0.80-1.80 ng/dL, respectively. 
 
Statistical analyses 
Because the laboratory measurements of TSH and thyroid hormones failed in one sample, all 
statistical analyses were conducted in the remaining 741 pairs of PTC cases and individually 
matched controls. Among the 12 congeners measured, seven PBDE congeners (BDE-28, -47, -85, 
-99, -100, -153, and -154) and one PBB congener (BB-153) that were detected in >20% of the 
control samples were included in the statistical analysis. Due to the right-skewed distribution, lipid-
corrected serum concentrations of PBDE and PBB congeners and serum levels of TSH and thyroid 
hormones were compared between cases and controls using the Mann-Whitney U test, respectively. 
 
Lipid-corrected serum concentrations of PBDE and PBB congeners that were below the limits of 
detection (LODs) were imputed as LOD/√2 for the correlation and regression analyses [142]. 
Lipid-corrected serum concentrations of PBDEs and PBB congeners were categorized into quartiles 
based on the distribution among controls, with the first quartile used as the reference category. 
Serum levels of TSH, TT3, TT4, and FT4 were divided into three categories on the basis of the 
normal range (i.e., below, within, and above the normal range). The correlations between serum 
concentrations of PBDE and PBB congeners and levels of TSH and thyroid hormones as continuous 
variables were estimated using the Pearson correlation coefficients. Kendall’s tau-b correlation 
coefficients were used to estimate the correlation between categorical levels of PBDE and PBB 
congeners, TSH, and thyroid hormones. 
 
According to the scatter plots with smooth curve fitted by locally weighted smoothing (LOESS), 
relationships between serum concentrations of PBDE and PBB congeners and levels of TSH and 
thyroid hormones fitted nonmonotonic curves (Supplementary Figures 1-1 to 1-4). Thus, 
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generalized additive models (GAMs) were used to depict the potential nonlinear relationships. 
Linear regression was also conducted using the categorical levels of PBDE and PBB congeners to 
estimate effects of different concentration groups of congeners on hormone levels. TSH and thyroid 
hormones were natural log transformed in the GAMs and linear regression models to better fit a 
normal distribution. In the GAMs, serum concentrations of PBDE and PBB congeners were also 
natural log transformed, and one congener was included in each model. For the linear regression, 
all the categorical PBDE and PBB congeners were included in one model to additionally control 
for potential confounding effect from other congeners. Other confounding variables include body 
mass index (BMI; <18.5, 18.5-24.9, 25-29.9, and 30 kg/m2) and branch of military service (army, 
air force, marines and coast guard, and navy). Relationships between serum concentrations of 
PBDE and PBB congeners and levels of TSH and thyroid hormones were examined in cases and 
controls, respectively. Stratified analyses were also performed by gender to investigate if estrogen 
impacts the relationships. 
 
Mediation effects of TSH on the association between PBDE and PBB congeners and risk of PTC 
were estimated by applying the R package mediation, which is recommended as a flexible and 
statistically powerful approach to conduct causal mediation analysis [143]. By performing this 
analysis, the average causal mediation effect (ACME) (i.e., effect of TSH on the risk of PTC) and 
the average direct effect (ADE) (i.e., effect of PBDEs/PBBs on the risk of PTC that not through 
alternation of TSH) could be distinguished and reported separately. The ACME was estimated 
using hierarchical linear model, and the ADE was evaluated by generalized linear mixed-effects 
model. Both models were adjusted for all PBDE and PBB congeners, BMI, and branch of military 
service. The proportion of mediation effect in the total effect was estimated by 𝐴𝐶𝑀𝐸/(𝐴𝐷𝐸 +
𝐴𝐶𝑀𝐸). The causal mediation analysis was also conducted in classical PTC and large tumors (>10 
mm) and was stratified by gender, according to the observed associations between BDE-28, TSH, 




All tests were 2-sided with α=0.05. Because seven PBDE and one PBB congeners were included 
in the final analysis, a Bonferroni-adjusted α of 0.05/8=0.006 was applied to control for multiple 
comparisons. Statistical analyses were conducted using SAS, version 9.4 (SAS Institute, Inc.; Cary, 
North Carolina) and R, version 3.6.3 (R Foundation, Vienna, Austria). 
 
Results 
Serum samples used for the measurement of PBDEs and PBBs were drawn during 1994 to 2009 
and approximately 3.1-12.0 years before the cases were diagnosed with PTC, while the samples 
used for measuring TSH and thyroid hormones were collected approximately 0.2-11.6 years before 
cancer diagnosis. The intervals between these two sampling dates were ranged from 0.1 to 12.1 
years, with the median of 2.6 years (interquartile range [IQR]=1.4-4.6 years) (data not shown). 
 
Except for TSH, distributions of serum concentrations of PBDE and PBB congeners and serum 
levels of thyroid hormones were similar among cases and controls (p-values from the Mann-
Whitney U tests range: 0.27-0.76) (Table 1). TSH level was significantly lower in cases than that 
in controls (P=0.0004). The Pearson correlation coefficients indicated that serum concentrations of 
PBDE congeners as continuous values were strongly correlated with each other (Pearson's r range: 
0.51-0.98), but the correlations between PBDE congeners and PBB-153 were very weak (|Pearson's 
r| <0.01) (Supplementary Table 1). Compared with the continuous values, the correlations between 
categorical concentrations of PBDE congeners were weakened (Kendall's τ range: 0.40-0.90) 
(Supplementary Table 2). Serum levels of TSH and thyroid hormones were just weakly correlated 





Based on results of the GAMs, nonmonotonic relationships were observed between serum 
concentrations of BDE-153 and BB-153 and levels of TT3 (P=0.033 and 0.0072 with BDE-153 
and BB-153, respectively) and TT4 (P=0.011 and 0.0010 with BDE-153 and BB-153, respectively) 
in PTC cases (Supplementary Figures 2-2 and 2-3). The effects of BDE-47 (P=0.0088), -100 
(P=0.0051), and -153 (P=0.025) on FT4 level were nonmonotonic in controls (Supplementary 
Figure 3-4). 
 
Results from the linear regression models showed stronger associations between serum 
concentrations of PBDE and PBB congeners and levels of TSH and thyroid hormones in PTC cases 
as compared to controls. Among cases, higher serum concentrations of BDE-153 and BB-153 were 
associated with increased TSH level and decreased levels of TT3 and TT4, while higher 
concentration of BDE-100 was associated with reduced level of TSH and elevated level of TT4 
(Figure 1). After Bonferroni correction, the associations between BDE-153 in relation to levels of 
TSH (β=0.63, 95% confidence interval [CI]: 0.29, 0.98 for the Q4 vs. Q1), TT3 (β=-0.11, 95% CI: 
-0.19, -0.04 for the Q4 vs. Q1), and TT4 (β=-0.10, 95% CI: -0.17, -0.03 for the Q4 vs. Q1) and 
between BB-153 in relation to levels of TT3 (β=-0.06, 95% CI: 0.-0.11, -0.02 for both Q3 vs. Q1) 
and TT4 (β=-0.08, 95% CI: -0.13, -0.04 for the Q4 vs. Q1) remained significant (data not shown). 
But in controls, only higher concentration of BB-153 was suggestively associated with a reduced 
level of TT4 (β=-0.046, 95% CI: -0.088, -0.005 for the Q4 vs. Q1), and this association was no 
longer significant after Bonferroni correction (Figure 2). The associations between concentrations 
of BDE-100, -153, and BB-153 in relation to TSH level were statistically stronger in cases than 
those in controls (Pinteraction=0.0004, 0.0024, and 0.0099, respectively) (data not shown). When 
stratified the analysis in cases by gender, the associations between higher concentration of BDE-
100 in relation to decreased level of TSH and increased level of TT4 was only observed among 
men (Pinteraction=0.0002 and <0.0001, respectively), while the positive association between higher 
concentration of BDE-153 and TSH level, as well as the inverse associations between higher 
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concentrations of BDE-153 and BB-153 in relation to levels of TT3 and TT4 were observed among 
women, but not among men (Pinteraction=0.0006 for BDE-153 and TSH; 0.0014 for BDE-153 and 
TT3; <0.0001 for BDE-153 and TT4; 0.0008 for BB-153 and TT3; and <0.0001 for BB-153 and 
TT4) (Figure 3). 
 
According to results from the causal mediation analysis, the ADE of BED-28 on increasing risk of 
large classical PTC (>10 mm) was statistically significant, and this effect is especially dominant in 
women. However, neither the ACME of TSH nor the proportion of mediation effect in the total 
effect are significant (Table 2). In addition, the mediation effect of TSH accounts for a 
nonsignificant proportion in the total effect of other PBDE and PBB congeners on the risk of PTC 
(Supplementary Table 3). 
 
Discussion 
This study observed significantly nonmonotonic relationships between serum concentrations of 
BDE-153 and BB-153 and levels of TT3 and TT4 in PTC cases, and between BDE-47, -100, and -
153 in relation to FT4 level in controls. The associations between PBDEs/PBBs and levels of TSH 
and thyroid hormones were stronger in cases than those in controls. Among cases, higher serum 
concentrations of BDE-153 and BB-153 were associated with increased level of TSH and decreased 
levels of TT3 and TT4, while higher concentration of BDE-100 was associated with reduced level 
of TSH and elevated level of TT4. When stratified by gender, the effects of BDE-100 on levels of 
TSH and TT4 were only observed among men, while the effects of BDE-153 and BB-153 on levels 
of TT3 and TT4 were only observed among women. Results from the causal mediation analysis 
did not support the hypothesis that the thyroid carcinogenesis of PBDEs/PBBs is mainly operated 




The geometric means of concentrations for BDE-28, -47, -99, -100, -153, and BB-153 in controls 
of this study (Table 1) were higher than those in the US general population from the NHANES 
2003-2004 [56]. When we restricted our comparisons to the subset of our study population with 
serum samples taken during 2003-2004, the geometric means were comparable to those in the 
NHANES 2003/04 population. However, the 90th and 95th percentiles of concentrations for most 
PBDE and PBB congeners in this study population were lower than those in the NHANES 2003/04 
population, indicating a more centralized range of concentrations in the current military population 
as compared to the NHANES general population. A similar range of concentrations was only 
observed for BDE-153 between the study population and NHANES 2003/04 population. The 
distributions of serum levels of TSH and thyroid hormones in majority of this study population 
were within the normal ranges (94% for TSH; 75% for TT3; 88% for TT4; and 99% for FT4 in 
controls) (data not shown). 
 
The significant associations between serum concentrations of BDE-100 and -153 in relation to 
levels of TSH and thyroid hormones from the current study are partially similar to those observed 
in several previous studies [133, 136, 137], but other studies did not report significant associations 
with these PBDE congeners [132, 134, 135]. The disparities between studies may be caused by the 
nonmonotonic relationships between PBDE congeners and levels of TSH and thyroid hormones. 
Due to the nature of nonmonotonicity, associations were varied with different concentrations of 
PBDEs. For example, Guo and colleagues investigated the associations between PBDEs and 
thyroid hormones in 174 school students lived near a petrochemical complex in South China, and 
did not find any significant associations with BDE-153 [131]. In this Chinese student population, 
serum concentrations of BDE-153 was lower than that in the highest quartile of our study 
population (median [range]: 2.9 [0.6-25.0] ng/g lipid vs. 27.0 [11.5-285.5] ng/g lipid). The 
associations between lower concentration of BDE-153 and levels of TSH and thyroid hormones 
were also nonsignificant in our study population. A meta-analysis performed to estimate the 
 
76 
association between PBDEs exposure and thyroid hormone levels suggested that the effects of 
PBDE congeners depend on their degree of bromination and inner concentrations [138]. The meta-
analysis also reported an approximate U-shaped relationship between PBDEs exposure and 
changes in thyroid hormone levels. Lower concentration of ∑PBDEs (median level <30 ng/g lipids) 
was associated with reduced serum level of TSH, while higher concentration (median level >100 
ng/g lipids) was associated with elevated serum level of TSH. Similarly, serum level of TT4 was 
negatively associated with lower ∑PBDEs concentration (median level <35 ng/g lipids) and 
positively associated with higher PBDEs concentration (median level between 35 and 100 ng/g 
lipids) [138]. In the current study, we also observed a statistically significant U-shaped relationship 
between BDE-153 and TT4 in cases (P=0.011) (Supplementary Figure 2-3). 
 
Variations in study populations and geometric distributions may also contribute to the 
heterogeneity between studies. Previous studies included school children [131, 135], pregnant 
women [132, 137], e-waste recycling workers [134], and residents living near a petrochemical 
complex [131] or a e-waste dismantling area [135, 136]. The circulating levels of TSH and thyroid 
hormones are significantly higher in children than those in adults [144, 145]. These physiological 
changes in thyroid gland and impact of placental human chorionic gonadotropin (hCG) during 
pregnancy may result in increased T3 and T4 and decreased TSH [146]. A review on human 
exposure to PBDEs in e-waste areas indicated that the residents and some vulnerable groups (e.g., 
occupational workers and children) in e-waste recycling areas may face higher exposure levels as 
compared to people living in other areas [147]. The variance in thyroid hormone levels and PBDEs 
exposure may partially explain the different observed relationships. 
 
According to the meta-analysis on the relationships between PBDEs and thyroid hormones, 
duration of exposure may also affect the effects of PBDEs [138]. The analyses stratified by intervals 
between sample dates for congeners and hormones (≤3 and >3 years; based on sample size) 
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suggested a significantly positive association between higher serum concentration of BDE-28 and 
TSH level in samples collected for >3 years (β=1.31, 95% CI: 0.45, 2.17 for the Q4 vs. Q1), but a 
nonsignificant negative association in samples collected for ≤3 years (β=-0.32, 95% CI: -0.83, 0.19 
for the Q4 vs. Q1) (data not shown). The effects of PBDEs on thyroid hormone levels by duration 
of exposure need to be further investigated by longitudinal measurements. 
 
Our study observed significant relationship between BB-153 and serum levels of TSH, TT3, and 
TT4, which was not reported by previous studies. One cross-sectional study in 715 participants of 
the Michigan PBB Registry reported a negative association between ∑PBBs and FT4, but 
nonsignificant relationships with TSH, TT3, and TT4 [130]. Since previous studies on PBBs were 
mainly conducted in the Michigan residents, whose exposure level was substantially higher than 
other populations due to an accidental contamination of the food supply during 1973 and 1974 [55, 
56, 121], the observed associations with PBB-153 in the DoDSR cohort need to be verified in other 
general populations. Previous studies suggested an estrogenic effect of PBBs, and speculated that 
the altered estrogen levels by PBBs exposure may affect the synthesis of TBG, which is a thyroid 
hormone transport protein that is able to bind the majority of T4 [129, 130]. In the current study, 
the effect of BB-153 on thyroid hormone levels was observed only among women, but not among 
men. 
 
This study did not find any evidence supporting a mediation effect of TSH on the association 
between PBDEs/PBBs and risk of PTC. After examining the carcinogenetic effect of PBDEs/PBBs 
on the risk of PTC by TSH level, an interaction between PBDEs/PBBs and TSH on PTC risk was 
not suggested as well (data not shown). Thus, the mechanisms underlying the potential thyroid 




The present study has several strengths. The sample size was relatively large, providing sufficient 
statistical power to investigate and compare the relationships by gender. Although we did not 
suspect a specific source of exposure to PBDEs related to military service, PBDEs are persistent, 
with half-lives range between 3-12 years, and temporal trends of levels measured in the 
environment suggest that human exposure is widespread, despite bans on the various BDEs. The 
serum concentrations of PBDE and PBB congeners and levels of TSH and thyroid hormones were 
respectively assessed in two serum samples collecting consecutively before cancer diagnosis, 
which provides an opportunity to estimate potentially causal relationships between exposure to 
PBDEs/PBBs and thyroid hormone homeostasis, without being influenced by the disease process 
or treatment. 
 
Limitations should be considered when interpreting results of this study. There was a high 
percentage of participants with missing BMI data, which may have led to insufficient adjustment 
for BMI. Previous evidence has suggested lower prevalence of obesity and larger lean body mass 
of military personnel than the US civilian population [69], indicating less variation of BMI among 
the US military personnel. Thus, any effect of under-adjustment for BMI would likely be 
minimized in this study population. PBDEs/PBBs and thyroid hormones were measured in one-
time serum samples, respectively. Misclassifications of inner levels of chemicals and hormones 
cannot be ruled out. Additionally, any changes in relationships by duration of exposure were not 
able to be captured in this study. The lack of data on medication use preclude us from carrying out 
sensitivity analyses excluding people who were taking thyroid hormones. Furthermore, the 
stratified analyses may have yielded unstable results due to the reduced subgroup counts. It is also 
possible that the relationships were observed by chance due to the multiple comparisons. However, 
the effects of BDE-153 and BB-153 on TSH and thyroid hormones remained statistically significant 




In conclusion, this study suggested significant disrupting effects of BDE-100, 153, and BB-153 on 
serum levels of TSH and thyroid hormones. The observed relationships were nonmonotonic and 
varied by gender. Results from the causal mediation analysis did not support a mediation effect of 
TSH on the association between PBDEs/PBBs and risk of PTC. Findings of this study contribute 
to the understanding of mechanisms underlying endocrine disrupting effect of PBDEs/PBBs. 
Further investigations using multiple longitudinal measurements and examining effect 
modification of genetic polymorphisms is warranted. Additionally, more epidemiological studies 
with PBDE alternatives among different populations are also warranted to confirm these findings 
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P-value c Detected b 
GM (GSD) Median (IQR) 
Detected b 
GM (GSD) Median (IQR) 
No. % No. % 
BDE-28 1.1 (0.9-1.3) 250 33.7 3.0 (2.5) <LOD (<LOD-1.5)  236 31.9 2.6 (2.3) <LOD (<LOD-1.3) 0.27 
BDE-47 2.5 (2.1-2.8) 707 95.4 21.5 (3.7) 16.3 (7.9-38.7)  706 95.3 21.0 (3.2) 16.8 (8.4-38.3) 0.74 
BDE-85 1.0 (0.8-1.3) 208 28.1 3.3 (3.0) <LOD (<LOD-1.0)  203 27.4 2.8 (2.6) <LOD (<LOD-1.0) 0.63 
BDE-99 2.0 (1.7-2.4) 548 74.0 9.1 (3.6) 4.3 (<LOD-10.6)  576 77.7 8.2 (3.2) 4.4 (2.2-10.6) 0.61 
BDE-100 1.0 (0.9-1.3) 620 83.7 5.7 (3.5) 3.4 (1.5-8.8)  642 86.6 5.3 (3.0) 3.7 (1.8-8.6) 0.44 
BDE-153 1.0 (0.8-1.3) 678 91.5 6.4 (3.4) 4.4 (2.1-11.5)  690 93.1 6.3 (3.0) 4.6 (2.5-11.3) 0.39 
BDE-154 1.0 (0.9-1.3) 217 29.3 3.0 (2.9) <LOD (<LOD-1.1)  209 28.2 2.6 (2.5) <LOD (<LOD-1.0) 0.56 
BB-153 1.0 (0.9-1.3) 543 73.3 3.0 (2.3) 2.0 (<LOD-3.5)   549 74.1 3.1 (2.2) 2.1 (0.9-3.6) 0.37 
TSH (µU/mL)    1.3 (2.8) 1.4 (0.9-2.1)    1.5 (1.9) 1.6 (1.1-2.3) 0.0004 
TT3 (ng/dL)    134.3 (1.2) 133.0 (120.0-148.0)    132.4 (1.2) 132.0 (118.0-149.0) 0.50 
TT4 (µg/dL)    8.7 (1.2) 8.6 (7.6-9.8)    8.6 (1.2) 8.6 (7.7-9.6) 0.76 
FT4 (ng/dL)       1.2 (1.2) 1.3 (1.1-1.4)       1.2 (1.1) 1.2 (1.1-1.4) 0.33 
Abbreviations: Abbreviations: PBED, polybrominated diphenyl ether; PBB, polybrominated biphenyl; TSH, thyroid-stimulating hormone; PTC, papillary 
thyroid cancer; LOD: limit of detection; IQR, interquartile range; GM, geometric mean; GSD, geometric standard deviation; BDE-28, 2,4,4'-
tribromodiphenyl ether; BDE-47, 2,2',4,4'-tetrabromodiphenyl ether; BDE-85, 2,2',3,4,4'-pentabromodiphenyl ether; BDE-99, 2,2',4,4',5-pentabromodiphenyl 
ether; BDE-100, 2,2',4,4',6-pentabromodiphenyl ether; BDE-153, 2,2',4,4',5,5'-hexabromodiphenyl ether; BDE-154, 2,2',4,4',5,6'-hexabromodiphenyl ether; 
BB-153, 2,2',4,4',5,5'-hexabromobiphenyl; TT3, total triiodothyronine; TT4, total thyroxine; FT4, free thyroxine. 
a Calculated among cases and controls combined. 
b Serum samples containing PBDE or PBB congener had an amount above the LOD, and the value of concentration is detectable. 































BDE-28                    
 <LOD ref.    ref.    ref.    ref.    ref.   
 >LOD-1.56 -0.0025 -0.0139 0.0136  -0.0021 -0.0233 0.0210  0.0047 0.0500 0.0362  0.0005 0.0795 0.0018  0.0159 0.0256 0.1110 
 1.57-3.18 -0.0036 0.0597 -0.0323  -0.0017 0.0926 -0.0125  -0.0040 0.1696* -0.0171  0.0001 0.1240 <0.0001  -0.0046 0.2328 -0.0087 
 3.19-80.10 -0.0059 0.1054 -0.0404  -0.0046 0.1602* -0.0236  0.0018 0.2915*** 0.0031  0.0014 0.2199 0.0026  -0.0165 0.4002** -0.0321 
Abbreviation: TSH, thyroid-stimulating hormone; BDE-28, 2,4,4'-tribromodiphenyl ether; PTC, papillary thyroid cancer; ACEM, average causal 
mediation effect; ADE, average direct effect; LOD: limit of detection; BMI, body mass index. 







Figure 1. Estimated effects of categorical serum concentrations of PBDE and PBB congeners on natural log transformed serum levels of 
TSH (A), TT3 (B), TT4 (C), and FT4 (D) in PTC cases, using linear regression models adjusted for all PBDE and PBB congeners, BMI, 




Figure 2. Estimated effects of categorical serum concentrations of PBDE and PBB congeners on natural log transformed serum levels of 
TSH (A), TT3 (B), TT4 (C), and FT4 (D) in controls, using linear regression models adjusted for all PBDE and PBB congeners, BMI, and 




Figure 3. Estimated effects of categorical serum concentrations of PBDE and PBB congeners on natural log transformed serum levels of 
TSH, TT3, TT4, and FT4 in male PTC cases (A) and female PTC cases (B), using linear regression models adjusted for all PBDE and 




Supplementary Table 1. Pearson correlation coefficients between continuous serum concentrations of PBDE and PBB congeners, TSH, and thyroid 
hormones. 
  BDE-28 BDE-47 BDE-85 BDE-99 BDE-100 BDE-153 BDE-154 BB-153 TSH TT3 TT4 FT4 
BDE-28 1 0.9338** 0.8928** 0.8483** 0.8959** 0.5828** 0.8840** -0.0042 -0.0139 -0.0320 -0.0286 -0.0509 
BDE-47  1 0.9728** 0.9470** 0.9511** 0.5908** 0.9482** 0.0011 -0.0166 -0.0259 -0.0150 -0.0470 
BDE-85   1 0.9718** 0.9360** 0.5821** 0.9761** -0.0036 -0.0207 -0.0258 -0.0119 -0.0468 
BDE-99    1 0.8795** 0.5115** 0.9542** -0.0050 -0.0140 -0.0304 -0.0174 -0.0471 
BDE-100     1 0.7424** 0.9511** -0.0003 -0.0119 -0.0291 -0.0214 -0.0451 
BDE-153      1 0.6322** -0.0025 0.0010 -0.0442 -0.0271 -0.0095 
BDE-154       1 -0.0054 -0.0152 -0.0302 -0.0146 -0.0477 
BB-153        1 0.0148 -0.0223 -0.0481 -0.0237 
TSH         1 -0.0596* -0.1720** -0.1896** 
TT3          1 0.6806** 0.3954** 
TT4           1 0.5164** 
FT4            1 
Abbreviations: PBED, polybrominated diphenyl ether; PBB, polybrominated biphenyl; TSH, thyroid-stimulating hormone; BDE-28, 2,4,4'-
tribromodiphenyl ether; BDE-47, 2,2',4,4'-tetrabromodiphenyl ether; BDE-85, 2,2',3,4,4'-pentabromodiphenyl ether; BDE-99, 2,2',4,4',5-
pentabromodiphenyl ether; BDE-100, 2,2',4,4',6-pentabromodiphenyl ether; BDE-153, 2,2',4,4',5,5'-hexabromodiphenyl ether; BDE-154, 2,2',4,4',5,6'-






Supplementary Table 2. Kendall’s tau-b correlation coefficients between categorical serum concentrations of PBDE and PBB congeners, TSH, and thyroid 
hormones. 
  BDE-28 BDE-47 BDE-85 BDE-99 BDE-100 BDE-153 BDE-154 BB-153 TSH TT3 TT4 FT4 
BDE-28 1 0.5401** 0.7339** 0.4647** 0.5193** 0.4049** 0.7395** 0.1025** 0.0030 0.0001 -0.0163 -0.0364 
BDE-47  1 0.4516** 0.8150** 0.8223** 0.5531** 0.4644** 0.0857** -0.0333 -0.0029 -0.0165 -0.0266 
BDE-85   1 0.4525** 0.4641** 0.3965** 0.8992** 0.0432* -0.0314 0.0191 -0.0001 -0.0415 
BDE-99    1 0.7764** 0.5369** 0.4531** 0.0709* -0.0386 0.0136 -0.0112 -0.0351 
BDE-100     1 0.6891** 0.4951** 0.0893** -0.0356 -0.0016 -0.0156 -0.0139 
BDE-153      1 0.4260** 0.0891** -0.0015 -0.0391 -0.0361 -0.0137 
BDE-154       1 0.0731* -0.0253 0.0155 -0.0066 -0.0426 
BB-153        1 0.0455 -0.1062** -0.1434** -0.0181 
TSH         1 -0.0942* -0.1472** -0.2564** 
TT3          1 0.4681** 0.1081** 
TT4           1 0.2954** 
FT4            1 
Abbreviations: PBED, polybrominated diphenyl ether; PBB, polybrominated biphenyl; TSH, thyroid-stimulating hormone; BDE-28, 2,4,4'-
tribromodiphenyl ether; BDE-47, 2,2',4,4'-tetrabromodiphenyl ether; BDE-85, 2,2',3,4,4'-pentabromodiphenyl ether; BDE-99, 2,2',4,4',5-
pentabromodiphenyl ether; BDE-100, 2,2',4,4',6-pentabromodiphenyl ether; BDE-153, 2,2',4,4',5,5'-hexabromodiphenyl ether; BDE-154, 2,2',4,4',5,6'-






Supplementary Table 3. Mediation effect of TSH and on the association between lipid-corrected serum concentrations of PBDE and PBB congeners (ng/g) and 



























BDE-47                    
 <LOD-8.43 ref.    ref.    ref.    ref.    ref.   
 8.44-16.91 -0.0027 0.0487 -0.0221  -0.0025 0.0446 -0.0207  -0.0067 0.0544 -0.0487  -0.0013 0.0613 -0.0030  -0.0061 0.0660 0.0041 
 16.92-38.63 -0.0069 0.0606 -0.0568  -0.0084 0.0881 -0.0642  -0.0079 0.0858 -0.0370  -0.0005 0.0021 0.0002  -0.0191 0.2062 -0.0621 
 38.64-2189.00 0.0090 0.0097 0.0384  0.0049 0.0072 0.0091  -0.0118 -0.1180 0.0433  <-0.0001 -0.1670 <-0.0001  -0.0536 -0.0567 0.1764 
BDE-85                    
 <LOD ref.    ref.    ref.    ref.    ref.   
 >LOD-1.68 -0.0012 0.0263 -0.0004  -0.0033 0.0229 -0.0092  -0.0020 -0.0735 0.0102  -0.0015 -0.1139 0.0052  0.0444 0.0409 0.1633 
 1.69-3.18 -0.0062 -0.1448 0.0357  -0.0074 -0.1732 0.0355  -0.0028 -0.2477* 0.0086  -0.0001 -0.2234 0.0005  -0.0204 -0.1994 0.0764 
 3.19-79.08 -0.0056 0.1595 -0.0224  -0.0073 0.1506 -0.0246  -0.0049 0.0538 -0.0058  -0.0017 -0.1347 0.0017  -0.0110 0.2540 -0.0072 
BDE-99                    
 <LOD-2.17 ref.    ref.    ref.    ref.    ref.   
 2.18-4.40 0.0012 -0.0472 -0.0120  0.0002 -0.0418 0.0024  0.0037 -0.0304 -0.0110  0.0001 -0.0294 0.0006  0.0148 -0.0640 -0.0451 
 4.41-10.61 0.0062 -0.0204 -0.0198  0.0070 -0.0434 -0.0375  0.0110 -0.0584 -0.0603  0.0004 -0.0141 0.0015  0.0403 -0.1674 -0.1916 
 10.62-993.30 -0.0011 -0.0270 0.0072  0.0033 -0.0656 -0.0073  0.0071 -0.0766 -0.0217  0.0007 -0.0389 0.0013  0.0504 -0.1544 -0.1635 
BDE-100                    
 <LOD-1.84 ref.    ref.    ref.    ref.    ref.   
 1.85-3.71 0.0069 -0.0828 -0.0713  0.0069 -0.0745 -0.0679  0.0013 -0.1067 -0.0046  0.0003 -0.0554 0.0004  -0.0150 -0.1183 0.0900 
 3.72-8.65 0.0107 -0.1232 -0.0773  0.0120 -0.1161 -0.0888  0.0093 -0.1367 -0.0519  0.0008 -0.0690 -0.0013  -0.0038 -0.1666 0.0293 
 8.66-368.00 0.0140 -0.0966 -0.0901  0.0170 -0.0927 -0.1025  0.0318* -0.0704 -0.1042  0.0011 0.0001 0.0012  0.0770 -0.1009 -0.0388 
BDE-153                    
 <LOD-2.49 ref.    ref.    ref.    ref.    ref.   
 2.50-4.61 -0.0086* -0.0109 0.1402  -0.0085* -0.0392 0.1188  -0.0119* 0.0045 0.0686  -0.0007 -0.0463 0.0025  -0.0166 0.0178 0.0325 
 4.62-11.23 -0.0077 -0.0332 0.1113  -0.0080 -0.0696 0.0883  -0.0132* 0.0009 0.0870  -0.0009 -0.0306 -0.0005  -0.0216 -0.0297 0.1339 
 11.24-285.50 -0.0189** -0.0123 0.2453  -0.0177** 0.0072 0.1443  -0.0310* -0.0347 0.2667  -0.0011 -0.0957 0.0022  -0.0845*** <0.0001 0.5340 
BDE-154                    
 <LOD ref.    ref.    ref.    ref.    ref.   
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 >LOD-1.60 -0.0007 0.0670 -0.0036  -0.0008 0.0920 -0.0033  -0.0060 0.2257*** -0.0224  <-0.0001 0.1930* <-0.0001  -0.0338 0.2458 -0.1133 
 1.61-3.11 -0.0062 0.0362 -0.0174  -0.0068 0.0747 -0.0366  -0.0069 0.2233* -0.0267  -0.0007 0.1920 <-0.0001  -0.0164 0.2243 -0.0323 
 3.12-66.22 0.0062 -0.1058 -0.0202  0.0033 -0.1168 -0.0081  0.0030 0.0653 0.0136  -0.0009 0.2110 -0.0001  0.0380 -0.1760 -0.0578 
BB-153                    
 <LOD-0.85 ref.    ref.    ref.    ref.    ref.   
 0.86-2.12 -0.0054 -0.0135 0.0780  -0.0077* -0.0128 0.1215  -0.0058 -0.0454 0.0556  -0.0004 -0.0914 0.0005  -0.0103 -0.0343 0.1154 
 2.13-3.60 -0.0065 -0.0105 0.1094  -0.0069 -0.0277 0.1046  -0.0080 -0.0555 0.0902  -0.0004 -0.0675 0.0005  -0.0129 -0.0363 0.1078 
 3.61-451.30 -0.0083* -0.0118 0.1385  -0.0106** -0.0040 0.1254  -0.0130* -0.0231 0.1689  -0.0007 -0.0649 0.0033  -0.0161 0.0093 0.0744 
Abbreviation: TSH, thyroid-stimulating hormone; PBED, polybrominated diphenyl ether; PBB, polybrominated biphenyl; PTC, papillary thyroid cancer; 
ACEM, average causal mediation effect; ADE, average direct effect; BDE-47, 2,2',4,4'-tetrabromodiphenyl ether; BDE-85, 2,2',3,4,4'-pentabromodiphenyl 
ether; BDE-99, 2,2',4,4',5-pentabromodiphenyl ether; BDE-100, 2,2',4,4',6-pentabromodiphenyl ether; BDE-153, 2,2',4,4',5,5'-hexabromodiphenyl ether; BDE-
154, 2,2',4,4',5,6'-hexabromodiphenyl ether; BB-153, 2,2',4,4',5,5'-hexabromobiphenyl; LOD: limit of detection; BMI, body mass index. 








Supplementary Figure 1-1. Scatter plots of TSH against BDE-28 (A), BDE-47 (B), BDE-85 (C), BDE-99 (D), BDE-100 (E), BDE-153 





Supplementary Figure 1-2. Scatter plots of TT3 against BDE-28 (A), BDE-47 (B), BDE-85 (C), BDE-99 (D), BDE-100 (E), BDE-153 (F), 





Supplementary Figure 1-3. Scatter plots of TT4 against BDE-28 (A), BDE-47 (B), BDE-85 (C), BDE-99 (D), BDE-100 (E), BDE-153 (F), 





Supplementary Figure 1-4. Scatter plots of FT4 against BDE-28 (A), BDE-47 (B), BDE-85 (C), BDE-99 (D), BDE-100 (E), BDE-153 (F), 





Supplementary Figure 2-1. Estimated effects of natural log transformed BDE-28 (A), BDE-47 (B), BDE-85 (C), BDE-99 (D), BDE-100 
(E), BDE-153 (F), BDE-154 (G), and BB-153 (H) on natural log transformed serum levels of TSH using generalized additive models, 




Supplementary Figure 2-2. Estimated effects of natural log transformed BDE-28 (A), BDE-47 (B), BDE-85 (C), BDE-99 (D), BDE-100 
(E), BDE-153 (F), BDE-154 (G), and BB-153 (H) on natural log transformed serum levels of TT3 using generalized additive models, 




Supplementary Figure 2-3. Estimated effects of natural log transformed BDE-28 (A), BDE-47 (B), BDE-85 (C), BDE-99 (D), BDE-100 
(E), BDE-153 (F), BDE-154 (G), and BB-153 (H) on natural log transformed serum levels of TT4 using generalized additive models, 




Supplementary Figure 2-4. Estimated effects of natural log transformed BDE-28 (A), BDE-47 (B), BDE-85 (C), BDE-99 (D), BDE-100 
(E), BDE-153 (F), BDE-154 (G), and BB-153 (H) on natural log transformed serum levels of FT4 using generalized additive models, 




Supplementary Figure 3-1. Estimated effects of natural log transformed BDE-28 (A), BDE-47 (B), BDE-85 (C), BDE-99 (D), BDE-100 
(E), BDE-153 (F), BDE-154 (G), and BB-153 (H) on natural log transformed serum levels of TSH using generalized additive models, 




Supplementary Figure 3-2. Estimated effects of natural log transformed BDE-28 (A), BDE-47 (B), BDE-85 (C), BDE-99 (D), BDE-100 
(E), BDE-153 (F), BDE-154 (G), and BB-153 (H) on natural log transformed serum levels of TT3 using generalized additive models, 




Supplementary Figure 3-3. Estimated effects of natural log transformed BDE-28 (A), BDE-47 (B), BDE-85 (C), BDE-99 (D), BDE-100 
(E), BDE-153 (F), BDE-154 (G), and BB-153 (H) on natural log transformed serum levels of TT4 using generalized additive models, 




Supplementary Figure 3-4. Estimated effects of natural log transformed BDE-28 (A), BDE-47 (B), BDE-85 (C), BDE-99 (D), BDE-100 
(E), BDE-153 (F), BDE-154 (G), and BB-153 (H) on natural log transformed serum levels of FT4 using generalized additive models, 
adjusted for BMI and branch of military service, among controls. 
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Genetic Polymorphisms in Phase I and Phase II Metabolism/Detoxification and Thyroid 
Hormone Metabolism Pathways, Polybrominated Diphenyl Ethers, Thyroid-Stimulating 
Hormones, and Risk of Papillary Thyroid Cancer 
 
Abstract 
Background: Increased risk of papillary thyroid cancer (PTC) has been linked to exposure to 
polybrominated diphenyl ethers (PBDEs) and reduced serum level of thyroid-stimulating hormone 
(TSH), but effect of genetic variation in genes coding for enzymes involved in metabolism of 
PBDEs and TSH on risk of PTC and whether this variation modifies the PBDEs and TSH related 
risk of thyroid carcinogenesis remain unclear. 
 
Methods: Using data from a case-control study nested within the Department of Defense Serum 
Repository (DoDSR) cohort, we evaluated 238 single nucleotide variants (SNVs) in 27 candidate 
genes in phase I and phase II metabolism/detoxification and thyroid hormone metabolism pathways 
in 317 papillary thyroid cancer (PTC) cases and 311 controls. Conditional logistic regression was 
used to estimate the associations between genetic polymorphisms and risk of PTC. Linear trend of 
the polymorphic effect was tested using an additive conditional logistic regression model. Gene-
environment interaction was tested by unconditional logistic regression to investigate if the 
magnitude of carcinogenic effect of BDE-28 and TSH on PTC differs depending on genetic 
polymorphisms. 
 
Results: Genetic polymorphism of GSTP1 rs4147581 was associated with risk of PTC in women 
and for large tumor (>10 mm), while GSTP1 rs1138272 was associated with risk of papillary 
microcarcinoma (≤10 mm). All the associations were non-significant after FDR-adjustment for 
multiple comparisons. Significant interactions were observed between BDE-28 and CYP2E1 
rs7092584 in women and DIO2 rs12885300 for large PTC. In addition, serum level of TSH 
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significantly interacted with UGT1Ax rs1875263 and DIO2 rs12885300 in men, and with UGT1Ax 
rs2011404 for large PTC. 
 
Conclusions: This study suggested that genetic polymorphisms in genes involved in phase I and 
phase II metabolism/detoxification and thyroid hormone metabolism pathways could modify the 
effects of BDE-28 and TSH on risk of PTC. The effect modification varied by gender and tumor 
size. More studies with prospective design and larger statistical power are warranted to confirm 
these findings and to further understand the underlying mechanisms of genetic polymorphisms and 
PBDEs/TSH related pathogenesis of PTC. 
 
Keywords: genetic polymorphism, metabolism and detoxification pathway, PBDEs, thyroid-




Increased risk of papillary thyroid cancer (PTC) has been linked to exposure to polybrominated 
diphenyl ethers (PBDEs) [43-45, 140] and abnormal, especially reduced, serum level of thyroid-
stimulating hormone (TSH) [64, 68] in previous epidemiological studies. However, effect of 
genetic variation in genes coding for enzymes involved in metabolism, regulation, or functional 
activation of PBDEs and TSH on risk of PTC and whether this variation modifies the PBDEs and 
TSH related risk of thyroid carcinogenesis are still unclear. 
 
As a class of brominated flame retardants (BFRs) that is widely distributed in the environment, 
PBDEs has been shown to be susceptible to several metabolic processes, including phase I 
oxidation via cytochrome P450 (CYP) isozymes and phase II conjugation via glucuronidation 
and/or sulfation enzymes (e.g., glutathione S-transferases [GSTs], uridine 5'-diphospho-
glucuronosyltransferases [UDPGTs], and sulfotransferases [SULTs]) [148]. In addition, exposure 
to PBDEs can induce the activity of major thyroid hormone metabolic enzymes, including CYP 
isozymes, UDPGTs, SULTs, and deiodinases, and then disrupt the metabolism and homeostasis of 
thyroid hormones [19]. Variants in genes involved in coding phase I and phase II 
metabolism/detoxification enzymes (e.g., CYP1A1, CYP2D6, CYP2E1, GSTM1, and GSTT1) have 
been suggested to be associated with risk of PTC in some epidemiological studies [46-49], but these 
findings are inconclusive and need to be confirmed in more populations [149, 150]. There is also 
some evidence of associations for risk of thyroid cancer with common variants in genes involved 
in regulation of thyroid hormones (e.g., FOXE1, NKX2-1, DIRC3, and NRG1) [111, 112]. 
Experimental studies observed upregulated expression of type 3 deiodinase (D3) gene (i.e., DIO3) 
and downregulated expression of type 2 deiodinase (D2) gene (i.e., DIO2) in human PTC tissue, 
indicating effects of deiodinases (i.e., D2 and D3) on tumor growth and aggressiveness [151, 152], 
but the role of deiodinases in initiation and promotion of PTC is still unstudied. Investigation of 
the effect modification of genetic variation on risk of PTC is yet limited. One nested case-control 
study examined the interactions of genetic variants in metabolism/detoxification pathways with 
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tobacco and alcohol use in relation to risk of PTC, and reported significant interactions between 
CYP26B1 and cigarette smoking and between UGT2B7 and alcohol consumption [50]. Another 
case-control study in children from the Chernobyl nuclear accident area found independent effects 
of genetic polymorphisms in FOXE1 and dose of ionizing radiation on the risk of PTC [153]. 
However, the role of genetic polymorphisms in phase I and phase II metabolism/detoxification and 
thyroid hormone metabolism pathways in modifying the association between environmental 
chemicals, thyroid hormones, and risk of PTC remains poorly understood. 
 
Investigation of variation in genes related to coding for enzymes involved in metabolism of PBDEs 
and thyroid hormones may provide a better understanding of the etiology of PTC. To test our 
hypothesis that genetic polymorphisms in phase I and phase II metabolism/detoxification and 
thyroid hormone metabolism pathways are associated with risk of PTC and these variants further 
modify the carcinogenic effects of PBDEs and TSH on PTC, we evaluated 238 single nucleotide 
variants (SNVs) in 27 candidate genes, using data from a case-control study nested within the 




Details of the nested case-control study design have been described in previous publications [64, 
140] and in the Aim 1. Briefly, 742 pairs of PTC cases diagnosed between 2000 and 2013 and non-
cancer (except for non-melanoma skin cancer) controls were recruited from the US military 
personnel who had serum samples drawn during active duty and stored in the DoDSR. Cases and 
controls were individually matched by date of birth (±1 year), gender, race/ethnicity, and midpoint 
of dates of selected four samples drawn (±1 year). All study procedures were approved by the 
Uniformed Services University Institutional Review Board, the Walter Reed National Military 
Medical Center, the DoD Joint Pathology Center, and the Human Investigation Committee of Yale 
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University. The involvement of the Centers for Disease Control and Prevention (CDC) laboratory 
did not constitute engagement in human subjects research. 
 
Laboratory analyses 
DNA samples were prepared using combinations of the last two 0.5-mL (total 1 mL) sera. At first, 
the combined serum samples were processed to extract human DNA using the QIAamp DNA Mini 
Kit (QIAGEN; Hilden, Germany). The extracted DNA samples were then quantified through a 
spectrophotometer. Since the minimum DNA quantity required for genotyping is 200 ng, a whole-
genome amplification (WGA) using the REPLI-g UltraFast Mini Kit (QIAGEN; Hilden, Germany) 
was performed to obtain sufficient DNA prior to genotyping. A minimum of 50 ng input DNA was 
set for the WGA reaction to obtain high quality WGA DNA, which yielded a total of 336 case-
control pairs (45.3%) who had satisfied the minimal amount of DNA for WGA and were qualified 
for genotyping. The distributions of demographic characteristics and military services were 
comparable between the 336 genotyped case-control pairs and the rest of participants 
(Supplementary Table 1). 
 
The prepared DNA samples were sent to the Yale Keck Biotechnology Resource Laboratory (Yale 
University; New Haven, CT) for genotyping, which was performed by employing the Infinium® 
Global Screening Array-24 (GSA-24) v2.0 platform (Illumina, Inc.; Madison, WI). A total of 
656,725 SNVs were genotyped for each DNA sample. The genotyping was repeated among 5% of 
the DNA samples for internal quality control (QC). External QC samples were also included in 
each assay. The external QC samples used were DNA extracted from human buffy coat with DNA 
concentration similar to the analytic samples. After each assay, the internal QC samples were 
evaluated to determine the quality and precision of genotyping. SNVs with repeat errors were 
removed from the genotyping results datafile. Upon passing the evaluation of internal QC, the 
results of genotyping were compared with the external QC samples for further assurance of quality. 
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The overall consistency rate was greater than 99%. Among the 672 genotyped samples, only 628 
(93.5%) had a call rate of 90% or greater. The 10% GenCall score of the 628 samples were all 
greater than 0.20, and no outliners have been identified by plotting the 10% GenCall score against 
the call rate. Thus, the 628 samples with a call rate of ≥90% were eligible to be included in the 
further statistical analyses. 
 
A total of 24 genes coding for the phase I and phase II metabolism/detoxification enzymes involved 
in the metabolism of PBDEs/PBBs and thyroid hormones were identified through the Gene 
database of National Center for Biotechnology Information (NCBI), including CYP1A1, CYP1B1, 
CYP1A2, CYP2D6, CYP2E1, CYP3A4, CYP3A5, GSTP1, GSTM1, GSTT1, UGT1A1, UGT1A3, 
UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9, UGT1A10, SULT1A1, SULT1A3, 
SULT1B1, SULT1E1, and SULT2A1. The genes DIO1, DIO2, and DIO3 coding for deiodinases 
that regulate activity and metabolism of thyroid hormones were also identified and included. 
Among the 656,725 SNVs that have been genotyped, a total of 2,039 loci in the 27 candidate genes 
were identified through the SNV database of NCBI. The tagging SNVs with a minor allele 
frequency (MAF) ≥0.05 were eligible for statistical analyses. The call frequency and Hardy-
Weinberg equilibrium (HWE) were also evaluated for each tagging SNV to determine the quality 
of genotyping. Acceptable threshold of SNV call frequency was set to be ≥95%. HWE was assessed 
among controls by performing the chi-squared test. SNVs with a p-value for HWE ≥10-5 were 
considered to be in HWE and were eligible for statistical analyses. At last, a total of 238 SNVs 
were included in the final statistical analyses to estimate their associations with risk of PTC and 
their effects of modifying the associations between serum concentration of a PBDE congener (i.e., 





Conditional logistic regression was used to estimate odds ratios (ORs) and 95% confidence 
intervals (CIs) for the associations between genetic polymorphisms and risk of PTC. For each SNV 
that included in a regression model, effect of rare homozygote (double-variant) and heterozygote 
(single-variant) on the risk of PTC was compared with that of common homozygote, respectively. 
The collective effect of allelic variation was examined by comparing the sum of rare homozygote 
and heterozygote to common homozygote. Linear trend of the polymorphic effect was tested using 
an additive conditional logistic regression model that assigns a value of 0 to common homozygote, 
1 to heterozygote, and 2 to rare homozygote. 
 
Analysis of gene-environment interaction was performed to investigate if the magnitude of 
carcinogenic effect of BDE-28 and TSH on PTC differs depending on genetic polymorphisms. This 
analysis was completed by fitting unconditional logistic regression models that include SNVs, 
categorical serum levels of BDE-28 or TSH, and an interaction term between SNVs and BDE-28 
or between SNVs and TSH, respectively [154]. A significant p-value for the interaction term 
suggests an existing of gene-environment interaction. For SNVs showing significant gene-
environment interaction, the associations between BDE-28, TSH, and risk of PTC were estimated 
and reported among homozygous genotype and a combination of heterozygous and rare 
homozygous genotypes, respectively. 
 
Both the conditional logistic regression and gene-environment interaction analyses were conducted 
among the entire genotyped population and also among subgroups stratified by gender, histologic 
subtype (classical PTC vs. follicular variant of PTC), and tumor size (≤10 vs. >10 mm), respectively. 
All models were adjusted for body mass index (BMI; <18.5, 18.5-24.9, 25-29.9, and 30 kg/m2) and 
branch of military service (army, air force, marines and coast guard, and navy). The gene-
environment interaction models were also adjusted for age, gender, race/ethnicity, and date of 
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sample collection. Models testing gene-environment interaction with BDE-28 were further adjusted 
for other PBDE/PBB congeners (i.e., BDE-47, -85, -99, -100, -153, -154, and BB-153). 
 
All tests were 2-sided with a priori significance level set to be 0.01. Analyses of genetic 
polymorphisms and risk of PTC were further corrected for multiple comparisons by adjusting the 
false discovery rate (FDR) [155]. The Bonferroni correction was not employed because it is too 
conservative. Statistical analyses were conducted using SAS, version 9.4 (SAS Institute, Inc.; Cary, 
North Carolina) and R, version 3.6.3 (R Foundation, Vienna, Austria). 
 
Results 
Demographic characteristics and military service of the genotyped PTC cases (n=317) and controls 
(n=311) were presented in Table 1.  Since cases were individual matched to controls in the parent 
nested case-control study [64, 140], distributions of age, gender, and race/ethnicity were similar 
between cases and controls. BMI was also similar distributed between cases and controls, although 
nearly half of participants had missing BMI data (43.9% for cases and 42.4% for controls). PTC 
cases were more likely to have served in the Army (45.1% vs. 35.1%) or Air Force (23.3% vs. 
18.7%) at the time of diagnosis, whereas controls were more likely to have served in the Navy 
(23.0% vs. 34.4%) or Marines/Coast Guard (8.5% vs. 11.9%) (P=0.0023). 
 
Risk of PTC was suggested to be associated with DIO2 rs225014 (Ptrend=0.026), SULT1B1 
rs11569731 (Ptrend=0.036), and GSTP1 rs4147581 (Ptrend=0.050) (Table 2). The heterozygote of 
CYP1A2 rs2472304 was associated with an elevated risk of PTC (OR=1.88, 95% CI: 1.20, 2.97; 
P=0.0063), but this SNV was failed to meet the a priori significance level of 0.01 in the additive 
model (data not shown). A complete list of raw and FDR-adjusted P-values for linear trend of all 
238 SNVs was available in the Supplementary Table 2. None of the associations remained 




Results from the subgroup analyses showed significant association between PTC risk and GSTP1 
rs4147581 in women (OR=2.78, 95% CI: 1.27, 6.08 for rare homozygote; Ptrend=0.0082) 
(Supplementary Table 3) and for large tumor (>10 mm) (OR=2.35, 95% CI: 1.25, 4.42 for rare 
homozygote; Ptrend=0.0085) (Supplementary Table 5). GSTP1 rs1138272 was significantly 
associated with risk of microcarcinoma (≤10 mm) (OR=3.69, 95% CI: 1.46, 9.33 for rare 
homozygote; Ptrend=0.0045). But all these SNVs were no longer significant after FDR adjustment 
(data not shown). The heterozygous or the rare homozygous genotypes of 
UGT1A10/UGT1A8/UGT1A9 rs17864684, CYP1A2 rs2472304, and DIO2 rs225014 yielded 
statistically significant ORs in women, while the heterozygous genotypes of CYP1A2 rs2472304 
and CYP2E1 rs6413419 yielded statistically significant ORs for large tumor. However, all these 
SNVs did not meet the significance level in the additive model (data not shown). No significant 
associations were observed for neither classical nor follicular variant of PTC (Supplementary Table 
4). 
 
Risk of classical PTC in relation to serum concentration of BDE-28 and serum level of TSH among 
the genotyped cases and controls were displayed in the Supplementary Table 6. The associations 
in genotyped population were similar to those in the entire study population for both men and 
women [64, 140]. The gene-environment interaction analysis for BDE-28 yielded a total of 7 SNVs 
with Pinteraction<0.05 (Table 3). Among the 7 SNVs, 3 were associated with UGT1Ax gene family 
(i.e., rs12995772, rs12469671, and rs1817154), while the other 4 were associated with CYP1A1 
(rs1048943), CYP1A2 (rs762551), DIO1 (rs2268181), and DIO2 (rs7145153), respectively. No 
SNVs reached the a priori significance level of 0.01. When stratified the analysis by gender, only 
one SNV (rs7092584) in CYP2E1 showed statistically significant effect modification with BDE-
28 on the risk of PTC in women (Pinteraction=0.0036) (Supplementary Table 8). Exposure to BDE-28 
was associated with an increased risk of PTC in women who carrying minor allele (OR=9.69, 95% 
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CI: 0.47, 199.25) as compared to those who with common homozygous genotype (OR=0.89, 95% 
CI: 0.36, 2.17). The sub-analysis in large tumors also yielded one SNV (rs12885300) in DIO2 with 
Pinteraction=0.0076 (Supplementary Table 11). The minor allele carriers were less likely to develop 
BDE-28 related large PTC (OR=0.44, 95% CI: 0.18, 1.10) as compared to the common homozygote 
carriers (OR=2.22, 95% CI: 0.78, 6.33). None of the SNVs met the significance level of 0.01 when 
the analyses were restricted in men (Supplementary Table 7), classical PTC (Supplementary Table 
9), or microcarcinoma (Supplementary Table 10). Results from the sub-analysis for follicular 
variation of PTC were not shown due to small numbers. 
 
Interactions between genetic variants and serum level of TSH on PTC risk were identified for 8 
SNVs at a significance level of 0.05, but no SNVs at the a priori significance level of 0.01 (Table 
4). Of the 8 SNVs with Pinteraction<0.05, 3 were associated with CYP2E1 (i.e., rs2249694, rs743534, 
and rs2515641), 3 were associated with UGT1Ax gene family (i.e., rs2011404, rs17862847, and 
rs35203651), while the others were associated with GSTP1 (rs1138272) and DIO2 (rs12885300), 
respectively. Results from the subgroup analysis demonstrated statistically significant interaction 
with rs1875263 in UGT1Ax gene family (Pinteraction=0.0038) and rs12885300 in DIO2 
(Pinteraction=0.0074) in men (Supplementary Table 12). Increased risk of PTC was associated with a 
lower level of TSH in men who carrying the common homozygous genotype of rs1875263 
(OR=3.23, 95% CI: 1.24, 8.46), and with a higher level of TSH in men who carrying the common 
homozygous genotype of rs12885300 (OR=2.35, 95% CI: 1.03, 5.36). When the analysis was 
restricted in cases with large PTC, a statistically significant interaction was observed for rs2011404 
in UGT1Ax gene family (Pinteraction=0.0075) (Supplementary Table 16). For participants carrying 
minor allele, risk of large PTC was inversely associated with TSH level (OR=2.63, 95% CI: 0.79, 
8.75 for lower level vs. OR=0.52, 95% CI: 0.15, 1.78 for higher level), but no association was 
observed for those who carrying the common homozygous genotype. None of the SNVs reached 
the significance level of 0.01 for women (Supplementary Table 13), classical PTC (Supplementary 
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Table 14), or microcarcinoma (Supplementary Table 15). Results from the sub-analysis for 
follicular variation of PTC were not shown due to limited numbers. 
 
Discussion 
In this study using data from a case-control study nested within the DoDSR cohort, we found that 
genetic polymorphism of GSTP1 rs4147581 was associated with risk of PTC in women and for 
large tumor (>10 mm), while GSTP1 rs1138272 was associated with risk of papillary 
microcarcinoma (≤10 mm). However, all these associations became non-significant after FDR-
adjustment for multiple comparisons. Results from this study also suggested significant interactions 
between BDE-28 and CYP2E1 rs7092584 in women and DIO2 rs12885300 for large PTC. In 
addition, serum level of TSH significantly interacted with rs1875263 in UGT1Ax gene family and 
rs12885300 in DIO2 among men, and with rs2011404 in UGT1Ax gene family for large PTC. 
 
Previous candidate gene studies did not reach a consensus on the association between risk of PTC 
and genetic variants in genes coding phase I and phase II metabolism/detoxification enzymes, 
which are the key enzymes involved in metabolism of endobiotics (e.g., TSH and thyroid hormones) 
and detoxification of xenobiotics (e.g., PBDEs) [46-50, 149, 150]. Several genes in the phase I 
pathway, including CYP1A1, CYP2D6, and CYP2E1, were reported to be significantly associated 
with risk of PTC/differentiated thyroid cancer (DTC) in the Middle Eastern and the European 
populations [46, 47, 49]. However, two studies in the US population did not find any significant 
associations with CYP genes after correction for the multiple comparisons [50, 149]. In the phase 
II pathway, one study in the Caucasian Portuguese population suggested that GSTM1 and GSTT1 
could weakly modify risk of PTC [48], while another study in the Korean population did not find 
any significant association between GSTM1/GSTT1 and PTC susceptibility [150]. Our study in the 
US military personnel only observed suggestive associations with GSTP1 in the servicewomen and 
by tumor size of PTC (Ptrend<0.01), but none of these associations remained significant after FDR-
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adjustment for multiple comparisons. To minimize the potential population heterogeneity, we also 
examined the associations restricted in the Whites, accounting for ~61% of all the genotyped 
participants. No significant SNVs were identified either before or after FDR-adjustment (data not 
shown). 
 
Results from this study did not support our hypothesis that genes involved in regulation of thyroid 
hormones (e.g., DIO1, DIO2, and DIO3) could modify the susceptibility of PTC. Although 
polymorphisms of DIO genes have been suggested to be associated with the thyroid hormone 
negative feedback regulation of TSH secretion [156, 157] and some benign thyroid diseases, such 
as autoimmune hypothyroidism [158], grave’s disease [159], and maternal thyroid dysfunction 
[160], evidence of DIO genes in developing thyroid cancer is still scanty. One case-control study 
investigated the association between four genetic variants (one in DIO1 and three in DIO2) and 
risk of DTC in the Saudi Arab population, and reported non-significant results [161]. More studies 
on the polymorphisms of DIO genes and susceptibility of thyroid cancer are need to clarify the role 
of DIO genes in thyroid carcinogenesis. 
 
This study is the first to examine the interaction between genetic polymorphisms and PBDEs in 
risk of PTC. Our results indicated interactions between BDE-28 and CYP2E1 in women a priori 
significance level of 0.01. Exposure to PBDEs was reported to be associated with an enhanced 
expression of CYP2E1 [162]. Since CYP2E1 enzyme metabolizes many endogenous and 
exogenous substrates, it may be involved in varied pathways and processes of carcinogenesis, such 
as head and neck cancer [163], respiratory system cancer [164], and bladder cancer [165].  
 
DIO2 was also observed to significantly interact with both BDE-28 for large tumors and with TSH 
in servicemen (Pinteraction<0.01). Exposure to PBDEs has been reported to decrease activity of DIO2 
[166]. The D2 protein encoded by DIO2 gene is the key enzyme that converts T4 to bioactive T3. 
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The decreased activity of DIO2 could cause a reduced conversion rate from T4 to T3, which in turn 
leads to a decrease in TSH secretion, because TSH secretion is a negative function of serum T4 
level. Thus, genetic polymorphisms of DIO2 gene may modify a mediation effect of TSH on the 
association between exposure to PBDEs and risk of developing PTC. This pathway is warranted to 
be further investigated in future mechanistic studies. 
 
This study also found significantly interactions between serum level of TSH and two SNVs in 
UGT1Ax gene family among servicemen and for large PTC (Pinteraction<0.01), respectively. The 
UGT1A genes encode several UDPGTs, which are responsible for the formation of glucuronides 
from a large variety of cytotoxic and genotoxic compounds, including carcinogens and reactive 
oxygen species [167]. UGT1A polymorphisms have been associated with levothyroxine (LT4) dose 
required for suppression of TSH secretion in DTC patients [168]. Mediated by the E3 ubiquitin 
ligases WSB-1 and/or TEB4, ubiquitination by T4 binding to and/or T4 catalysis triggers D2 
inactivation is an important step to regulate the activity of D2 [169]. Thus, UGT1A polymorphisms 
may also influence the activity of D2, thereby triggering an alteration in TSH level [161], which is 
suggested to increase risk of PTC [64]. 
 
Strengths of this study include a relatively large number of male cases. Since women are 
approximately three times more likely to develop thyroid cancer than men, this provides sufficient 
statistical power to investigate and compare the effect of genetic polymorphisms by gender. The 
study population was composed entirely of the US active-duty military personnel, a younger 
population represents the age groups at which PTC risk is at its highest. Also, the heterogeneity in 
genetic predisposition of PTC could be minimized in this study population. The single-payer 
universal (i.e., equal access) military healthcare system minimizes potential selection bias from 
differences in access to medical care. Additionally, the serum concentrations of BDE-28 and TSH 




Several limitations merit further consideration. There was a a high percentage of participants with 
missing BMI data, which may have led to insufficient adjustment for BMI. Previous evidence has 
suggested lower prevalence of obesity and larger lean body mass of military personnel than the US 
civilian population [69], indicating less variation of BMI among the US military personnel. Thus, 
any effect of under-adjustment for BMI would likely be minimized in this study population. 
Furthermore, the stratified and gene-environment interaction analyses may have yielded unstable 
results due to the small subgroup counts. It is also possible that the findings for gene-environment 
interaction at a priori significance level of 0.01 were observed by chance due to the multiple 
comparisons. Future studies in general populations with increased statistical power are warranted 
to confirm our findings. 
 
In conclusion, this study suggested that genetic polymorphisms in several genes involved in phase 
I and phase II metabolism/detoxification and thyroid hormone metabolism pathways could modify 
the effects of exposure to PBDEs and alternation in serum TSH level on risk of PTC. The effect 
modification varied by gender and tumor size. This exploratory study provides novel evidence to 
understand the underlying mechanisms of genetic polymorphisms and PBDEs/TSH related 
pathogenesis of PTC. More studies with prospective design and larger statistical power are merited 
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  P-value* 
No. (%) No. (%) 
Age at diagnosis (year)      
 <30 96 (30.3)  91 (29.3)   
 30-39 123 (38.8)  123 (39.6)   
 40-49 79 (24.9)  79 (25.4)   
 ≥50 19 (6.0)  18 (5.8)  0.99 
Gender      
 Male 168 (53.0)  168 (54.0)   
 Female 149 (47.0)  143 (46.0)  0.80 
Race/Ethnicity      
 White 192 (60.6)  189 (60.8)   
 Black 57 (18.0)  56 (18.0)   
 Hispanic 35 (11.0)  34 (10.9)   
 Other 26 (8.2)  25 (8.0)   
 Unknown 7 (2.2)  7 (2.3)  1.00 
BMI (kg/m2)      
 <25 111 (35.0)  123 (39.6)   
 25-29.9 58 (18.3)  51 (16.4)   
 ≥30 9 (2.8)  5 (1.6)   
 Missing 139 (43.9)  132 (42.4)  0.51 
Service      
 Army 143 (45.1)  109 (35.1)   
 Air Force 74 (23.3)  58 (18.7)   
 Marines and Coast Guard combined 27 (8.5)  37 (11.9)   
 Navy 73 (23.0)  107 (34.4)  0.0023 
Histologic subtype      
 Classical PTC 265 (83.6)  -   
 Follicular variation of PTC 52 (16.4)  -  - 
Tumor size (mm)      
 ≤10 104 (32.8)  -   
 >10 196 (61.8)  -   
 Missing 17 (5.4)  -  - 
Abbreviation: PTC, papillary thyroid cancer; BMI, body mass index. 




Table 2. Association between genotypes and risk of PTC at Ptrend≤0.05. 
Chromosome Gene/Region SNV Genotype Cases Controls OR* (95% CI) P-value 
14 DIO2 rs225014 TT 122 112 1.00  
   TC 155 129 1.16 (0.80-1.68) 0.44 
   CC 34 67 0.36 (0.20-0.65) 0.0007 
   P for trend    0.026 
   TC+CC 189 196 0.90 (0.64-1.27) 0.54 
4 SULT1B1 rs11569731 AA 286 265 1.00  
   AG 30 44 0.59 (0.34-1.02) 0.059 
   GG 0 1 - - 
   P for trend    0.036 
   AG+GG 30 45 0.57 (0.33-0.98) 0.044 
11 GSTP1 rs4147581 GG 101 123 1.00  
   CG 156 144 1.38 (0.92-2.08) 0.12 
   CC 60 44 1.68 (0.98-2.89) 0.060 
   P for trend    0.050 
       CG+CC 216 188 1.45 (0.97-2.15) 0.067 
Abbreviations: PTC, papillary thyroid cancer; SNV, single nucleotide variant; OR, odds ratio; BMI, body mass index. 
*Conditional logistic regression adjusted for BMI (<18.5, 18.5-24.9, 25-29.9, and 30 kg/m2) and branch of military service (army, air force, 




Table 3. Effect modification of genotypes between serum concentration of BDE-28 (ng/g) and risk of PTC at Pinteraction<0.05. 




Cases Controls OR* (95% CI) Cases Controls OR* (95% CI) 
15 CYP1A1 rs1048943 TT 191 182 1.00  87 86 1.02 (0.60-1.72) 
   TG+GG 26 19 1.00  11 21 0.09 (0.01-0.67) 
   P for interaction      0.012 
1 DIO1 rs2268181 TT 152 154 1.00  71 68 1.05 (0.59-1.89) 
   TC+CC 65 47 1.00  27 39 0.39 (0.14-1.06) 
   P for interaction      0.017 
2 UGT1A10, 
UGT1A8 
rs12995772 CC 199 176 1.00  90 97 0.78 (0.46-1.32) 
  AC+AA 18 25 1.00  8 10 1.60 (0.17-14.96) 
   P for interaction      0.026 
15 CYP1A2 rs762551 AA 106 96 1.00  39 51 0.83 (0.40-1.75) 
   AC+CC 111 105 1.00  59 56 0.88 (0.45-1.73) 
      P for interaction      0.031 
14 DIO2 rs7145153 GG 156 151 1.00  67 86 0.75 (0.42-1.33) 
   AG+AA 61 50 1.00  31 21 0.71 (0.25-2.02) 




rs12469671 CC 84 84 1.00  38 27 1.75 (0.70-4.40) 
  TC+TT 133 117 1.00  60 80 0.57 (0.31-1.03) 
  P for interaction      0.040 
2 UGT1A10, 
UGT1A8 
rs1817154 AA 135 128 1.00  68 62 1.19 (0.63-2.26) 
  AC+CC 82 73 1.00  30 45 0.48 (0.21-1.07) 
   P for interaction      0.042 
Abbreviations: BDE-28, 2,4,4'-tribromodiphenyl ether; PTC, papillary thyroid cancer; LOD: limit of detection; SNV, single nucleotide variant; 
OR, odds ratio; PBED, polybrominated diphenyl ether; PBB, polybrominated biphenyl; BMI, body mass index. 
*Unconditional logistic regression adjusted for age, gender, race/ethnicity, date of serum sample collection, BMI, branch of military service, and 





Table 4. Effect modification of genotypes between serum level of TSH (μU/mL) and risk of PTC at Pinteraction<0.05. 






Cases Controls OR* (95% CI) Cases Controls OR* (95% CI) Cases Controls OR* (95% CI) 
14 DIO2 rs12885300 CC 71 64 1.51 (0.88-2.61)  45 59 1.00  44 43 1.26 (0.68-2.33) 
   TC+TT 67 36 1.63 (0.91-2.93)  55 47 1.00  35 62 0.53 (0.30-0.96) 
   P for interaction          0.011 
2 UGT1A10, UGT1A8, 
UGT1A7, UGT1A6, UGT1A5, 
UGT1A9, UGT1A4 
rs2011404 CC 99 85 1.32 (0.85-2.04)  79 85 1.00  61 74 0.91 (0.56-1.46) 
  TC+TT 39 15 2.51 (1.01-6.20)  21 21 1.00  18 31 0.67 (0.27-1.63) 
   P for interaction          0.019 
10 CYP2E1 rs2249694 GG 71 36 2.67 (1.50-4.77)  46 59 1.00  41 57 0.92 (0.52-1.63) 
   AG+AA 67 64 0.95 (0.55-1.64)  54 47 1.00  38 48 0.71 (0.39-1.32) 
   P for interaction          0.034 
11 GSTP1 rs1138272 CC 114 94 1.23 (0.81-1.87)  87 88 1.00  66 92 0.72 (0.46-1.13) 
   TC+TT 24 6 6.91 (1.53-31.26)  13 18 1.00  13 13 1.04 (0.24-4.41) 
   P for interaction          0.036 
2 UGT1A10, UGT1A8 rs17862847 TT 106 79 1.77 (1.12-2.81)  61 77 1.00  61 82 0.94 (0.58-1.53) 
   TA+AA 32 21 1.16 (0.51-2.61)  39 29 1.00  18 23 0.63 (0.26-1.52) 
   P for interaction          0.036 
10 CYP2E1 rs743534 AA 90 50 2.06 (1.24-3.41)  38 68 1.00  54 75 0.75 (0.45-1.25) 
   AC+CC 48 50 0.92 (0.48-1.74)  62 38 1.00  25 30 0.96 (0.46-2.03) 
   P for interaction          0.040 
2 UGT1A10, UGT1A8, 
UGT1A7, UGT1A6, UGT1A5, 
UGT1A9, UGT1A4, UGT1A1, 
UGT1A3 
rs35203651 TT 123 85 1.72 (1.12-2.62)  83 90 1.00  67 85 0.84 (0.53-1.32) 
  TC+CC 15 15 0.77 (0.24-2.46)  17 16 1.00  12 20 0.63 (0.21-1.89) 
   P for interaction          0.041 
10 CYP2E1 rs2515641 CC 89 50 2.04 (1.23-3.38)  62 68 1.00  54 75 0.75 (0.45-1.25) 
   TC+TT 49 50 0.93 (0.49-1.77)  38 38 1.00  25 30 0.96 (0.45-2.02) 
      P for interaction                   0.049 
Abbreviations: TSH, thyroid stimulating hormone; PTC, papillary thyroid cancer; SNV, single nucleotide variant; OR, odds ratio; BMI, body mass index. 









  P-value* 
No. (%) No. (%) 
Age at diagnosis (year) 35.2 (8.5)  35.1 (7.7)  0.92 
Gender      
 Male 360 (53.6)  442 (54.4)   
 Female 312 (46.4)  370 (45.6)  0.74 
Ethnicity      
 White 412 (61.3)  523 (64.4)   
 Black 124 (18.5)  139 (17.1)   
 Hispanic 70 (10.4)  66 (8.1)   
 Other 52 (7.7)  58 (7.1)   
 Unknown 14 (2.1)  26 (3.2)  0.30 
BMI (kg/m2)      
 <25 254 (37.8)  288 (35.5)   
 25-29.9 115 (17.1)  162 (20.0)   
 ≥30 14 (2.1)  12 (1.5)   
 Missing 289 (43.0)  350 (43.1)  0.41 
Service      
 Army 254 (37.8)  298 (36.7)   
 Air Force 154 (22.9)  189 (23.3)   
 Marines and Coast Guard combined 72 (10.7)  83 (10.2)   
 Navy 192 (28.6)  242 (29.8)  0.94 
Abbreviations: SD, standard deviation; BMI, body mass index. 




Supplementary Table 2. Raw and FDR-adjusted p-values for linear trend of 238 tagging SNVs. 
SNV Gene/Region Raw Ptrend 
FDR-adjusted 
Ptrend 
rs225014 DIO2 0.0256 0.9932 
rs11569731 SULT1B1 0.0359 0.9932 
rs4147581 GSTP1 0.0499 0.9932 
rs17862873 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A3 0.0675 0.9932 
rs17854828 UGT1A10, UGT1A8 0.0676 0.9932 
rs17874938 UGT1A8 0.0702 0.9932 
rs28900371 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A3 0.0735 0.9932 
rs6731242 UGT1A10, UGT1A8, UGT1A9 0.0767 0.9932 
rs17862847 UGT1A10, UGT1A8 0.0784 0.9932 
rs13009407 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A3 0.0831 0.9932 
rs12471030 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A9 0.0891 0.9932 
rs12995772 UGT1A10, UGT1A8 0.0896 0.9932 
rs7145153 DIO2 0.0926 0.9932 
rs17864690 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A9 0.0941 0.9932 
rs28969975 UGT1A8 0.0973 0.9932 
rs17864684 UGT1A10, UGT1A8, UGT1A9 0.1050 0.9932 
rs15524 CYP3A5 0.1055 0.9932 
rs2246709 CYP3A4 0.1098 0.9932 
rs12476197 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A9 0.1114 0.9932 
rs2910393 SULT2A1 0.1124 0.9932 
rs3736599 SULT1E1 0.1136 0.9932 
rs2235544 DIO1 0.1147 0.9932 
rs6706988 UGT1A10, UGT1A8 0.1206 0.9932 
rs4114768 UGT1A8 0.1254 0.9932 
rs2741030 UGT1A8 0.1265 0.9932 
rs4485562 UGT1A10, UGT1A8, UGT1A7, UGT1A9 0.1415 0.9932 
rs12472689 UGT1A10, UGT1A8, UGT1A7, UGT1A9 0.1486 0.9932 
rs12474215 UGT1A10, UGT1A8, UGT1A7, UGT1A9 0.1486 0.9932 
 
123 
rs12474980 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A9 0.1486 0.9932 
rs62529877 SULT2A1 0.1487 0.9932 
rs4663325 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A9 0.1657 0.9932 
rs1138272 GSTP1 0.1692 0.9932 
rs2602374 UGT1A10, UGT1A8 0.1777 0.9932 
rs12053462 UGT1A10, UGT1A8, UGT1A9 0.1825 0.9932 
rs11892031 UGT1A10, UGT1A8 0.1875 0.9932 
rs9685617 SULT1B1 0.1966 0.9932 
rs1597941 UGT1A8 0.1985 0.9932 
rs2070673 CYP2E1 0.1985 0.9932 
rs1056836 CYP1B 0.2042 0.9932 
rs2011404 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4 0.2043 0.9932 
rs2602373 UGT1A10, UGT1A8 0.2082 0.9932 
rs17862875 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4 0.2096 0.9932 
rs17863787 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A9 0.2140 0.9932 
rs1800440 CYP1B1 0.2225 0.9932 
rs1823803 UGT1A8 0.2307 0.9932 
rs1695 GSTP1 0.2491 0.9932 
rs6413419 CYP2E1 0.2632 0.9932 
rs1453322 UGT1A10, UGT1A8 0.2639 0.9932 
rs2547231 SULT2A1 0.2790 0.9932 
rs2294512 DIO1 0.2857 0.9932 
rs2239892 GSTM1 0.3173 0.9932 
rs1018124 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A1, UGT1A3 0.3221 0.9932 
rs177037 SULT2A1 0.3468 0.9932 
rs11695484 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A3 0.3732 0.9932 
rs6725478 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A9 0.3833 0.9932 
rs10929303 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A1, UGT1A3 0.3935 0.9932 
rs34468125 SULT2A1 0.3964 0.9932 
rs9678241 UGT1A8 0.3979 0.9932 
rs2070672 CYP2E1 0.4013 0.9932 
 
124 
rs6413423 CYP2E1 0.4034 0.9932 
rs2470893 CYP1A1 0.4194 0.9932 
rs7579530 UGT1A10, UGT1A8, UGT1A7, UGT1A9 0.4206 0.9932 
rs9677829 UGT1A8 0.4231 0.9932 
rs10189426 UGT1A10, UGT1A8, UGT1A9 0.4296 0.9932 
rs1042640 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A1, UGT1A3 0.4302 0.9932 
rs1968752 SULT1A1 0.4309 0.9932 
rs4663969 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A3 0.4330 0.9932 
rs17868323 UGT1A10, UGT1A8, UGT1A7, UGT1A9 0.4369 0.9932 
rs8192766 CYP2E1 0.4413 0.9932 
rs7583278 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A9 0.4415 0.9932 
rs1056837 CYP1B1 0.4423 0.9932 
rs10929302 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A3 0.4427 0.9932 
rs4663327 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A9 0.4437 0.9932 
rs2472304 CYP1A2 0.4461 0.9932 
rs10199293 UGT1A10, UGT1A8, UGT1A7, UGT1A9 0.4505 0.9932 
rs2070677 CYP2E1 0.4517 0.9932 
rs17864701 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A3 0.4556 0.9932 
rs7556676 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A3 0.4596 0.9932 
rs6760588 UGT1A10, UGT1A8 0.4742 0.9932 
rs4233633 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9 0.4757 0.9932 
rs2741045 UGT1A10, UGT1A8, UGT1A9 0.4759 0.9932 
rs10168416 UGT1A10, UGT1A8, UGT1A7, UGT1A9 0.4833 0.9932 
rs3771341.2 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A1, UGT1A3 0.4848 0.9932 
rs4261716 UGT1A10, UGT1A8, UGT1A7, UGT1A9 0.4897 0.9932 
rs10190976 UGT1A10, UGT1A8, UGT1A9 0.4954 0.9932 
rs762551 CYP1A2 0.4971 0.9932 
rs2070959 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A9 0.4980 0.9932 
rs8330 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A1, UGT1A3 0.5041 0.9932 
rs762803 GSTP1 0.5052 0.9932 
rs2221198 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A3 0.5068 0.9932 
 
125 
rs6761246 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A9 0.5112 0.9932 
rs62191898 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A9 0.5124 0.9932 
rs11206244 DIO1 0.5131 0.9932 
rs6754100 UGT1A10, UGT1A8, UGT1A7, UGT1A9 0.5154 0.9932 
rs12469671 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A9 0.5182 0.9932 
rs2070676 CYP2E1 0.5229 0.9932 
rs3771341.1 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A1, UGT1A3 0.5258 0.9932 
rs7586110 UGT1A10, UGT1A8, UGT1A7, UGT1A9 0.5269 0.9932 
rs743534 CYP2E1 0.5305 0.9932 
rs10173355 UGT1A10, UGT1A8, UGT1A7, UGT1A9 0.5501 0.9932 
rs6707947 UGT1A10, UGT1A8, UGT1A7, UGT1A9 0.5522 0.9932 
rs162558 CYP1B1 0.5563 0.9932 
rs2741044 UGT1A10, UGT1A8, UGT1A9 0.5588 0.9932 
rs2268181 DIO1 0.5596 0.9932 
rs6744284 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9 0.5667 0.9932 
rs45615240 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A9 0.5754 0.9932 
rs6759892 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A9 0.5754 0.9932 
rs7587916 UGT1A10, UGT1A8, UGT1A9 0.5794 0.9932 
rs11888492 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A1, UGT1A3 0.5851 0.9932 
rs17863791 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9 0.5864 0.9932 
rs2515641 CYP2E1 0.5951 0.9932 
rs3806598 UGT1A10, UGT1A8, UGT1A9 0.5987 0.9932 
rs6753320 UGT1A10, UGT1A8, UGT1A7, UGT1A9 0.5989 0.9932 
rs6753569 UGT1A10, UGT1A8, UGT1A7, UGT1A9 0.5989 0.9932 
rs10171367 UGT1A10, UGT1A8, UGT1A7, UGT1A9 0.5997 0.9932 
rs4646421 CYP1A1 0.6015 0.9932 
rs6736508 UGT1A10, UGT1A8, UGT1A7, UGT1A9 0.6135 0.9932 
rs7595138 UGT1A10, UGT1A8, UGT1A9 0.6158 0.9932 
rs13401281 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4 0.6198 0.9932 
rs36211089 GSTP1 0.6209 0.9932 
rs11891311 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A3 0.6221 0.9932 
 
126 
rs6736743 UGT1A10, UGT1A8, UGT1A7, UGT1A9 0.6332 0.9932 
rs1105880 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A9 0.6342 0.9932 
rs7563561 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A9 0.6365 0.9932 
rs12885300 DIO2 0.6370 0.9932 
rs929596 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A1, UGT1A3 0.6396 0.9932 
rs2547238 SULT2A1 0.6433 0.9932 
rs749174 GSTP1 0.6446 0.9932 
rs10445704 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A9 0.6519 0.9932 
rs12468274 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4 0.6621 0.9932 
rs3732219 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4 0.6748 0.9932 
rs35984508 UGT1A10, UGT1A8, UGT1A9 0.6903 0.9932 
rs10179094 UGT1A10, UGT1A8, UGT1A7, UGT1A9 0.6905 0.9932 
rs4663968 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A3 0.6919 0.9932 
rs3796088 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A3 0.6923 0.9932 
rs12463641 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4 0.6939 0.9932 
rs12468356 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4 0.6943 0.9932 
rs904855 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4 0.6948 0.9932 
rs904856 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4 0.6948 0.9932 
rs4148326 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A1, UGT1A3 0.6957 0.9932 
rs7604115 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A3 0.6957 0.9932 
rs12466779 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4 0.6969 0.9932 
rs2551188 CYP1B1 0.7014 0.9932 
rs869283 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4 0.7087 0.9932 
rs11773597 CYP3A4 0.7091 0.9932 
rs3806592 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4 0.7147 0.9932 
rs1871042 GSTP1 0.7255 0.9932 
rs7608175 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A9 0.7420 0.9932 
rs4663965 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A3 0.7450 0.9932 
rs12479208 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4 0.7674 0.9932 
rs6741669 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A3 0.7737 0.9932 
rs2003569 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A1, UGT1A3 0.7766 0.9932 
 
127 
rs1048943 CYP1A1 0.7801 0.9932 
rs62191918 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A3 0.7833 0.9932 
rs7608713 UGT1A10, UGT1A8 0.7880 0.9932 
rs3755321 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9 0.7887 0.9932 
rs3892170 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9 0.7896 0.9932 
rs10179091 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A3 0.7905 0.9932 
rs2013018 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9 0.7928 0.9932 
rs1113193 UGT1A10, UGT1A8 0.7929 0.9932 
rs3732218 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4 0.7930 0.9932 
rs3732220 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4 0.7930 0.9932 
rs3732221 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4 0.7930 0.9932 
rs2567207 CYP1B1 0.7937 0.9932 
rs28898596 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9 0.7967 0.9932 
rs10168333 UGT1A10, UGT1A8, UGT1A7, UGT1A9 0.7987 0.9932 
rs1817154 UGT1A10, UGT1A8 0.7991 0.9932 
rs5020121 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9 0.8046 0.9932 
rs1983023 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A3 0.8073 0.9932 
rs4347832 UGT1A10, UGT1A8, UGT1A7, UGT1A9 0.8117 0.9932 
rs6742078 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A1, UGT1A3 0.8126 0.9932 
rs17862870 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9 0.8242 0.9932 
rs10168155 UGT1A10, UGT1A8, UGT1A7, UGT1A9 0.8243 0.9932 
rs5839490 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9 0.8285 0.9932 
rs4663964 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A3 0.8295 0.9932 
rs17862867 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9 0.8321 0.9932 
rs3806594 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4 0.8321 0.9932 
rs3771342 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A1, UGT1A3 0.8375 0.9932 
rs3806595 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4 0.8427 0.9932 
rs28898605 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4 0.8427 0.9932 
rs17863792 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9 0.8428 0.9932 
rs35623965 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9 0.8428 0.9932 
rs10175809 UGT1A10, UGT1A8, UGT1A7, UGT1A9 0.8430 0.9932 
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rs12468543 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4 0.8444 0.9932 
rs28371725 CYP2D6 0.8453 0.9932 
rs871514 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4 0.8475 0.9932 
rs35269037 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A3 0.8483 0.9932 
rs17864696 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9 0.8500 0.9932 
rs887829 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A1, UGT1A3 0.8506 0.9932 
rs1377460 UGT1A8 0.8508 0.9932 
rs17863798 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A3 0.8527 0.9932 
rs4663963 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A3 0.8544 0.9932 
rs17868335.1 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9 0.8591 0.9932 
rs7092584 CYP2E1 0.8698 0.9932 
rs17874943 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9 0.8716 0.9932 
rs10176426 UGT1A10, UGT1A8, UGT1A9 0.8743 0.9932 
rs10167119 UGT1A10, UGT1A8, UGT1A7, UGT1A9 0.8777 0.9932 
rs72084011 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9 0.8829 0.9932 
rs4148324 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A1, UGT1A3 0.8854 0.9932 
rs1104892 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9 0.8885 0.9932 
rs12466997 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A3 0.8889 0.9932 
rs2008595 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A3 0.8905 0.9932 
rs62191917 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A3 0.8940 0.9932 
rs2089075 SULT1B1 0.8989 0.9932 
rs4148325 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A1, UGT1A3 0.9010 0.9932 
rs2013030 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9 0.9038 0.9932 
rs3813867 CYP2E1 0.9045 0.9932 
rs4663967 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A3 0.9134 0.9932 
rs6977165 CYP3A5 0.9200 0.9932 
rs296365 SULT2A1 0.9213 0.9932 
rs17864705 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A1, UGT1A3 0.9228 0.9932 
rs3806591 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4 0.9244 0.9932 
rs4663333 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A3 0.9249 0.9932 
rs10929301 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A3 0.9288 0.9932 
 
129 
rs1105879 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A9 0.9292 0.9932 
rs7572563 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A9 0.9292 0.9932 
rs4399719 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A3 0.9327 0.9932 
rs17863790 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9 0.9358 0.9932 
rs6431628 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A3 0.9405 0.9932 
rs2018985 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A3 0.9407 0.9932 
rs4294999 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4 0.9445 0.9932 
rs4663945 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9 0.9477 0.9932 
rs2885295 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9 0.9494 0.9932 
rs4556969 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9 0.9605 0.9932 
rs3806597 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A3 0.9613 0.9932 
rs2249694 CYP2E1 0.9637 0.9932 
rs3755319 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A1, UGT1A3 0.9659 0.9932 
rs28898621 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A3 0.9682 0.9932 
rs12052787 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A3 0.9683 0.9932 
rs2567206 CYP1B1 0.9713 0.9932 
rs3806596 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A3 0.9725 0.9932 
rs17862878 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A3 0.9752 0.9932 
rs17868342 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A1, UGT1A3 0.9754 0.9932 
rs7592281 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A9 0.9830 0.9932 
rs4149448 SULT2A1 0.9881 0.9932 
rs35203651 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A1, UGT1A3 0.9904 0.9932 
rs4124874 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4, UGT1A3 0.9908 0.9932 
rs1875263 UGT1A10, UGT1A8, UGT1A7, UGT1A6, UGT1A5, UGT1A9, UGT1A4 0.9932 0.9932 
Abbreviations: FDR, false discovery rate; SNV, single nucleotide variant. 




Supplementary Table 3. Association between genotypes and risk of PTC by gender. 
Chromosome Gene SNV Genotype 
Men (n=336)  Women (n=292) 
Cases Controls OR* (95% CI) P-value Cases Controls OR* (95% CI) P-value 
14 DIO2 rs225014 TT 55 59 1.00   67 53 1.00  
   TC 90 76 1.17 (0.69-1.99) 0.56  65 53 1.06 (0.60-1.86) 0.84 
   CC 18 32 0.40 (0.16-0.98) 0.045  16 35 0.30 (0.13-0.70) 0.0052 
   P for trend    0.25     0.021 
   TC+CC 108 108 0.98 (0.59-1.62) 0.93  81 88 0.75 (0.45-1.25) 0.27 
4 SULT1B1 rs11569731 AA 150 142 1.00   136 123 1.00  
   AG 17 26 0.61 (0.30-1.24) 0.17  13 18 0.52 (0.21-1.32) 0.17 
   GG 0 0 - -  0 1 - - 
   P for trend    0.17     0.097 
   AG+GG 17 28 0.61 (0.30-1.24) 0.17  13 19 0.48 (0.19-1.20) 0.12 
11 GSTP1 rs4147581 CC 59 62 1.00   42 61 1.00  
   GC 83 82 0.96 (0.53-1.74) 0.90  73 62 1.93 (1.04-3.60) 0.037 
   GG 26 24 0.97 (0.43-2.21) 0.94  34 20 2.78 (1.27-6.08) 0.010 
   P for trend    0.93     0.0082 
      GC+GG 109 106 0.96 (0.54-1.72) 0.90   107 82 2.14 (1.18-3.87) 0.012 
Abbreviations: PTC, papillary thyroid cancer; SNV, single nucleotide variant; OR, odds ratio; BMI, body mass index. 




Supplementary Table 4. Association between genotypes and risk of PTC by histologic subtype. 
Chromosome Gene SNV Genotype 
Classical PTC (n=510)  Follicular variant of PTC (n=100) 
Cases Controls OR* (95% CI) P-value Cases Controls OR* (95% CI) P-value 
14 DIO2 rs225014 TT 98 92 1.00   24 15 1.00  
   TC 132 101 1.21 (0.82-1.80) 0.34  23 21 0.73 (0.30-1.82) 0.50 
   CC 29 49 0.54 (0.31-0.93) 0.028  5 12 0.27 (0.07-0.96) 0.044 
   P for trend    0.13     0.056 
   TC+CC 161 150 0.99 (0.68-1.43) 0.94  28 33 0.57 (0.24-1.32) 0.19 
4 SULT1B1 rs11569731 AA 240 208 1.00   46 40 1.00  
   AG 24 35 0.61 (0.35-1.07) 0.086  6 8 0.57 (0.16-2.00) 0.38 
   GG 0 1 - -  0 0 - - 
   P for trend    0.053     0.38 
   AG+GG 24 36 0.59 (0.34-1.03) 0.065  6 8 0.57 (0.16-2.00) 0.38 
11 GSTP1 rs4147581 GG 82 96 1.00   19 20 1.00  
   CG 135 114 1.38 (0.93-2.04) 0.11  21 22 0.82 (0.32-2.09) 0.68 
   CC 48 35 1.62 (0.95-2.76) 0.079  12 6 1.71 (0.50-5.86) 0.40 
   P for trend    0.051     0.56 
      CG+CC 183 149 1.44 (0.99-2.08) 0.056   33 28 1.02 (0.44-2.40) 0.96 
Abbreviations: PTC, papillary thyroid cancer; SNV, single nucleotide variant; OR, odds ratio; BMI, body mass index. 




Supplementary Table 5. Association between genotypes and risk of PTC by tumor size. 
Chromosome Gene SNV Genotype 
≤10 mm (n=201)  >10 mm (n=378) 
Cases Controls OR* (95% CI) P-value Cases Controls OR* (95% CI) P-value 
14 DIO2 rs225014 TT 33 32 1.00   81 70 1.00  
   TC 61 39 1.61 (0.83-3.11) 0.16  89 76 0.99 (0.63-1.55) 0.95 
   CC 9 24 0.37 (0.15-0.94) 0.036  21 35 0.48 (0.25-0.92) 0.027 
   P for trend    0.16     0.070 
   TC+CC 70 63 1.11 (0.60-1.04) 0.75  110 111 0.83 (0.54-1.26) 0.37 
4 SULT1B1 rs11569731 AA 93 82 1.00   178 154 1.00  
   AG 11 14 0.71 (0.29-1.72) 0.44  17 27 0.55 (0.28-1.06) 0.074 
   GG 0 0 - -  0 1 - - 
   P for trend    0.44     0.042 
   AG+GG 11 14 0.71 (0.29-1.72) 0.44  17 28 0.52 (0.27-1.01) 0.055 
11 GSTP1 rs4147581 GG 38 36 1.00   59 73 1.00  
   CG 51 47 1.05 (0.56-1.98) 0.87  95 86 1.39 (0.88-2.20) 0.16 
   CC 15 14 0.99 (0.41-2.38) 0.98  42 23 2.35 (1.25-4.42) 0.0082 
   P for trend    0.97     0.0085 
   CG+CC 66 61 1.04 (0.57-1.88) 0.90  137 109 1.58 (1.02-2.44) 0.039 
11 GSTP1 rs1138272 CC 81 90 1.00   171 154 1.00  
   TC 22 7 3.69 (1.46-9.33) 0.0058  25 25 0.94 (0.51-1.73) 0.83 
   TT 1 0 - -  0 2 - - 
   P for trend    0.0045     0.58 
   TC+TT 23 7 3.81 (1.51-9.59) 0.0045  25 27 0.89 (0.48-1.64) 0.71 
Abbreviations: PTC, papillary thyroid cancer; SNV, single nucleotide variant; OR, odds ratio; BMI, body mass index. 




Supplementary Table 6. Risk of classical PTC associated with lipid-corrected serum concentration of BDE-28 and serum level of TSH 





  P for interaction 
Cases Controls OR (95% CI) Cases Controls OR (95% CI) 
BDE-28 a (ng/g)          
 <LOD 97 98 1.00  86 92 1.00   
 >LOD-1.56 17 13 1.32 (0.51-3.40)  9 14 0.65 (0.20-2.14)   
 1.57-3.18 12 19 0.52 (0.20-1.36)  19 12 1.78 (0.48-6.58)   
 3.19-80.10 20 17 1.27 (0.33-4.96)  18 13 1.73 (0.31-9.75)   
 P for trend   0.56    0.25  0.33 
TSH b (μU/ml)          
 <0.30 1 2 0.90 (0.05-15.39)  8 3 2.54 (0.43-15.09)   
 0.30-1.19 35 50 1.27 (0.56-2.87)  29 53 0.49 (0.19-1.29)   
 1.20-1.93 26 57 1.00  25 48 1.00   
 1.94-4.20 22 65 0.70 (0.30-1.63)  11 44 0.15 (0.04-0.59)   
 >4.20 9 6 4.72 (0.82-27.27)  3 8 0.60 (0.06-5.76)   
 P for trend (within the normal range) 0.18    0.13   
 P for trend (overall) 0.48    0.088  0.13 
Abbreviations: PTC, papillary thyroid cancer; BDE-28, 2,4,4'-tribromodiphenyl ether; TSH, thyroid stimulating hormone; OR, odds 
ratio; LOD: limit of detection; PBED, polybrominated diphenyl ether; PBB, polybrominated biphenyl; BMI, body mass index. 
a Multi-chemical conditional logistic regression, adjusted for all PBDE and PBB congeners, BMI, and branch of military service. 




Supplementary Table 7. Effect modification of genotypes between serum concentration of BDE-28 (ng/g) and risk of PTC in men at Pinteraction<0.05. 




Cases Controls OR* (95% CI) Cases Controls OR* (95% CI) 
2 UGT1A10, UGT1A8 rs1817154 AA 73 68 1.00  34 31 0.89 (0.37-2.15) 
   AC+CC 45 39 1.00  15 30 0.36 (0.12-1.06) 
   P for interaction      0.018 
1 DIO1 rs2235544 CC 43 26 1.00  12 18 0.31 (0.06-1.47) 
   AC+AA 75 81 1.00  37 43 0.75 (0.35-1.58) 
   P for interaction      0.024 
2 UGT1A10, UGT1A8, 
UGT1A7, UGT1A6, 
UGT1A9 
rs12469671 CC 43 47 1.00  17 11 2.07 (0.55-7.80) 
  TC+TT 75 60 1.00  32 50 0.37 (0.17-0.82) 
  P for interaction      0.029 
2 UGT1A10, UGT1A8 rs12995772 CC 109 93 1.00  48 57 0.55 (0.28-1.09) 
   AC+AA 9 14 1.00  1 4 - 
   P for interaction      0.031 
10 CYP2E1 rs743534 AA 75 69 1.00  39 37 0.68 (0.30-1.52) 
   AC+CC 43 38 1.00  10 24 0.37 (0.10-1.42) 
   P for interaction      0.037 
10 CYP2E1 rs2515641 CC 75 69 1.00  39 37 0.68 (0.30-1.52) 
   TC+TT 43 38 1.00  10 24 0.37 (0.10-1.42) 
   P for interaction      0.037 
10 CYP2E1 rs2070677 AA 75 68 1.00  39 37 0.68 (0.31-1.52) 
   TA+TT 43 39 1.00  10 24 0.37 (0.10-1.42) 
      P for interaction           0.041 
Abbreviations: BDE-28, 2,4,4'-tribromodiphenyl ether; PTC, papillary thyroid cancer; LOD: limit of detection; SNV, single nucleotide variant; OR, odds 
ratio; PBED, polybrominated diphenyl ether; PBB, polybrominated biphenyl; BMI, body mass index. 
*Unconditional logistic regression adjusted for age, gender, race/ethnicity, date of serum sample collection, BMI, branch of military service, and other 





Supplementary Table 8. Effect modification of genotypes between serum concentration of BDE-28 (ng/g) and risk of PTC in women at Pinteraction<0.05. 




Cases Controls OR* (95% CI) Cases Controls OR* (95% CI) 
10 CYP2E1 rs7092584 CC 80 67 1.00  34 37 0.89 (0.36-2.17) 
   TC+TT 19 27 1.00  15 9 9.69 (0.47-199.25) 
   P for interaction      0.0036 
10 CYP2E1 rs3813867 GG 91 89 1.00  44 44 1.26 (0.54-2.93) 
   GC+CC 8 5 1.00  5 2 - 
   P for interaction      0.026 
15 CYP1A2 rs762551 AA 53 44 1.00  20 25 0.84 (0.25-2.76) 
   AC+CC 46 50 1.00  29 21 2.74 (0.66-11.28) 
   P for interaction      0.034 
2 UGT1A10, UGT1A8, 
UGT1A7, UGT1A6, 
UGT1A5, UGT1A9 
rs17863790 CC 90 84 1.00  44 38 1.94 (0.78-4.84) 
  TC+TT 9 10 1.00  5 8 175.73 (0.002->999.99) 
  P for interaction      0.045 
Abbreviations: BDE-28, 2,4,4'-tribromodiphenyl ether; PTC, papillary thyroid cancer; LOD: limit of detection; SNV, single nucleotide variant; OR, odds 
ratio; PBED, polybrominated diphenyl ether; PBB, polybrominated biphenyl; BMI, body mass index. 
*Unconditional logistic regression adjusted for age, gender, race/ethnicity, date of serum sample collection, BMI, branch of military service, and other 




Supplementary Table 9. Effect modification of genotypes between serum concentration of BDE-28 (ng/g) and risk of classical PTC at Pinteraction<0.05. 




Cases Controls OR* (95% CI) Cases Controls OR* (95% CI) 
2 UGT1A10, UGT1A8, UGT1A7, 
UGT1A9 
rs10168416 CC 88 85 1.00  43 49 0.90 (0.40-2.02) 
  CG+GG 89 77 1.00  43 32 1.37 (0.61-3.05) 
   P for interaction      0.019 
2 UGT1A10, UGT1A8, UGT1A7, 
UGT1A9 
rs6736508 GG 76 60 1.00  35 38 0.75 (0.30-1.93) 
  AG+AA 101 102 1.00  51 43 1.29 (0.63-2.63) 
   P for interaction      0.020 
1 DIO1 rs2235544 CC 70 42 1.00  26 23 0.50 (0.16-1.59) 
   AC+AA 107 120 1.00  60 58 1.24 (0.66-2.34) 
   P for interaction      0.021 
2 UGT1A10, UGT1A8, UGT1A7, 
UGT1A9 
rs10168155 CC 76 60 1.00  35 38 0.79 (0.31-1.99) 
  TC+TT 101 102 1.00  51 43 1.26 (0.62-2.58) 
   P for interaction      0.021 
2 UGT1A10, UGT1A8, UGT1A7, 
UGT1A9 
rs6753320 AA 76 59 1.00  35 38 0.75 (0.30-1.92) 
  AC+CC 101 103 1.00  51 43 1.29 (0.63-2.64) 
   P for interaction      0.023 
2 UGT1A10, UGT1A8, UGT1A7, 
UGT1A9 
rs6753569 AA 76 59 1.00  35 38 0.75 (0.30-1.92) 
  AC+CC 101 103 1.00  51 43 1.29 (0.63-2.64) 
   P for interaction      0.023 
2 UGT1A10, UGT1A8, UGT1A7, 
UGT1A6, UGT1A9 
rs6759892 TT 76 59 1.00  35 38 0.75 (0.30-1.92) 
  TG+GG 101 103 1.00  51 43 1.29 (0.63-2.64) 
   P for interaction      0.023 
2 UGT1A10, UGT1A8, UGT1A7, 
UGT1A9 
rs10171367 CC 76 59 1.00  35 38 0.75 (0.30-1.92) 
  GC+GG 101 103 1.00  51 43 1.29 (0.63-2.64) 
   P for interaction      0.023 
2 UGT1A10, UGT1A8, UGT1A7, 
UGT1A6, UGT1A9 
rs45615240 TT 76 59 1.00  35 38 0.75 (0.30-1.92) 
  TC+CC 101 103 1.00  51 43 1.29 (0.63-2.64) 
   P for interaction      0.023 
2 UGT1A8 rs2741030 CC 95 97 1.00  50 58 1.05 (0.51-2.17) 
 
137 
   TC+TT 82 65 1.00  36 23 1.33 (0.52-3.44) 
   P for interaction      0.024 
15 CYP1A1 rs1048943 TT 154 147 1.00  78 69 1.31 (0.73-2.36) 
   TG+GG 23 15 1.00  8 12 0.26 (0.01-4.91) 
   P for interaction      0.027 
2 UGT1A10, UGT1A8, UGT1A7, 
UGT1A9 
rs10173355 AA 88 83 1.00  43 49 0.89 (0.40-2.00) 
  TA+TT 89 79 1.00  43 32 1.36 (0.61-3.02) 
   P for interaction      0.029 
2 UGT1A10, UGT1A8, UGT1A7, 
UGT1A9 
rs4347832 TT 76 60 1.00  35 38 0.78 (0.31-1.98) 
  TC+CC 101 102 1.00  51 43 1.27 (0.62-2.59) 
   P for interaction      0.031 
2 UGT1A10, UGT1A8, UGT1A7, 
UGT1A6, UGT1A9 
rs12469671 CC 71 63 1.00  33 19 1.34 (0.48-3.77) 
  TC+TT 106 99 1.00  53 62 0.86 (0.44-1.67) 
   P for interaction      0.035 
2 UGT1A10, UGT1A8, UGT1A7, 
UGT1A6, UGT1A9 
rs7563561 TT 76 59 1.00  36 38 0.77 (0.30-1.96) 
  TG+GG 101 103 1.00  50 43 1.27 (0.62-2.59) 
   P for interaction      0.041 
2 UGT1A10, UGT1A8, UGT1A7, 
UGT1A6, UGT1A9 
rs7608175 CC 76 59 1.00  36 38 0.77 (0.30-1.96) 
  GC+GG 101 103 1.00  50 43 1.27 (0.62-2.59) 
   P for interaction      0.041 
2 UGT1A10, UGT1A8, UGT1A7, 
UGT1A9 
rs10167119 TT 88 76 1.00  40 45 0.81 (0.36-1.84) 
  TC+CC 89 86 1.00  46 36 1.26 (0.56-2.82) 
   P for interaction      0.041 
2 UGT1A10, UGT1A8, UGT1A7, 
UGT1A9 
rs6736743 GG 76 60 1.00  35 38 0.79 (0.31-1.99) 
  AG+AA 101 102 1.00  51 43 1.26 (0.62-2.58) 
   P for interaction      0.044 
2 UGT1A10, UGT1A8, UGT1A7, 
UGT1A9 
rs10168333 CC 76 59 1.00  35 38 0.75 (0.30-1.92) 
  TC+TT 101 103 1.00  51 43 1.29 (0.63-2.64) 
   P for interaction      0.045 
2 UGT1A10, UGT1A8, UGT1A7, 
UGT1A6, UGT1A9 
rs1105879 AA 82 73 1.00  41 44 0.94 (0.39-2.22) 
  AC+CC 95 89 1.00  45 37 1.24 (0.58-2.63) 
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   P for interaction      0.048 
2 UGT1A10, UGT1A8, UGT1A7, 
UGT1A6, UGT1A5, UGT1A9, 
UGT1A4, UGT1A3 
rs10179091 TT 57 47 1.00  27 31 0.70 (0.24-2.06) 
  TC+CC 120 115 1.00  59 50 1.38 (0.71-2.68) 
    P for interaction           0.048 
Abbreviations: BDE-28, 2,4,4'-tribromodiphenyl ether; PTC, papillary thyroid cancer; LOD: limit of detection; SNV, single nucleotide variant; OR, odds ratio; 
PBED, polybrominated diphenyl ether; PBB, polybrominated biphenyl; BMI, body mass index. 
*Unconditional logistic regression adjusted for age, gender, race/ethnicity, date of serum sample collection, BMI, branch of military service, and other PBDE 




Supplementary Table 10. Effect modification of genotypes between serum concentration of BDE-28 (ng/g) and risk of papillary microcarcinoma (≤10 mm) at 
Pinteraction<0.05. 




Cases Controls OR* (95% CI) Cases Controls OR* (95% CI) 
19 SULT2A1 rs2547238 GG 34 37 1.00  17 20 1.67 (0.46-6.05) 
   GC+CC 39 20 1.00  13 17 0.20 (0.03-1.37) 
   P for interaction      0.012 
2 UGT1A10, UGT1A8 rs1113193 GG 41 38 1.00  15 17 0.98 (0.29-3.37) 
   AG+AA 32 19 1.00  15 20 0.09 (0.01-0.85) 
   P for interaction      0.019 
2 UGT1A8 rs2741030 CC 38 32 1.00  20 30 0.73 (0.19-2.79) 
   TC+TT 35 25 1.00  10 7 5.48 (0.60-50.31) 
   P for interaction      0.020 
2 UGT1A10, UGT1A8, UGT1A9 rs6731242 TT 51 43 1.00  20 24 0.99 (0.33-2.93) 
   TG+GG 22 14 1.00  10 13 0.01 (<0.001-1.83) 
   P for interaction      0.021 
2 UGT1A10, UGT1A8 rs2602374 CC 40 34 1.00  20 30 0.59 (0.15-2.31) 
   TC+TT 33 23 1.00  10 7 4.62 (0.54-39.68) 
   P for interaction      0.031 
15 CYP1A1 rs1048943 TT 61 48 1.00  28 28 0.71 (0.26-1.93) 
   TG+GG 12 9 1.00  2 9 10.65 (<0.001->999.99) 
   P for interaction      0.036 
2 UGT1A10, UGT1A8 rs7608713 CC 42 39 1.00  17 15 1.50 (0.43-5.18) 
   TC+TT 31 18 1.00  13 22 0.07 (0.01-0.86) 
   P for interaction      0.037 
15 CYP1A2 rs762551 AA 33 29 1.00  11 23 1.12 (0.23-5.42) 
   AC+CC 40 28 1.00  19 14 0.38 (0.10-1.54) 
   P for interaction      0.039 
2 UGT1A10, UGT1A8 rs11892031 AA 60 49 1.00  25 24 0.81 (0.29-2.27) 
   AC+CC 13 8 1.00  5 13 - 
   P for interaction      0.041 
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2 UGT1A10, UGT1A8, 
UGT1A7, UGT1A6, UGT1A9 
rs12469671 CC 30 21 1.00  12 10 1.79 (0.10-33.61) 
  TC+TT 43 36 1.00  18 27 0.65 (0.20-2.08) 
      P for interaction           0.042 
Abbreviations: BDE-28, 2,4,4'-tribromodiphenyl ether; LOD: limit of detection; SNV, single nucleotide variant; OR, odds ratio; PBED, polybrominated diphenyl 
ether; PBB, polybrominated biphenyl; BMI, body mass index. 





Supplementary Table 11. Effect modification of genotypes between serum concentration of BDE-28 (ng/g) and risk of large PTC (>10 mm) at Pinteraction<0.05. 




Cases Controls OR* (95% CI) Cases Controls OR* (95% CI) 
14 DIO2  rs12885300 CC 65 71 1.00  34 23 2.22 (0.78-6.33) 
   TC+TT 64 47 1.00  32 41 0.44 (0.18-1.10) 
   P for interaction      0.0076 
1 DIO1 rs2268181 TT 95 91 1.00  49 38 1.47 (0.68-3.19) 
   TC+CC 34 27 1.00  17 26 0.28 (0.06-1.28) 
   P for interaction      0.016 
2 CYP1B1 rs2551188 CC 52 51 1.00  41 29 2.32 (0.76-7.09) 
   TC+TT 77 67 1.00  25 35 0.61 (0.25-1.49) 
   P for interaction      0.025 
15 CYP1A1 rs1048943 TT 117 111 1.00  57 52 1.38 (0.68-2.80) 
   TG+GG 12 7 1.00  9 12 - 
   P for interaction      0.035 
2 UGT1A10, UGT1A8 rs1817154 AA 86 77 1.00  50 37 1.31 (0.55-3.10) 
   AC+CC 43 41 1.00  16 27 0.55 (0.18-1.67) 
   P for interaction      0.035 
1 DIO1 rs2294512 GG 64 43 1.00  27 33 0.68 (0.24-1.99) 
   AG+AA 65 75 1.00  39 31 1.27 (0.53-3.08) 
   P for interaction      0.038 
2 UGT1A10, UGT1A8 rs12995772 CC 119 104 1.00  61 57 0.88 (0.44-1.77) 
   AC+AA 10 14 1.00  5 7 - 
      P for interaction           0.047 
Abbreviations: BDE-28, 2,4,4'-tribromodiphenyl ether; PTC, papillary thyroid cancer; LOD: limit of detection; SNV, single nucleotide variant; OR, odds 
ratio; PBED, polybrominated diphenyl ether; PBB, polybrominated biphenyl; BMI, body mass index. 
*Unconditional logistic regression adjusted for age, gender, race/ethnicity, date of serum sample collection, BMI, branch of military service, and other PBDE 





Supplementary Table 12. Effect modification of genotypes between serum level of TSH (μU/mL) and risk of PTC in men at Pinteraction<0.05. 






Cases Controls OR* (95% CI) Cases Controls OR* (95% CI) Cases Controls OR* (95% CI) 
2 UGT1A10, UGT1A8, UGT1A7, 
UGT1A6, UGT1A5, UGT1A9, 
UGT1A4 
rs1875263 CC 31 13 3.23 (1.24-8.46)  23 26 1.00  26 30 1.07 (0.46-2.50) 
  TC+TT 35 36 1.22 (0.58-2.57)  26 32 1.00  27 31 1.07 (0.50-2.31) 
   P for interaction          0.0038 
14 DIO2 rs12885300 CC 33 30 1.66 (0.76-3.63)  22 33 1.00  33 21 2.35 (1.03-5.36) 
   TC+TT 33 19 1.43 (0.61-3.33)  27 25 1.00  20 40 0.48 (0.21-1.06) 
   P for interaction          0.0074 
2 
UGT1A10, UGT1A8, UGT1A7, 
UGT1A9 
rs6736743 GG 33 14 2.70 (1.04-6.97)  26 25 1.00  22 28 0.67 (0.28-1.60) 
   AG+AA 33 35 1.53 (0.70-3.33)  23 33 1.00  31 33 1.48 (0.69-3.21) 
   P for interaction          0.016 
2 UGT1A10, UGT1A8, UGT1A7, 
UGT1A6, UGT1A5, UGT1A9, 
UGT1A4 
rs2011404 CC 41 41 1.06 (0.56-2.02)  40 44 1.00  42 40 1.18 (0.62-2.23) 
  TC+TT 25 8 3.53 (0.97-12.80)  9 14 1.00  11 21 0.78 (0.22-2.77) 
   P for interaction          0.019 
2 
UGT1A10, UGT1A8, UGT1A7, 
UGT1A9 
rs6736508 GG 33 15 2.49 (0.98-6.37)  25 25 1.00  23 28 0.69 (0.29-1.64) 
   AG+AA 33 34 1.60 (0.73-3.50)  23 33 1.00  30 33 1.45 (0.67-3.14) 
   P for interaction          0.024 
2 
UGT1A10, UGT1A8, UGT1A7, 
UGT1A6, UGT1A9 
rs45615240 TT 33 14 2.70 (1.04-6.97)  26 25 1.00  22 28 0.67 (0.28-1.60) 
   TC+CC 33 35 1.53 (0.70-3.33)  23 33 1.00  31 33 1.48 (0.69-3.21) 
   P for interaction          0.027 
2 
UGT1A10, UGT1A8, UGT1A7, 
UGT1A9 
rs10168333  33 14 2.70 (1.04-6.97)  26 25 1.00  22 28 0.67 (0.28-1.60) 
    33 35 1.53 (0.70-3.33)  23 33 1.00  31 33 1.48 (0.69-3.21) 
   P for interaction          0.028 
2 UGT1A10, UGT1A8, UGT1A7, 
UGT1A6, UGT1A5, UGT1A9, 
UGT1A4, UGT1A3 
rs11695484 AA 37 26 2.00 (0.90-4.43)  28 34 1.00  29 38 0.90 (0.42-1.93) 
  AG+GG 29 23 1.45 (0.60-3.51)  21 24 1.00  24 23 1.18 (0.50-2.77) 
   P for interaction          0.028 
2 UGT1A10, UGT1A8, UGT1A7, 
UGT1A6, UGT1A5, UGT1A9, 
UGT1A4, UGT1A1, UGT1A3 
rs4148325 CC 33 18 2.98 (1.20-7.42)  23 30 1.00  24 34 0.98 (0.43-2.25) 
  TC+TT 33 31 1.11 (0.51-2.40)  26 28 1.00  29 27 1.10 (0.50-2.38) 




UGT1A10, UGT1A8, UGT1A7, 
UGT1A9 
rs4347832 TT 33 14 2.83 (1.10-7.27)  26 26 1.00  22 28 0.69 (0.29-1.65) 
   TC+CC 33 35 1.48 (0.68-3.24)  23 32 1.00  31 33 1.44 (0.66-3.11) 
   P for interaction          0.029 
2 
UGT1A10, UGT1A8, UGT1A7, 
UGT1A6, UGT1A5, UGT1A9, 
UGT1A4, UGT1A1, UGT1A3 
rs10929303 CC 30 31 1.05 (0.50-2.20)  32 34 1.00  32 31 1.07 (0.51-2.24) 
  TC+TT 36 18 2.31 (0.91-5.85)  17 24 1.00  21 30 0.80 (0.32-2.02) 
  P for interaction          0.030 
2 UGT1A10, UGT1A8, UGT1A7, 
UGT1A6, UGT1A5, UGT1A9, 
UGT1A4, UGT1A1, UGT1A3 
rs3755319 AA 22 9 2.99 (0.92-9.77)  15 19 1.00  19 23 0.95 (0.34-2.66) 
  AC+CC 44 40 1.21 (0.63-2.33)  34 39 1.00  34 38 1.09 (0.55-2.16) 
   P for interaction          0.032 
2 
UGT1A10, UGT1A8, UGT1A7, 
UGT1A9 
rs10168155 CC 33 15 2.35 (0.93-5.94)  26 25 1.00  22 28 0.68 (0.29-1.62) 
   TC+TT 33 34 1.58 (0.72-3.45)  23 33 1.00  31 33 1.48 (0.69-3.20) 
   P for interaction          0.032 
2 
UGT1A10, UGT1A8, UGT1A7, 
UGT1A9 
rs10175809 TT 33 15 2.38 (0.94-6.04)  26 25 1.00  22 28 0.67 (0.28-1.60) 
   AT+AA 33 34 1.60 (0.73-3.50)  23 33 1.00  31 33 1.49 (0.69-3.23) 
   P for interaction          0.033 
2 UGT1A10, UGT1A8, UGT1A7, 
UGT1A6, UGT1A5, UGT1A9, 
UGT1A4, UGT1A3 
rs4399719 TT 22 8 3.51 (1.04-11.84)  14 19 1.00  18 23 1.01 (0.35-2.89) 
  TG+GG 44 41 1.11 (0.57-2.14)  35 39 1.00  35 38 1.06 (0.54-2.09) 
   P for interaction          0.037 
2 UGT1A10, UGT1A8, UGT1A7, 
UGT1A6, UGT1A9 
rs7572563 GG 15 15 1.26 (0.39-4.05)  15 14 1.00  17 11 1.88 (0.58-6.05) 
  AG+AA 51 34 2.00 (1.03-3.90)  34 44 1.00  36 50 0.97 (0.50-1.88) 
   P for interaction          0.040 
2 UGT1A10, UGT1A8, UGT1A7, 
UGT1A6, UGT1A5, UGT1A9, 
UGT1A4, UGT1A3 
rs4124874 TT 22 8 3.18 (0.93-10.88)  14 18 1.00  18 23 0.89 (0.30-2.61) 
  TG+GG 44 41 1.16 (0.60-2.23)  35 40 1.00  35 38 1.10 (0.56-2.17) 
   P for interaction          0.041 
2 UGT1A10, UGT1A8, UGT1A9 rs10190976 TT 18 15 1.77 (0.58-5.36)  17 22 1.00  21 17 1.96 (0.70-5.48) 
   TG+GG 48 34 1.47 (0.74-2.92)  32 36 1.00  32 44 0.84 (0.41-1.72) 
   P for interaction          0.044 
2 UGT1A10, UGT1A8, UGT1A7, 
UGT1A6, UGT1A5, UGT1A9, 
UGT1A4, UGT1A3 
rs2008595 CC 22 8 3.18 (0.93-10.88)  14 18 1.00  18 23 0.89 (0.30-2.61) 
  TC+TT 44 41 1.16 (0.60-2.23)  35 40 1.00  35 38 1.10 (0.56-2.17) 
   P for interaction          0.045 
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2 UGT1A10, UGT1A8, UGT1A9 rs3806598 AA 62 41 1.68 (0.93-3.01)  46 53 1.00  45 57 0.91 (0.51-1.63) 
   AC+CC 4 8 0.09 (0.004-2.34)  3 5 1.00  8 4 1.18 (0.07-18.79) 
   P for interaction          0.046 
2 UGT1A10, UGT1A8, UGT1A7, 
UGT1A6, UGT1A5, UGT1A9, 
UGT1A4 
rs17862875 GG 36 24 2.31 (1.03-5.17)  27 34 1.00  26 37 0.91 (0.42-1.96) 
  AG+AA 30 25 1.25 (0.53-2.96)  22 24 1.00  27 24 1.14 (0.50-2.63) 
   P for interaction          0.047 
2 UGT1A10, UGT1A8, UGT1A7, 
UGT1A6, UGT1A5, UGT1A9, 
UGT1A4 
rs869283 GG 27 15 2.51 (0.98-6.42)  22 27 1.00  24 29 1.04 (0.44-2.45) 
  AG+AA 39 34 1.28 (0.61-2.66)  27 31 1.00  29 32 1.02 (0.48-2.17) 
   P for interaction          0.048 
2 UGT1A10, UGT1A8 rs1817154 AA 38 32 1.19 (0.58-2.43)  36 35 1.00  33 35 0.98 (0.48-2.01) 
   AC+CC 28 17 2.56 (0.93-7.02)  13 23 1.00  20 26 1.46 (0.52-4.06) 
   P for interaction          0.048 
Abbreviations: TSH, thyroid stimulating hormone; PTC, papillary thyroid cancer; SNV, single nucleotide variant; OR, odds ratio; BMI, body mass index. 




Supplementary Table 13. Effect modification of genotypes between serum level of TSH (μU/mL) and risk of PTC in women at Pinteraction<0.05. 






Cases Controls OR* (95% CI) Cases Controls OR* (95% CI) Cases Controls OR* (95% CI) 
2 UGT1A10, UGT1A8, UGT1A7, 
UGT1A6, UGT1A5, UGT1A9, 
UGT1A4 
rs1875263 CC 18 19 0.60 (0.20-1.77)  21 11 1.00  15 18 0.53 (0.17-1.67) 
  TC+TT 54 32 2.41 (1.19-4.89)  30 37 1.00  11 26 0.48 (0.19-1.20) 
   P for interaction          0.020 
19 SULT2A1 rs2547238 GG 50 25 2.78 (1.28-6.03)  26 31 1.00  14 23 0.60 (0.24-1.54) 
   GC+CC 22 26 0.64 (0.25-1.65)  25 17 1.00  12 21 0.41 (0.15-1.17) 
   P for interaction          0.021 
2 UGT1A10, UGT1A8, UGT1A7, 
UGT1A6, UGT1A9 
rs6725478 CC 17 22 0.45 (0.15-1.31)  21 12 1.00  13 19 0.35 (0.11-1.12) 
  TC+TT 55 29 2.77 (1.33-5.78)  30 36 1.00  13 25 0.53 (0.21-1.29) 
   P for interaction          0.021 
2 UGT1A8 rs2741030 CC 33 38 0.67 (0.30-1.48)  30 24 1.00  15 27 0.38 (0.15-0.95) 
   TC+TT 39 13 3.77 (1.50-9.48)  21 24 1.00  11 17 0.70 (0.23-2.18) 
   P for interaction          0.025 
10 CYP2E1 rs2070673 TT 40 21 1.60 (0.72-3.59)  29 26 1.00  12 31 0.35 (0.14-0.85) 
   AT+AA 32 30 1.54 (0.65-3.66)  22 22 1.00  14 13 1.32 (0.45-3.89) 
   P for interaction          0.031 
2 UGT1A10, UGT1A8, UGT1A7, 
UGT1A6, UGT1A5, UGT1A9, 
UGT1A4, UGT1A1, UGT1A3 
rs929596 AA 26 27 0.73 (0.32-1.72)  29 21 1.00  17 24 0.51 (0.21-1.24) 
  AG+GG 46 24 2.78 (1.24-6.25)  22 27 1.00  9 20 0.47 (0.15-1.42) 
   P for interaction          0.044 
11 GSTP1 rs36211089 CC 32 22 0.78 (0.29-2.13)  23 14 1.00  14 21 0.32 (0.11-0.96) 
   TC+TT 40 29 1.78 (0.85-3.76)  28 34 1.00  12 23 0.62 (0.25-1.54) 
   P for interaction          0.048 
Abbreviations: TSH, thyroid stimulating hormone; PTC, papillary thyroid cancer; SNV, single nucleotide variant; OR, odds ratio; BMI, body mass index. 




Supplementary Table 14. Effect modification of genotypes between serum level of TSH (μU/mL) and risk of classical PTC at Pinteraction<0.05. 






Cases Controls OR* (95% CI) Cases Controls OR* (95% CI) Cases Controls OR* (95% CI) 
14 DIO2 rs12885300 CC 59 53 1.44 (0.77-2.69)  38 43 1.00  38 32 1.43 (0.71-2.86) 
   TC+TT 52 31 1.10 (0.56-2.14)  48 32 1.00  30 54 0.41 (0.21-0.78) 
   P for interaction          0.011 
11 GSTP1 rs1138272 CC 89 80 0.95 (0.59-1.52)  73 61 1.00  57 76 0.65 (0.39-1.07) 
   TC+TT 22 4 5.45 (1.01-29.42)  13 14 1.00  11 10 1.21 (0.26-5.59) 
   P for interaction          0.016 
19 SULT2A1 rs2547238 GG 74 45 1.68 (0.95-2.99)  46 48 1.00  36 47 0.78 (0.42-1.46) 
   GC+CC 37 39 0.76 (0.37-1.55)  40 27 1.00  32 39 0.59 (0.29-1.22) 
   P for interaction          0.040 
2 UGT1A10, UGT1A8, UGT1A7, 
UGT1A6, UGT1A5, UGT1A9, 
UGT1A4 
rs17862875 GG 53 42 1.51 (0.80-2.86)  48 44 1.00  33 53 0.63 (0.33-1.20) 
  AG+AA 58 42 1.11 (0.58-2.12)  38 31 1.00  35 33 0.85 (0.42-1.71) 
   P for interaction          0.043 
2 UGT1A10, UGT1A8, UGT1A7, 
UGT1A6, UGT1A5, UGT1A9, 
UGT1A4, UGT1A3 
rs3806596 TT 26 15 1.55 (0.60-4.02)  28 21 1.00  24 33 0.64 (0.27-1.52) 
  TC+CC 85 69 1.16 (0.70-1.93)  58 54 1.00  44 53 0.78 (0.44-1.38) 
   P for interaction          0.045 
2 UGT1A10, UGT1A8, UGT1A7, 
UGT1A6, UGT1A5, UGT1A9, 
UGT1A4 
rs2011404 CC 84 72 1.10 (0.67-1.81)  67 60 1.00  53 59 0.84 (0.50-1.44) 
  TC+TT 27 12 1.56 (0.53-4.60)  19 15 1.00  15 27 0.47 (0.17-1.29) 
   P for interaction          0.049 
Abbreviations: TSH, thyroid stimulating hormone; PTC, papillary thyroid cancer; SNV, single nucleotide variant; OR, odds ratio; BMI, body mass index. 




Supplementary Table 15. Effect modification of genotypes between serum level of TSH (μU/mL) and risk of papillary microcarcinoma (≤10 mm) at 
Pinteraction<0.05. 






Cases Controls OR* (95% CI) Cases Controls OR* (95% CI) Cases Controls OR* (95% CI) 
19 SULT2A1 rs177037 AA 20 10 1.30 (0.35-4.83)  15 11 1.00  6 18 0.12 (0.03-0.53) 
   AC+CC 25 17 2.42 (0.86-6.80)  15 23 1.00  23 18 1.70 (0.64-4.52) 
   P for interaction          0.022 
10 CYP2E1 rs6413423 TT 43 21 2.17 (0.98-4.84)  28 31 1.00  26 35 0.80 (0.37-1.71) 
   TG+GG 2 6 -  2 3 1.00  3 1 0.003 (<0.0001->999.99) 
   P for interaction          0.028 
19 SULT2A1 rs296365 CC 21 10 2.78 (0.71-10.94)  16 12 1.00  10 20 0.39 (0.11-1.42) 
   CG+GG 24 17 2.66 (0.89-7.91)  14 22 1.00  19 16 1.83 (0.62-5.41) 
   P for interaction          0.036 
14 DIO2 rs12885300 CC 20 17 1.44 (0.50-4.18)  15 20 1.00  16 14 1.33 (0.43-4.05) 
   TC+TT 25 10 2.36 (0.76-7.37)  15 14 1.00  13 22 0.43 (0.14-1.35) 
   P for interaction          0.048 
Abbreviations: TSH, thyroid stimulating hormone; PTC, papillary thyroid cancer; SNV, single nucleotide variant; OR, odds ratio; BMI, body mass index. 




Supplementary Table 15. Effect modification of genotypes between serum level of TSH (μU/mL) and risk of large PTC (>10 mm) at Pinteraction<0.05. 






Cases Controls OR* (95% CI) Cases Controls OR* (95% CI) Cases Controls OR* (95% CI) 
2 UGT1A10, UGT1A8, UGT1A7, 
UGT1A6, UGT1A5, UGT1A9, 
UGT1A4 
rs2011404 CC 57 55 1.06 (0.60-1.87)  49 52 1.00  35 40 1.00 (0.53-1.89) 
  TC+TT 28 7 2.63 (0.79-8.75)  17 13 1.00  10 15 0.52 (0.15-1.78) 
   P for interaction          0.0075 
19 SULT2A1 rs2547238 GG 57 31 1.85 (0.97-3.56)  40 40 1.00  21 30 0.67 (0.32-1.42) 
   GC+CC 28 31 0.84 (0.36-1.96)  26 25 1.00  24 25 1.00 (0.42-2.39) 
   P for interaction          0.013 
2 UGT1A10, UGT1A8 rs17862847 TT 64 51 1.60 (0.89-2.90)  37 48 1.00  33 40 1.14 (0.59-2.22) 
   TA+AA 21 11 0.87 (0.29-2.60)  29 17 1.00  12 15 0.32 (0.10-1.03) 
   P for interaction          0.036 
Abbreviations: TSH, thyroid stimulating hormone; PTC, papillary thyroid cancer; SNV, single nucleotide variant; OR, odds ratio; BMI, body mass index. 






This study used data from a nested case-control study including 742 pairs of cases diagnosed with 
papillary thyroid cancer (PTC) and individually matched controls with pre-diagnostic serum 
concentrations of polybrominated diphenyl ethers (PBDEs), as well as serum levels of thyroid-
stimulating hormone (TSH) and thyroid hormones, from the Department of Defense Serum 
Repository (DoDSR). We tested the hypothesis that exposure to elevated PBDEs increases the risk 
of PTC and the increased risk posed by PBDEs is through the disruption of thyroid hormones. We 
also investigated the effects of genetic polymorphisms in genes involved in 
metabolism/detoxification of PBDEs and thyroid hormones on the association between PBDEs, 
thyroid hormones, and risk of PTC. 
 
Results from this study suggested that exposure to PBDEs (i.e., BDE-28) and dysregulate serum 
levels of TSH were associated with increased risk of PTC. We found that increasing serum levels 
of BDE-28 were associated with an elevated risk of classical PTC. The association between BDE-
28 and risk of classical PTC was mainly observed for cases with large tumors (tumor size >10 mm), 
and was stronger among women. Serum TSH level below the normal range (<0.3 μU/ml) was 
associated with an elevated risk of PTC among women, while TSH level above the normal range 
(>4.2 μU/ml) was associated with an increased risk of PTC among men. There was an inverse 
association between PTC risk and TSH level within the normal range (0.3-4.2 μU/ml) among men 
and women. The observed associations between serum level of TSH and risk of PTC varied by 
histological subtype (classical vs. follicular variant PTCs) and by tumor size (≤10 vs. >10 mm) 
among both genders.  
 
This study also found relationships between PBDE/polybrominated biphenyl (PBB) congeners and 
serum levels of TSH and thyroid hormones. We observed significantly nonmonotonic relationships 
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between serum concentrations of BDE-153 and BB-153 and serum levels of TT3 and TT4 in PTC 
cases, and between BDE-47, -100, and -153 in relation to FT4 level in controls. The associations 
between PBDEs/PBBs and serum levels of TSH and thyroid hormones were stronger in cases than 
those in controls. Among cases, higher serum concentrations of BDE-153 and BB-153 were 
associated with increased level of TSH and decreased levels of TT3 and TT4, while higher 
concentration of BDE-100 was associated with reduced level of TSH and elevated level of TT4. 
When stratified by gender, the effects of BDE-100 on levels of TSH and TT4 were only observed 
among men, while the effects of BDE-153 and BB-153 on levels of TT3 and TT4 were only 
observed among women. However, results from the causal mediation analysis did not support our 
hypothesis that the thyroid carcinogenesis of PBDEs/PBBs is mainly operated through disruption 
of thyroid hormone homeostasis and fluctuation of TSH level. 
 
Investigation on the genetic polymorphisms and gene-environment interactions in genes involved 
in phase I and phase II metabolism/detoxification and thyroid hormone metabolism pathways 
identified several genes that could modify the effects of exposure to BDE-28 and alternation in 
serum TSH level on risk of PTC. Results suggested significant interactions between BDE-28 and 
CYP2E1 rs7092584 in women and DIO2 rs12885300 for large PTC (tumor size >10 mm) at a priori 
significance level of 0.01. In addition, serum level of TSH significantly interacted with rs1875263 
in UGT1A gene and rs12885300 in DIO2 gene among men, and with rs2011404 in UGT1A gene 
for large PTC. 
 
Further investigation into the association between BDE-28, other PBDE/PBB congeners, 
alternatives of brominated flame retardants (BFRs), and PTC risk is warranted among different 
populations to confirm our findings and identify high risk populations who are susceptible to these 
chemicals. More studies using multiple longitudinal measurements are also warranted to further 
understand mechanisms underlying the endocrine disrupting effect of PBDEs/PBBs. Future studies 
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with prospective design and larger statistical power are also merited to confirm our findings on the 
gene-environment interactions in other populations and to explore the underlying mechanisms of 
genetic polymorphisms and PBDEs/TSH related pathogenesis of PTC. 
 
Findings of this study provides valuable evidence to the link between exposure to PBDEs and risk 
of PTC, which will promote further regulations on production and application of PBDEs. Since 
serum level of TSH has been improved to be associated with risk of PTC, there could be significant 
clinical implications to monitor and regulate thyroid hormone levels among the most susceptible 
populations, such as patients with abnormal thyroid functions and those with benign thyroid disease 
or thyroidectomy, to mitigate the risk of thyroid carcinogenesis. Results from the gene-environment 
interaction analysis provide novel evidence to understand the basis of the molecular biology behind 
the initiation and promotion of PTC. With further understanding the pathogenesis of PTC, as well 
as implementing appropriate regulation and intervention, it should be pursued to decrease the 
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